Drug, bio-affecting and body treating compositions inventions 06/09

20090162275 - Contrast agents anchored by thiols on nanoparticles: The present invention is directed toward a multivalent product including a nanoparticle with a metal, metal alloy, or metal oxide core, a plurality of non-polymerizing ligands bound to the nanoparticle, and a plurality of paramagnetic ions coupled to the nanoparticle by the ligands. Methods of making and using the multivalent... Agent: Nixon Peabody LLP - Patent Group

20090162276 - Medical devices containing melt-blown non-wovens of poly-4-hydroxybutyrate and copolymers thereof: Continuous processing methods for making absorbable polymeric non-wovens with one or more of the following properties: high burst strength, fine fibers of average diameter from 1 μm to 50 μm, and thickness from 10 μm to 50 mm, have been developed. Improved fiber cohesion is made possible by allowing the... Agent: Pabst Patent Group LLP

20090162277 - Lysophospholipids solubilized single-walled carbon nanotubes: Lipophilic compounds extracted from cell growth mediums, particularly lysophospholipids are used to solubilize single-walled nanotubes. The naturally occurring lysophospholipids were found to readily bond to the exterior wall of the single-walled nanotubes to enhance the biocompatibility of the single-walled nanotubes in therapeutic and diagnostic conditions. The solubilization protocol is simple,... Agent: J. Bennett Mullinax, LLC

20090162278 - Method for production of radioisotope preparations and their use in life science, research, medical application and industry: The present invention relates to an universal method for the large scale production of high-purity carrier free or non carrier added radioisotopes by applying a number of “unit operations” which are derived from physics and material science and hitherto not used for isotope production. A required number of said unit... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20090162279 - Oligonucleotide or its functional homologue, a composition comprising the same and a method of treating b cell neoplasm: The invention provides an oligonucleotide with a sequence of SEQ ID NO: 1 or its functional homolgue, a composition comprising the same and a method for treating B cell neoplasm by using the oligonucleotide or its functional homologue or the composition comprising the oligonucleotide. The oligonulceotide induces the apoptosis of... Agent: Morgan, Lewis & Bockius LLP (sf)

20090162280 - Detecting soluble a-beta: Agents, methods, and kits for qualitatively or quantitatively determining the presence of soluble A-beta in source of A-beta are provided, wherein the agents comprise the compound of formula III or the compound of formula III labeled with a signal generator.... Agent: General Electric Company Global Research

20090162281 - Radionuclide labeling of vitamin b12 and co-enzymes thereof: e

20090162282 - Substituted 4--piperidine-1-carboxylic acid esters as a2ar agonists: The present invention provides substituted 4-{3-[6-amino-9-(3,4-dihydroxy-tetrahydro-furan-2-yl)-9H-purin-2-yl]-prop-2-ynyl}-piperidine-1-carboxylic acid esters and pharmaceutical compositions containing the same that are selective agonists of A2A adenosine receptors (ARs). These compounds and compositions are useful as pharmaceutical agents.... Agent: Schwegman, Lundberg & Woessner, P.A.

20090162283 - Diagnostic and remedy for disease caused by amyloid aggregation and/or deposition: ring B represents an optionally substituted 5-membered aromatic heterocyclic group which is bonded to the benzene ring or the pyridine ring via a carbon atom of ring B), a salt thereof, a solvate of any of these, or a transition metal coordination compound of any of these, and a diagnostic,... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20090162284 - Anti-igf-i receptor antibody: Antibodies, humanized antibodies, resurfaced antibodies, antibody fragments, derivatized antibodies, and conjugates of these molecules with cytotoxic agents, which specifically bind to and inhibit insulin-like growth factor-I receptor, antagonize the effects of IGF-I and are substantially devoid of agonist activity toward the insulin-like growth factor-I receptor. These molecules can be conjugated... Agent: Sughrue Mion, PLLC

20090162285 - Anti-inflammatory fusion protein: The present invention relates to a fusion protein comprising therapeutical and diagnostic potential against chronic vascular diseases, such as atherosclerosis, a nucleic acid molecule encoding said fusion protein, a pharmaceutical and diagnostic composition which comprises the fusion protein or the nucleic acid molecule, the use of the fusion protein or... Agent: Klarquist Sparkman, LLP

20090162286 - Phosphodiesterase 10 inhibition as treatment for obesity-related and metabolic syndrome-related conditions: The present invention provides methods to decrease body weight and/or body fat in animals, e.g., in the treatment of overweight or obese patients (e.g., humans or companion animals), or as a means to produce leaner meat in food stock animals (e.g., cattle, chickens, pigs), methods to treat non-insulin dependent diabetes... Agent: Pfizer Inc.

20090162287 - Method of cardiac imaging: The invention relates to a method of cardiac imaging using hyperpolarised 13C-pyruvate as MR imaging agent, which allows determination of the viability of cells in the myocardium.... Agent: Ge Healthcare, Inc.

20090162288 - Use of modified vaccinia virus strains in combination with a chemotherapeutic agent for use in therapeutic methods: Modified or attenuated therapeutic viruses in combination with a chemotherapeutic agent, and methods for administering therapeutic viruses in combination with a chemotherapeutic agent to a subject for controlling viral titer, are provided. The combination of a therapeutic virus and chemotherapeutic agent can be used in methods of treating diseases, such... Agent: K&l Gates LLP

20090162289 - Water soluble tetrapyrollic photosensitizers for photodynamic therapy: or a pharmaceutically acceptable derivative thereof, wherein R1-R8 and R10 are various substituents and R9 is substituted or unsubstituted —CH2CH2CON(CH2CON(CH2COOH)2)2; or —N(CH2COOH)2. The invention also includes a method of treatment by photodynamic therapy by treatment with light after injecting the compound and a method of imaging by fluorescence after injection... Agent: Michael L. Dunn

20090162291 - Magnetic resonance contrast medium using polyethylene glycol and magnetic resonance image pick-up method:

20090162290 - Method for the synthesis of penta-pendant enantiomer-pure chelators and process for therapeutically active bioconjugates preparation by a covalent binding thereof: The present invention provides a method for synthesis and binding methods of pentapendant enantiomer-pure chelators of formula (VII) wherein R1, R2, R3, R4 are groups forming an adequate enantiomer of the chelator; and X1-X5, Y1-Y5, Z1-Z5 each individually forming pendant chelating groups.... Agent: Ursula B. Day, Esq.

20090162292 - Substituted 4--piperidine-1-carboxylic acid esters as a2ar agonists: The present invention provides substituted 4-{3-[6-amino-9-(3,4-dihydroxy-tetrahydro-furan-2-yl)-9H-purin-2-yl]-prop-2-ynyl}-piperidine-1-carboxylic acid esters and pharmaceutical compositions containing the same that are selective agonists of A2A adenosine receptors (ARs). These compounds and compositions are useful as pharmaceutical agents.... Agent: Clinical Data, Inc.

20090162293 - Methods and compositions for ultrasound imaging of apoptosis: In some aspects, there are provided compositions and kits including annexin coupled to ultrasound contrast particles as well as methods utilizing these particles for diagnosis and treatment of pathological conditions characterized by apoptosis.... Agent: Dechert LLP

20090162294 - Disposable inhaler: The inventive inhaler functions in a similar way to a cigarette but without the formation of carcinogenic substances and carbon monoxide, as instead of tobacco or other substances containing carbon, metallic components of a combustion body (3) are burnt. The air thus heated is used to evaporate the stimulant or... Agent: David A. Guerra International Patent Group, LLC

20090162296 - Approach to treat intraocular hypertension: The present invention relates to the use of antisecretory factors, such as antisecretory proteins, homologues, derivatives and/or fragments thereof having antisecretory activity, for the manufacture of a pharmaceutical composition for use in the treatment and/or prevention of intraocular hypertension. The invention thus relates to the use of pharmaceutical compositions comprising... Agent: Bingham Mccutchen LLP

20090162300 - Buccal, polar and non-polar spray containing alprazolam: Buccal aerosol sprays or capsules using polar and non-polar solvents have now been developed which provide alprazolam for rapid absorption through the oral mucosa, resulting in fast onset of effect. The buccal polar compositions of the invention comprise formulation I: aqueous polar solvent, alprazolam, and optional flavoring agent; formulation II:... Agent: Dickstein Shapiro LLP

20090162297 - Buccal, polar and non-polar spray containing ondansetron: Buccal aerosol sprays or capsules using polar and non-polar solvents have now been developed which provide ondansetron for rapid absorption through the oral mucosa, resulting in fast onset of effect. The buccal polar compositions of the invention comprise formulation I: aqueous polar solvent, ondansetron, and optional flavoring agent; formulation II:... Agent: Dickstein Shapiro LLP

20090162298 - Buccal, polar and non-polar spray containing sumatriptan: Buccal aerosol sprays or capsules using polar and non-polar solvents have now been developed which provide sumatriptan for rapid absorption through the oral mucosa, resulting in fast onset of effect. The buccal polar compositions of the invention comprise formulation I: aqueous polar solvent, sumatriptan, and optional flavoring agent; formulation II:... Agent: Dickstein Shapiro LLP

20090162299 - Caffeine salt complexes and methods for using the same in the prevention or treatment of cancer: The present invention relates to pharmaceutical compositions containing a caffeine salt complex and a pharmaceutically acceptable carrier for use in methods for preventing or treating cancer or solar dermatitis. Methods for inducing apoptosis or inhibiting proliferation in a cancer cell or cell which as UVB-induced DNA damage using a caffeine... Agent: Licata & Tyrrell P.c

20090162295 - Setting polymers based on polyester acrylates: The present invention relates to cosmetic preparations which comprise at least one polymer A which comprises, in copolymerized form, at least one ester of (meth)acrylic acid, at least one olefinically unsaturated anionogenic or anionic compound, at least one polyester or polyether with at least two free-radically polymerizable, olefinically unsaturated double... Agent: Connolly Bove Lodge & Hutz, LLP

20090162301 - Antiseptic compositions: The present invention provides antiseptic compositions that contain DMSO or DMA, an alcohol (e.g., isopropanol), and/or an additional antiseptic agent such as iodine. In certain embodiments, the antiseptic compositions may be used for skin disinfection and/or skin antisepsis (e.g., as applied via a swab).... Agent: Fulbright & Jaworski L.L.P.

20090162303 - Composition containing two polyesters: Composition containing two polyesters. Treatment method employing the composition and use of this composition for caring for or making up the skin or lips. Novel polyesters.... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20090162302 - Organic inorganic composite powder, method of producing the same, and composition containing the powder: The present invention provides an organic inorganic composite powder which has a specific particle shape in accordance with to a washing solvent, which contains fine inorganic particles, and which easily disperses in water by: precipitating a metal salt dissolved in a reaction solvent from the reaction solvent through neutralization or... Agent: Knobbe Martens Olson & Bear LLP

20090162304 - Compositions and methods for treating skin conditions in mammals: A topical composition for treating skin diseases is provided. The composition comprises calendula, tea tree oil, eucalyptus oil, grape seed oil, and Aloe vera. In some embodiment, the composition may also include beeswax, vegetable oil, vitamin E, rosemary oil, or shea butter or combinations thereof to further enhance its beneficial... Agent: Fox Rothschild LLP Princeton Pike Corporate Center

20090162305 - Formulations of low oil content comprising diphenylmethane derivatives: The present invention relates to specific (cosmetic) formulations for improving the bioavailability and activity of skin- or hair-lightening or senile keratosis-reducing diphenylmethane derivatives (tyrosinase inhibitors) of the following formula 1:... Agent: Connolly Bove Lodge & Hutz LLP

20090162306 - Topical composition comprising coloring antioxidants: Topical compositions for delivering a desirable color are described. The color suitable to be delivered is stable and the result of colorants comprising an antioxidant like lycopene and a second colorant which is a dye or pigment. The topical compositions are stable notwithstanding the fact that they are free of... Agent: Unilever Patent Group

20090162307 - Photolatent systems: The instant invention relates to new photolatent compounds of the formula I wherein R1 and R2 are each independently of the other C1-C10alkyl or C3-C8cycloalkyl, R3 is hydrogen or C1-C4alkyl, and wherein the photochemically cleaved group R4OH is selected from the group consisting of fragrances, UV absorbers, anti-microbials, anti-fogging agents... Agent: Joann Villamizar Ciba Corporation/patent Department

20090162308 - Use of 2,4'-dimethylpropiophenone as a fragrance substance: The use of 2,4′-dimethylpropiophenone as a fragrance substance is described, preferably as a fragrance substance for imparting, modifying and/or reinforcing one, two, three or all the odor notes floral, rosy, rose oxide-like and herbal-like, preferably both of the odor notes rose oxide-like and herbal-like.... Agent: Connolly Bove Lodge & Hutz LLP

20090162310 - Shower and shave preparation: A cosmetic cleansing and shaving preparation which comprises a surfactant system of (i) one or more amphoteric surfactants and (ii) one or more anionic surfactants, the weight ratio (i):(ii) being greater than about 1:1. This Abstract is not intended to define the invention disclosed in the specification, nor intended to... Agent: Greenblum & Bernstein, P.L.C

20090162309 - Method for lightening human keratin fibers using at least one anhydrous composition, at least one organic amine, and at least one oxidizing agent, and device for use thereof: A novel process for lightening human keratin fibers comprising applying to the fibers at least one anhydrous composition (A) comprising at least one fatty substance and at least one surfactant, at least one composition (B) comprising at least one organic amine having a pKb less than 12, and at least... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20090162312 - Novel biodegradable biofouling control coating and method of formulation: An antifouling coating including a polymer made by crosslinking a chitosan with a blocked polyisocyanate.... Agent: Naval Research Laboratory Associate Counsel (patents)

20090162311 - Agent for prevention and/or treatment of glomerulopathy: Provided is a novel prophylactic and/or therapeutic agent for glomerular disease wherein a pharmaceutically acceptable anion exchange resin, typified by colestimide, is an active ingredient thereof.... Agent: Wenderoth, Lind & Ponack, L.L.P.

20090162313 - High-molecular weight conjugate of podophyllotoxins: o

20090162314 - Magnesium-containing polymers for the treatment of hyperphosphatemia: A pharmaceutical composition comprising an aliphatic amine polymer or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable magnesium compound comprising a magnesium ion is disclosed. A method of treating hyperphosphatemia in a patient is also disclosed. The method comprises the step of administering to the subject an effective amount... Agent: Hamilton, Brook, Smith & Reynolds, P.C.

20090162318 - Cyclopropyl fused indolobenzazepine hcv ns5b inhibitors: The invention encompasses compounds of formula I as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and are useful in treating those infected with HCV.... Agent: Louis J. Wille Bristol-myers Squibb Company

20090162315 - Enterotoxin gene cluster (egc) superantigens to treat malignant disease: The use of classical superantigens for treatment of cancer has resulted in a low response rates and serious toxicity in humans which is attributable, in part, to the presence of preformed superantigen specific antibodies in the plasma of treated patients. The present invention addresses this problem by providing a method... Agent: Central Coast Patent Agency, Inc

20090162316 - Liver targeted conjugates: Therapeutic conjugates containing a statin or a modified statin (collectively “statin”) linked to a therapeutic agent (also referred to as a drug herein) are targeted to the liver by the statin or modified statin and thereby deliver the therapeutic agent to liver cells.... Agent: Fish & Richardson PC

20090162317 - Polynucleotide encoding hcv epitopes which can bind to various hla supertypes, immunogenic composition comprising same and method of inducing an hcv-specific immune response using same: There are provided a polynucleotide encoding HCV epitopes, an immunogenic composition including same, and a method of inducing an HCV-specific immune response using same.... Agent: Sughrue Mion, PLLC

20090162319 - Reverse transcriptase inhibitors: Described herein are novel enzyme inhibitors. In some embodiments, the enzyme inhibitors are reverse transcriptase inhibitors, particularly HIV reverse transcriptase inhibitors. Also described herein are compositions containing them and methods of using them. Thus, the compounds and compositions described herein are useful for the in vitro and in vivo inhibition... Agent: Wilson Sonsini Goodrich & Rosati

20090162320 - Gene transfer into airway epithelial stem cell by using lentiviral vector pseudotyped with rna virus or dna virus spike protein: The present inventors successfully introduced genes into stem cells of airway epithelial tissues using simian immunodeficiency virus vectors pseudotyped with F and HN, which are envelope glycoproteins of Sendai virus. Gene transfer into airway epithelial tissue stem cells using a vector of the present invention is useful for gene therapy... Agent: Clark & Elbing LLP

20090162321 - Methods for packaging propagation-defective vesicular stomatitis virus vectors using a stable cell line that expresses g protein: A method of producing propagation-defective Vesicular Stomatitis Virus (VSV) is provided. The method involves providing a cell that includes an optimized VSV G gene, wherein expression of VSV G protein from the optimized VSV G gene is inducible; and inducing the cell to express VSV G protein from the optimized... Agent: Wyeth Patent Law Group

20090162331 - Compositions containing sertoli cells and myoid cells and use thereof in cellular transplants: The present invention relates to the use of Sertoli cells and myoid cells for creating an immunologically privileged site in a mammalian subject, thereby facilitating the transplantation of cells that produce a biological factor in the treatment of a disease that results from a deficiency of such biological factor. Pharmaceutical... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20090162332 - Methods and compositions for treating brain diseases: The present disclosure provides targeting peptides and vectors containing a sequence that encodes targeting peptides that deliver agents to the brain.... Agent: Viksnins Harris & Padys Pllp

20090162333 - Pharmaceutical composition comprising apolipoproteins for the treatment of human diseases: A pharmaceutical composition has an adequate pharmaceutical carrier or diluent and an element selected from a pharmaceutical composition having an adequate pharmaceutical carrier or diluent and an element selected from: —apolipoprotein apoL-III; —a pharmaceutically active fragment of this apolipoprotein apoL-III; —a nucleotide sequence encoding this apolipoprotein apoL-III or the fragment;... Agent: Merchant & Gould PC

20090162323 - Method for stimulating the intestinal flora: The present invention relates to methods for feeding and to compositions to be administered to infants delivered via caesarian section and in particular to the use of a) at least two different microorganisms; or b) at least one microorganism and at least one indigestible oligosaccharide; or c) at least two... Agent: Bacon & Thomas, PLLC

20090162322 - Oral administration form comprising probiotic bacteria: The invention relates to an oral administration form which comprises at least one species of probiotic microorganisms, where it itself and/or the probiotic bacteria is/are provided with a coating which comprises at least two cellulose ethers.... Agent: Millen, White, Zelano & Branigan, P.C.

20090162324 - Use of whole cell actinomycetales bacteria to treat stress-induced pulmonary haemorrhage: Use of whole cells of bacteria from the genera of aerobic organisms in the order of Actinomycetales in the manufacture of a medicament for the treatment or prevention of stress-induced pulmonary haemorrhage (SIPH), preferably exercise induced pulmonary haemorrhage (EIPH), and methods of treating or preventing SIPH, preferably EIPH, in a... Agent: Steptoe & Johnson LLP

20090162327 - Bone marrow transplantation for treatment of stroke: There is provided a treatment for patients suffering from neurodegenerative disease or neural injury including the steps of transplanting cultured bone marrow cells into the spinal cord or brain or injecting intravascularly bone marrow cells of a patient in need. Also provided is a method of activating the differentiation of... Agent: Seed Intellectual Property Law Group PLLC

20090162325 - Cell implantation to prevent and/or treat autoimmune disease: The present invention is directed to the prevention or treatment of autoimmune diseases, and in particular, of type I diabetes, by administering a therapeutically effective amount of an implantable composition comprising living choroid plexus cells.... Agent: Greenlee Winner And Sullivan P C

20090162329 - Compositions comprising hdac inhibitors and methods of their use in restoring stem cell function and preventing heart failure: The invention provides compositions of histone deacetylase (HDAC) inhibitors and progenitor cells useful for treating heart failure in a subject. The invention also provides methods of restoring progenitor cell function to aged progenitor cells and methods for enhancing progenitor cell proliferation and/or differentiation using HDAC inhibitors.... Agent: Cooley Godward Kronish LLP Attn: Patent Group

20090162328 - In vivo assay and molecular markers for testing the phenotypic stability of cell populations and selected cell populations for autologous transplantation: An in vivo assay to measure anchorage-independent growth and phenotypic stability of a certain cell population comprising subcutaneous or intramuscular injection in a mammal of a cell suspension of articular chondrocytes in an iso-osmotic liquid, the same suspension comprising articular chondrocytes in an amount equivalent to at least 1×106 chondrocytes... Agent: Clark & Elbing LLP

20090162326 - Method for isolating stem cells and stem cells derived from a pad-like tissue of teeth: The invention relates to a method for isolating non-embryonic stem cells from a tissue that is located in immediate vicinity of immature, developing teeth or wisdom teeth. The invention further relates to non-embryonic stem cells derived from said tissue. The method according to the invention utilises a living soft tissue... Agent: Joyce Von Natzmer Pequignot + Myers LLC

20090162330 - Method of isolating human neuroepithelial precursor cells from human fetal tissue: A method for isolating human neuroepithelial precursor cells from human fetal tissue by culturing the human fetal cells in fibroblast growth factor and chick embryo extract and immunodepleting from the cultured human fetal cells any cells expressing A2B5, NG2 and eNCAM is provided. In addition, methods for transplanting these cells... Agent: Licata & Tyrrell P.C.

20090162334 - Production and use of regulatory t cells: An ex vivo method for generating a population of Treg capable of suppressing rejection of an organ or tissue transplant from a donor animal, comprises culturing CD4+ T cells from a recipient animal in the presence of IFN-γ plus either donor specific or third-party antigen presenting cells, and harvesting a... Agent: Brooks Kushman P.C.

20090162335 - Melatonin and immunostimulating substance-based compositions: The present invention relates to synergistic associations of melatonin and other active substances and cosmetic compositions suitable for treating all those manifestations causing or accompanying the aging of skin, hair and other tissues. In particular, the invention is based on the use of melatonin associated with immunoactive and antioxidant substances... Agent: Nixon & Vanderhye, PC

20090162338 - Compositions and methods for identifying agents which modulate pten function and pi-3 kinase pathways: Methods are provided for the identification, biochemical characterization and therapeutic use of agents which impact PTEN, p53, PI-kinase and AKT mediated cellular signaling.... Agent: Dann, Dorfman, Herrell & Skillman

20090162337 - Embedded enzymes in polymers to regulate their degradation rate: A biodegradable material, capable of carrying a bioactive agent, comprising a polymer matrix and an enzyme capable of degrading the polymer matrix to enable the release of the bioactive agent.... Agent: Smith, Gambrell & Russell

20090162339 - Galenic formulation for colon-targeted delivery of active ingredients: The invention concerns multiparticulate galenic formulations for oral administration and designed for colon targeted delivery of active principles selected from the group comprising enzymes capable of inactivating macrolides and the like, enzymes capable of inactivating quinolones and β-lactamases.... Agent: Intellectual Property / Technology Law

20090162336 - Novel tools for the diagnosis and treatment of alzheimer's disease: The invention relates to epitopes of the tau protein which are specifically occurring in a phosphorylated state in tau protein from Alzheimer paired helical filaments, to protein kinases which are responsible for the phosphorylation of the amino acids of the tau protein giving rise to said epitopes, and to antibodies... Agent: Marshall, Gerstein & Borun LLP

20090162340 - Stable galenic freeze-dried pharmaceutical preparation of recombinant carbohydrate-binding polypeptides: The invention relates to a method for the production of a medicament containing a polypeptide comprising at least one recombinant carbohydrate-binding polypeptide, or a functional fragment or derivative of said carbohydrate-binding polypeptide in a form stable for storage. The polypeptide mentioned comprises polypeptides or functional derivatives thereof, which are fused... Agent: Connolly Bove Lodge & Hutz, LLP

20090162341 - Non-cytotoxic protein conjugates: A non-cytotoxic protein conjugate for inhibition or reduction of exocytic fusion in a nociceptive sensory afferent cell, comprising: (i) a Targeting Moiety (TM), wherein said TM is an agonist of a receptor present on said nociceptive sensory afferent cell, and wherein said receptor undergoes endocytosis to be incorporated into an... Agent: Merchant & Gould - Syntaxin

20090162343 - Recombinant elastase proteins and methods of manufacturing and use thereof: The present invention relates to methods for the manufacture, purification, formulation, and use of biologically active recombinant elastase proteins. Described are recombinant methods for producing therapeutically useful elastase proteins, as are pharmaceutical compositions comprising said elastase proteins. Novel recombinant elastase proteins and protein preparations are also disclosed. Methods are described... Agent: Dechert LLP

20090162342 - Therapeutic uses of glandular kallikrein: The present invention relates to pharmaceutical compositions comprising glandular kallikrein in combination with myelin basic protein or copaxone for use in the treatment of multiple sclerosis. The present invention further relates to a method of suppressing autoimmune responses in a patient afflicted with or suffering at least one clinical sign... Agent: Alston & Bird LLP

20090162344 - Method for fermentation and culture, fermented plant extract, fermented plant extract composition, method for producing lipopolysaccharide and lipopolysaccharide: In order to provide a method for culturing an immunopotentiator-containing organism having the experience of being eaten, inexpensively without requiring usage of a component derived from an animal, Acetobacter, Gluconobacter, Xanthomonas, Zymomonas or Enterobacter which is an edible gram-negative bacterium having an immunopotentiation function is cultured using a culture solution... Agent: Edwards Angell Palmer & Dodge LLP

20090162348 - Genetic polymorphisms associated with psoriasis, methods of detection and uses thereof: The present invention is based on the discovery of genetic polymorphisms that are associated with psoriasis and related pathologies. In particular, the present invention relates to nucleic acid molecules containing the polymorphisms, including groups of nucleic acid molecules that may be used as a signature marker set, such as a... Agent: Celera Corporation

20090162346 - Genetic polymorphisms associated with rheumatoid arthritis, methods of detection and uses thereof: The present invention provides compositions and methods based on genetic polymorphisms that are associated with autoimmune disease, particularly rheumatoid arthritis. For example, the present invention relates to nucleic acid molecules containing the polymorphisms, variant proteins encoded by these nucleic acid molecules, reagents for detecting the polymorphic nucleic acid molecules and... Agent: Celera Corporation

20090162345 - Materials and methods for reversing type-1 diabetes: In accordance with the subject invention, anti-thymocyte globulin (ATG) can be used to modulate a patient's immune response in order to prevent and/or delay the onset or the progression of type 1 diabetes. ATG treatment augments CD4+CD25+ cell frequencies and their functional activities.... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20090162349 - Method for prevention or treatment of diseases or disorders related to excessive formation of vascular tissue or blood vessels: This invention concerns a method for treating or preventing a disease or disorder related to excessive formation of vascular tissue or blood vessels in a patient, said method comprising administering to said patient an agent affecting the NPY Y2 receptor.... Agent: Rothwell, Figg, Ernst & Manbeck, P.C.

20090162347 - Methods, compositions, and kits relating to chitinases and chitinase-like molecules and inflammatory disease: The present invention includes compositions and methods for the treatment of inflammatory disease (e.g., asthma, COPD, inflammatory bowel disease, atopic dermatitis, atopy, allergy, allergic rhinitis, scleroderma, and the like), relating to inhibiting a chitinase-like molecule. The invention further includes methods to identify new compounds for the treatment of inflammatory disease,... Agent: Ropes & Gray LLP

20090162352 - Antibody formulation: The present invention relates to a pharmaceutical formulation comprising an anti-CD20 antibody. The formulation may additionally comprise a buffer, a surfactant and/or an isotonicity agent.... Agent: Hoffmann-la Roche Inc. Patent Law Department

20090162353 - Compositions for the prevention and treatment of smallpox: The present invention relates to improved compositions for the prevention and treatment of smallpox, and in particular to the use of compositions containing an antibody that binds to an epitope found on the MV form of the smallpox virus and an antibody that binds to an epitope found on the... Agent: Edell, Shapiro & Finnan, LLC

20090162354 - Inhibitors of placental growth factor for the treatment of pathological angiogenesis, pathological arteriogenesis, inflammation, tumor formation and/or vascular leakage: The present invention relates to the field of pathological angiogenesis and arteriogenesis and, in particular, to a stress-induced phenotype in a transgenic mouse (PIGF−/−) that does not produce Placental Growth Factor (PIGF) and that demonstrates an impaired vascular endothelial growth factor (VEGF)-dependent response PIGF deficiency has a negative influence on... Agent: Nixon & Vanderhye, PC

20090162350 - Novel composition and methods for the treatment of immune related disease: The present invention relates to compositions containing a novel protein and methods of using those compositions for the diagnosis and treatment of immune related disease.... Agent: Goodwin Procter LLP

20090162351 - Transdiscal administration of inhibitors of p38 map kinase: The present invention relates to methods, formulations and kits for administering a p38 MAP kinase inhibitor or other therapeutic agent into an intervertebral disc, such as a diseased disc, for example, for purposes of prevention and treatment of degenerative and other disorders.... Agent: Hamilton, Brook, Smith & Reynolds, P.C.

20090162355 - Treatment of tumors using specific anti-l1 antibody: The present invention relates to the anti-L1 monoclonal antibody 9.3 as well as to related antibodies or binding molecules and well as to the uses thereof, especially in tumor treatment.... Agent: Foley And Lardner LLP Suite 500

20090162358 - Antigen binding proteins: Antigen binding proteins that bind β-amyloid peptide, in particular human β-amyloid peptide; methods of treating diseases or disorders characterised by elevated β-amyloid levels or β-amyloid deposits, particularly Alzheimer's disease and diseases or disorders affecting the eye or optic nerve characterised by elevated β-amyloid levels or β-amyloid deposits, including age related... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220

20090162359 - Bivalent, bispecific antibodies: The present invention relates to novel domain exchanged, bivalent, bispecific antibodies, their manufacture and use.... Agent: Hoffmann-la Roche Inc. Patent Law Department

20090162360 - Bivalent, bispecific antibodies: The present invention relates to novel domain exchanged, bivalent, bispecific antibodies, their manufacture and use.... Agent: Hoffmann-la Roche Inc. Patent Law Department

20090162356 - Crig antagonists: The present invention concerns blocking antibodies specifically binding a recently discovered macrophage specific receptor, CRIg, and their use to prevent cellular entry of intracellular pathogens, such as viruses, bacteria or parasites as well as for prevention of unwanted clearance of erythrocytes and platelets.... Agent: Goodwin Procter LLP Attn: Patent Administrator

20090162357 - Diagnosis, prevention, and/or treatment of atherosclerosis and underlying and/or related diseases: Complement is recognized as an important, humoral defense system involved in the innate (nonspecific) recognition and elimination of microbial invaders, other foreign particles or molecules, and antigen-antibody complexes from the body. The present invention makes use of the surprising notion that the handling of lipids by the body, rather than... Agent: Traskbritt, P.C.

20090162361 - Method for diagnosing pancreatic cancer: Objective methods for detecting and diagnosing pancreatic cancer (PNC) are described herein. In one embodiment, the diagnostic method involves determining the expression level of PNC-associated gene that discriminates between PNC cells and normal cells. The present invention further provides methods of screening for therapeutic agents useful in the treatment of... Agent: Townsend And Townsend And Crew, LLP

20090162362 - Alzheimer's disease treatment method: The invention relates to antibodies which are used in the preparation of a medicament for the treatment of Alzheimer's disease. More specifically, the invention relates to the use of an antibody specifically recognizing any one of the predominant variants of the amyloid beta peptide, Ab40 and Ab42, in the preparation... Agent: Crowell & Moring LLP Intellectual Property Group

20090162371 - Anti-il-23 antibodies, compositions, methods and uses: An anti-IL-23p19 antibody, including isolated nucleic acids that encode at least one anti-IL-23p19 antibody, vectors, host cells, transgenic animals or plants, and methods of making and using thereof have applications in diagnostic and/or therapeutic compositions, methods and devices.... Agent: Philip S. Johnson Johnson & Johnson

20090162364 - Apo-2 ligand: A novel cytokine, designated Apo-2 ligand, which induces mammalian cell apoptosis is provided. The Apo-2 ligand is believed to be a member of the TNF cytokine family. Compositions including Apo-2 ligand chimeras, nucleic acid encoding Apo-2 ligand, and antibodies to Apo-2 ligand are also provided. Methods of using Apo-2 ligand... Agent: Genentech, Inc.

20090162370 - Compositions and methods for conditioning a subject for hematopoietic cell transplantation: Allogeneic hematopoietic cell transplantation (HCT) is an effective therapy for treatment of hematological malignancies and various autoimmune conditions. However, HCT traditionally requires conditioning by total body irradiation and/or chemotherapy, both of which are toxic and induce GVHD. Provided herein are compositions and methods for conditioning a subject for HCT by... Agent: Perkins Coie LLP

20090162366 - Human monoclonal antibodies to influenza m2 protein and methods of making and using same: Human, humanized and chimeric monoclonal antibodies that bind to influenza M2 protein. The antibodies are useful for, among other things, treatment, diagnostics, purifying and isolating M2 or influenza virus, and identifying the presence of M2 or influenza virus in a sample or a subject.... Agent: Pillsbury Winthrop Shaw Pittman LLP

20090162368 - Mechanosensitive mammalian potassium channel activatable by polyunsaturated fatty acids: A purified protein comprising a mechanosensitive potassium channel activated by at least one polyunsaturated fatty acid and riluzole and the use of said channels in drug screening.... Agent: Ip Group Of Dla Piper US LLP

20090162365 - Novel sirnas and methods of use thereof: The invention relates to compounds, in particular siRNAs, which inhibit the expression of specific human genes. The invention also relates to pharmaceutical compositions comprising such compounds and a pharmaceutically acceptable carrier. The present invention also provides a method of treating and/or preventing the incidence or severity of various diseases or... Agent: Cooper & Dunham, LLP

20090162367 - Nucleotide and protein sequences of nogo genes and methods based thereon: The present invention relates to the gene, $i(Nogo), its encoded protein products, as well as derivatives and analogs thereof. Production of Nogo proteins, derivatives, and antibodies is also provided. The invention further relates to therapeutic compositions and methods of diagnosis and therapy.... Agent: Edwards Angell Palmer & Dodge LLP

20090162363 - Pedf-r receptor and uses: A pigment epithelium derived factor (“PEDF”) receptor designated PEDF-R and PEDF-R encoding nucleic acid and amino acid sequences. Wild type PEDF-R, PEDF-R variants, soluble PEDF-R variants, chimeric PEDF-R, and antibodies which bind to the PEDF-R (including agonist and neutralizing antibodies), as well as various uses for these molecules are described.... Agent: Woodcock Washburn LLP

20090162369 - Synthetic chimeric peptides: The present invention relates generally to chimeric peptides comprising one or more protective epitopes in a conformation enabling immunological interactivity and to vaccine compositions comprising same. The present invention is particularly directed to a chimeric peptide capable of inducing protecting antibodies against Group A streptococci.... Agent: Bozicevic, Field & Francis LLP

20090162372 - Fibronectin ed-b antibodies, conjugates thereof, and methods of use: The present invention provides anti-ED-B antibodies, antibody fragments, and antibody mimetics and such antibodies conjugated to a partner molecule, wherein the antibody or the antibody-partner molecule conjugate provides a therapeutic effect regardless of whether the ED-B-antibody or ED-B-conjugate complex is internalized within a targeted cell.... Agent: Medarex, Inc.

20090162373 - Materials and methods for treatment of hepatitis c: The present invention relates to materials and methods for treatment of hepatitis C. More closely, the invention relates to human monoclonal antibodies against HCV E1 antigen, to a reagent comprising such antibodies, and to vaccine compositions comprising such antibodies. Furthermore, the invention relates to a method of treating or preventing... Agent: Dann, Dorfman, Herrell & Skillman

20090162374 - Specific removal of activated immune cells: The present invention provides a method of detecting an immune response in a mammalian subject by (a) withdrawing blood or a blood fraction containing immune cells from the subject, (b) contacting the blood with an antibody that specifically binds to the cell surface HLA-F histocompatibility protein of activated mammalian immune... Agent: Myers Bigel Sibley & Sajovec

20090162377 - Immunoglobulins comprising predominantly a gal2glcnac2man3glcnac2 glycoform: The present invention relates to immunoglobulin glycoprotein compositions having predominant N-glycan structures on an immunoglobulin glycoprotein which confer a specific effector function. Additionally, the present invention relates to pharmaceutical compositions comprising an antibody having a particular enriched N-glycan structure, wherein said N-glycan structure is Gal2GlcNAc2Man3GlcNAc2 lacking fucose.... Agent: Merck And Co., Inc

20090162375 - Resistin antagonists and their use: Resistin antagonists, including antibodies reactive with defined epitopes, are disclosed. Antigens useful for raising antibodies against human resistin are also disclosed. Methods of utilizing resistin antagonists to treat or alleviate the symptoms of the diseases with aberrant fibroblast activity including interstitial lung diseases, hypertrophic scarring, keloid scarring and scleroderma are... Agent: Philip S. Johnson Johnson & Johnson

20090162376 - Trans-capsular administration of p38 map kinase inhibitors into orthopedic joints: The present invention relates to trans-capsularly administering into a diseased joint an inhibitor of p38 MAP kinase or a different therapeutic agent.... Agent: Hamilton, Brook, Smith & Reynolds, P.C.

20090162378 - Anti-human cytomegalovius antibodies: The present invention features a human antibody that specifically binds to human cytomegalovirus (HCMV), its encoding nucleic acid(s), and use of the antibody/nucleic acid(s) in treating HCMV infection.... Agent: Occhiuti Rohlicek & Tsao, LLP

20090162379 - Inhibitors of s. aureus sdrd protein attachment to cells and uses therefor: Provided herein is a method for identifying small molecule inhibitors of S. aureus SdrD protein attachment to a host cell receptor using a structural model of SdrD protein-receptor interaction. Also provided are the small molecule inhibitors so identified and synthetic small molecules effective to bind SdrD protein and/or the host... Agent: Benjamin Aaron Adler Adler & Associates

20090162381 - Method for treating vascular disorders: o

20090162380 - Multispecific binding molecules comprising connecting peptides: The instant invention describes novel multispecific binding molecules comprising synthetic connecting peptides. The synthetic connecting peptides result in the preferential synthesis of multispecific binding molecules comprising polypeptide chains that are linked via at least one interchain disulfide linkage. In addition, the invention pertains to compositions in which a majority of... Agent: Lahive & Cockfield, LLP / Biogen Idec Floor 30, Suite 3000

20090162382 - Optimized ca9 antibodies and methods of using the same: The present invention describes antibodies that target CA9, wherein the antibodies comprise at least one modification relative to a parent antibody, wherein the modification alters affinity to an FcγR or alters effector function as compared to the parent antibody. Also disclosed are methods of using the antibodies of the invention.... Agent: Dorsey & Whitney, LLP Intellectual Property Department

20090162386 - Chondrocyte therapeutic delivery system: Systems and methods for modifying the environment of target cell using genetically altered chondrocytes are provided. The genetically engineered chondrocytes can be used to express a therapeutic agent in a subject, including in an environment typically associated with chondrocytes and in an environment not typically associated with chondrocytes.... Agent: Nutter Mcclennen & Fish LLP

20090162385 - Compositions for and methods of enhancing the immune response to antigens: Compositions comprising the compound of formula are provided herein. Also provided are methods of enhancing an immune response of a subject to an antigen by administering the antigen and the composition. The enhanced immune response may be an humoral immune response, a CD4+ T cell response, a CD8+ T cell... Agent: Michael Best & Friedrich LLP

20090162384 - Consensus/ancestral immunogens: The present invention relates, in general, to an immunogen and, in particular, to an immunogen for inducing antibodies that neutralize a wide spectrum of HIV primary isolates and/or to an immunogen that induces a T cell immune response. The invention also relates to a method of inducing anti-HIV antibodies, and/or... Agent: Nixon & Vanderhye, PC

20090162383 - Method for designing vaccines against constantly mutating pathogens: A unique method is disclosed for identifying and replacing surface amino acid residues of a protein antigen that reduces the antigenicity of the putative immunodominant epitopes of the antigen and makes all the accessible regions of the molecule essentially antigenically equivalent, so that the antibody response will be directed against... Agent: Eduardo A. Padlan

20090162387 - Preventive and therapeutic vaccine for alzheimer's disease: A method for producing therapeutic vaccine which consist of NMDA-NRI subunit expressed in insect cells to produce recombinant protein which was encapsulated in PLGA or poly(lactide-co-glycolic acid) micro particles by solvent exchange and used for oral immunization. Excitotoxicity (i.e., a process in which an excessive amount of extracellular glutamate overexcites... Agent: Jeeri R. Reddy

20090162388 - Fish vaccine: The present invention relates to veterinary immunology, namely to the immunological response of fish to a virus. More specifically, the invention provides an epitope of salmonid alphaviruses which epitope is capable of inducing a virus neutralising immune response. In particular the invention relates to a polypeptide comprising a certain amino... Agent: Intervet/schering-plough Animal Health Patent Department

20090162389 - Methods for inducing a natural killer (nk) cell-mediated immune response and for increasing nk cell activity: The present invention relates to the discovery of novel methods of inducing a natural killer (NK) cell-mediated immune response and increasing NK activity in a mammal for the treatment of tumors and virus infections. The method comprises the steps of isolating peripheral blood mononuclear cells (PBMCs) from the subject, exposing... Agent: Perkins Coie LLP

20090162390 - Molecular scaffolds for hiv-1 immunogens: Methods and compositions are provided which employ chimeric polypeptides having at least one heterologous epitope for a human immunodeficiency virus type 1 (HIV-1) neutralizing antibody. These chimeric polypeptides behave as molecular scaffolds which are capable of presenting the various heterologous HIV-1 epitopes. The invention demonstrates that a heterologous epitope recognized... Agent: Alston & Bird LLP

20090162392 - Mutant forms of streptolysin o: Forms of GAS25 (streptolysin O) which are not toxic but which still maintain the ability to induce protection against S. pyogenes are useful in vaccine compositions to induce protection against S. pyogenes.... Agent: Novartis Vaccines And Diagnostics Inc.

20090162391 - Vaccine antigens from piscirickettsia salmonis: The present invention discloses novel proteins, e.g., antigens, from Piscirickettsia salmonis. The present invention further discloses nucleic acids that encode these proteins. The present invention also discloses the use of the proteins, e.g., antigens, and nucleic acids to prepare vaccines against salmonid rickettsial septicemia (SRS). The present invention also discloses... Agent: Schering-plough Corporation Patent Department (k-6-1, 1990)

20090162393 - Vaccine composition and uses thereof: The present invention provides a vaccine composition including a nucleic acid that encodes an amoeba-derived antigen (or a peptide molecule encoded thereby), or fragments or variants thereof. The present invention also provides for the use of such vaccine compositions in eliciting an immune response and/or protective immunity in a host... Agent: Scully Scott Murphy & Presser, PC

20090162394 - Vaccine: The present invention is in the field of pneumococcal capsular saccharide conjugate vaccines. Specifically, a multivalent Streptococcus pneumoniae immunogenic composition is provided with various (for instance 9 or more) conjugated capsular saccharides from different S. pneumoniae serotypes, wherein the composition comprises conjugated capsular saccharide 18C which is less than 80,... Agent: Glaxosmithkline Corporate Intellectual Property, Mai B482

20090162396 - Gm-negative ehv-mutants without heterologous elements: The present invention relates to the field of animal health and in particular of Equine Herpes Viruses (EHV) wherein the gene encoding the protein gM is absent, and which is free of heterologous elements. Further aspects of the invention relate to pharmaceutical compositions comprising said viruses, uses thereof, and methods... Agent: Michael P. Morris Boehringer Ingelheim Usa Corporation

20090162395 - Vaccine for rsv and mpv: The present invention is directed to alphavirus vectored vaccine contructs encoding paramyxovirus proteins that find use in the prevention of respiratory syncytial virus or human metapneumovirus infections. In particular, these vaccines induce cellular and humoral immune responses that inhibit RSV. Also disclosed are improved methods for producing alphavirus vectored paramyxovirus... Agent: Fulbright & Jaworski L.L.P.

20090162397 - Heat treated bacterins, and emulsion vaccines prepared from such heat treated bacterins: Heat treated bacterins, a method of producing heat treated bacterins, and porcine emulsion vaccines prepared from such heat treated bacterins are disclosed.... Agent: Pharmacia & Upjohn

20090162398 - Methods and compositions for immunizing pigs against porcine circovirus: The present invention relates to the isolation and identification of two new strains of type 2B porcine circovirus. These two new strains of porcine circovirus may be used for the preparation of vaccine or immunogenic compositions for immunizing pigs against postweaning multisystemic wasting syndrome (PMWS). Accordingly, the invention provides methods... Agent: Wyeth Patent Law Group

20090162399 - Nef deleted human immunodeficiency virus for the restoration of t-lymphocyte signaling and activation for the treatment and prevention of human immunodeficiency virus infection: A therapeutic suspension for the treatment of human immunodeficiency virus type I (HIV-1) infection in humans using isolated and purified HIV-1 nef-deficient viral particles having a nef-deletion between the endonuclease cleavage sites Nco I and Xho I.... Agent: Theodore J. Bielen Jr. Bielen, Lampe, & Thoeming

20090162400 - Compositions of influenza viral proteins and methods of use thereof: Compositions, fusion proteins and polypeptides comprise at least one pathogen-associated molecular pattern and at least a portion of at least one integral membrane protein of an influenza viral antigen. The compositions, fusion proteins and polypeptides are used to stimulate an immune response in a subject.... Agent: Hamilton, Brook, Smith & Reynolds, P.C.

20090162401 - Streptococcus iniae phosphoglucomutase is a virulence factor and target for vaccine development: The present invention relates generally to the identification of virulence factors from Streptococcus iniae. Specifically, the present invention relates to the identification, characterization and sequencing of a gene for phosphoglucomutase gene, and to a live attenuated strain of S. iniae deficient in phosphoglucomutase useful as a vaccine in aquatic species,... Agent: Dla Piper LLP (us)

20090162402 - Immunizing compositions and methods of use: The present invention provides compositions including siderophore receptor polypeptides and porins from gram negative microbes, and preferably, lipopolysaccarhide at a concentration of no greater than about 10.0 endotoxin units per milliliter. The present invention also provides methods of making and methods of using such compositions.... Agent: Mueting, Raasch & Gebhardt, P.A.

20090162403 - Process for producing an allergen extract: e

20090162405 - Proteinase-engineered cancer vaccine induces immune responses to prevent cancer and to systemically kill cancer cells: A harmless cancer vaccine is made from cancer cells with extracellular proteins including self-recognition molecular patterns being digested by a proteinase. The cancer vaccine is used to vaccinate an individual to induce immune responses against cancer cells systemically. Cancer cells become harmless when they are digested by Tumorase™. Some proteinases... Agent: Yong Qian

20090162404 - Tumor vaccine: The invention provides a tumor cell genetically modified to express a nucleic acid encoding CD80 (B7.1) and a nucleic acid encoding an HLA antigen. The invention also provides a method of stimulating an immune response to a tumor by administering an allogeneic tumor cell such as a lung cancer cell... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.c

20090162406 - Wound healing with zeolite-based hemostatic devices: A method for decreasing the time it takes for a wound to heal includes applying hemostatic agent to the wound, inflaming tissue surrounding the wound to facilitate the deposition of fibroblast, thereby accelerating the subsequent contraction of the wound and the onset of the proliferative healing stage, and causing the... Agent: Knobbe Martens Olson & Bear LLP

20090162408 - Compositions containing cationically surface-modified microparticulate carrier for benefit agents: A coated microparticulate composition comprising a microparticulate; wherein the microparticulate comprises a benefit agent; and wherein the microparticulate is coated with: a Type-1 Polymer, wherein the Type-1 Polymer comprises a cationic polymer with a cationic atom content greater than about 3 wt. % and a weight average molecular weight less... Agent: Marshall, Gerstein & Borun LLP

20090162407 - Process for preparing microparticles having a low residual solvent volume: The disclosed processes for forming microparticles utilize low volumes of processing water while still providing microparticles having low residual solvent levels. The processes are adaptable to both continuous and batch processes using oil/water or water/oil or water/oil/water or oil/water/oil emulsions.... Agent: Ballard Spahr Andrews & Ingersoll, LLP

20090162409 - Microencapsulated pesticide: A microcapsule can be produced readily by (a) pulverizing a solid pesticidal compound in terpineol, dihydroterpineol, terpinel acetate, dihydroterpinel acetate or a mixture thereof to form a suspension, (b) mixing the resulting suspension and water to prepare a liquid droplet, and (c) forming a coating film of a resin around... Agent: Foley And Lardner LLP Suite 500

20090162410 - Process for preparing fine particle dispersion for wood preservation: The present invention provide a method for producing micronized solid particles through a two-step process. The solid particles of the invention comprise metals or metal compounds, especially copper and copper compounds. The solid particle of the invention further comprise organic biocides. The invention further provides a wood preservative composition and... Agent: Milbank, Tweed, Hadley & Mccloy LLP

20090162411 - Encapsulated kidney tissue: Provided are therapeutic implants comprising renal tissue encapsulated within a polymer bead. Also disclosed are methods for treating a disease state in a subject comprising implanting within said subject a therapeutic implant comprising renal tissue encapsulated within a polymer bead. Also provided are methods for making a therapeutic implant comprising:... Agent: Patton Boggs LLP

20090162412 - Implantable polymeric device for sustained release of dopamine agonist: The present invention provides compositions, methods, and kits for treatment of Parkinson's disease and other conditions for which treatment with a dopamine agonist is therapeutically beneficial. The invention provides a biocompatible nonerodible polymeric device which releases dopamine agonist continuously with generally linear release kinetics for extended periods of time. Dopamine... Agent: Morrison & Foerster LLP

20090162413 - Compositions and methods of administering rapamycin analogs with paclitaxel using medical devices: Systems and compositions comprising paclitaxel and a second drug, such as rapamycin, analogs, derivatives, salts and esters thereof are disclosed, as well as methods of delivery wherein the drugs have effects that complement each other. Medical devices comprising supporting structures capable of including or supporting a pharmaceutically acceptable carrier or... Agent: Squire, Sanders & Dempsey L.L.P.

20090162414 - Foamed ceramics: A method for the production of a macroporous ceramic foam, wherein: (a) forming a ceramic slip comprising a substantially homogeneous mixture of a ceramic particulate, an organic binder in a liquid carrier, and optionally one or more surfactants, wherein at least one surfactant is present if the organic binder does... Agent: Bacon & Thomas, PLLC

20090162415 - Gel scaffolds for tissue engineering: The present invention discloses a colloid scaffolds for tissue engineering, comprising collagen and hyaluronic acid (HA). The collagen and the hyaluronic acid (HA) are mixed to form colloidal suspension. The ratio of the collagen and the hyaluronic acid is less than or equal to 300, and the best is less... Agent: Wpat, PC

20090162416 - Polymer implants for timed release of drugs with particular emphasis on ovulation or spermiation of fish: An improved cellulose acetate implant is able to more cost effectively provide ovulation of female fish. The time required for a production run of implants in CA is about 2-3 hours rather than days of the previous procedure. The method of generating the improved implant includes dissolving a hormone in... Agent: Haverstock & Owens LLP

20090162417 - Drug eluting ocular conformer: A coated, drug eluting ocular conformer includes an ocular conformer and at least one substantially purified anti-fibrosis agent. The ocular conformer is formed from a base material having inner and outer sides, including apical and basal portions configured to contact one or more conjunctival tissues in an eye of a... Agent: Brinks Hofer Gilson & Lione/chicago/cook

20090162418 - Indicia-bearing package for delivery systems for managing release of flavors in an edible composition: A package assembly for supporting a delivery system for inclusion in an edible composition is disclosed. The edible composition is formulated to have at least one ingredient encapsulated with an encapsulating material. The delivery system and the resulting edible composition may include other ingredients to create a desired release profile... Agent: Hoffmann & Baron, LLP

20090162419 - Live bacteria product: A live bacteria product including dormant viable bacteria suspended in a liquid carrier. The carrier contains mineral oil and polymers and may also include an adsorbent. The product is stored and shipped in a plastic bag and is sprayed onto livestock feed or the like. The treated livestock feed is... Agent: Thomte Law Office, L.L.C.

20090162420 - Matrix-controlled transdermal system comprising salts of ace inhibitor dicarboxylic acids: The invention relates to a salt of an ACE inhibitor dicarboxylic acid with an organic amine and/or an alkali compound, a transdermal therapeutic system comprising the salt, and a method of producing the transdermal therapeutic system.... Agent: Licata & Tyrrell P.C.

20090162421 - Drugs as well as their production and use in the treatment of pain-associated neuropathies: The present invention relates to the use of tarenflurbil and/or a pharmaceutically tolerable salt or derivative thereof in enantiomerically-pure and/or essentially enantiomerically-pure form or a form that is enriched with respect to flurbiprofen racemate and/or a racemate of said salt or derivative, for the production of a drug for the... Agent: Foley And Lardner LLP Suite 500

20090162424 - Compositions and methods for making and using multifunctional polymerized liposomes: According to some embodiments, the present invention provides compositions and methods for making and using multifunctional polymerized liposomes finding relevant application in medical sciences, particularly in bioimaging, diagnostics, drug delivery, and drug formulation. The compositions and methods involve lipids that are both polymerizable and have a “clickable” group that provides... Agent: Winstead PC

20090162423 - Formulations for cosmetic and wound care treatments with photosensitizes as fluorescent markers: Photoactive materials, such as photosensitizers, are used as fluorescent markers for in vivo detection of the distribution of the injected filler material during cosmetic treatments. In one preferred embodiment, liposomal formulated temoporfin is used, as the photoactive component, in very small concentrations along with fillers for cosmetic and wound healing... Agent: Bolesh J. Skutnik Ceramoptec Industries, Inc.

20090162425 - Methods and compositions for inhibiting undesirable cellular proliferation by targeted liposome delivery of active agents: Provided are methods for inhibiting undesirable proliferation of a tumor cell or a tumor in a subject including administering to the subject a composition that includes an effective amount of an active agent, wherein the active agent is entrapped by one or more liposomes, the active agent has activity in... Agent: Jenkins, Wilson, Taylor & Hunt, P. A.

20090162422 - Single-domain brain-targeting antibody fragments derived from llama antibodies: A phage-displayed library of llama single heavy domain antibodies (sdAbs) was enriched for species that selectively bind to and are internalized by human cerebromicrovascular endothelial cells (HCEC). From the enriched library, two sdAbs were selected, sequenced, subcloned, and expressed as fusion proteins with c-myc-His5 tags. Similarly as phage-displayed sdAbs, these... Agent: Wolf Greenfield & Sacks, P.C.

20090162426 - Use of a compound with rankl activity: The present invention relates to the use of a compound with receptor activator of nuclear factor-kB ligand (RANKL) activity for the manufacture of a topical pharmaceutical formulation for the modulation of local or systemic Treg numbers and the treatment or the prevention of skin-associated or systemic diseases.... Agent: Fulbright & Jaworski L.L.P.

20090162427 - Vaccines using nucleic acid-lipid complexes: This invention relates to a vaccine and a method for immune activation which is effective for eliciting both a systemic, non-antigen specific immune response and a strong antigen-specific immune response in a mammal. The method is particularly effective for protecting a mammal from a disease including cancer, a disease associated... Agent: Dla Piper LLP (us)

20090162428 - Immediate disintegration polyvalent polymeric matrix for modified release solid oral preparations and method of preparation thereof: An immediate disintegrating polymeric matrix for oral administration with modified release is disclosed, obtained without using inert supports such as sugar spheres, comprising particles of active substance directly covered with a release regulating membrane. Use of such a matrix to prepare various administration forms for oral use as well as... Agent: Dilworth & Barrese, LLP

20090162429 - Slow-release composition, method for the preparation thereof, and use thereof: The pharmaceutical or nutraceutical composition with sustained release of an active ingredient according to the present invention comprises at least one coated granule; the coated granule being composed of a particle that comprises said active ingredient and is coated with at least two coatings that comprise a combination of excipients.... Agent: The Firm Of Hueschen And Sage

20090162430 - Gelatin capsule with extra cap for combined therapies: A new pharmaceutical dosage form for the administration of combined therapies without interaction between them is disclosed. It consists of an upper gelatin capsule, hard or soft, with extra lower hard gelatin cap. The upper capsule contains one or more biologically active agent and the lower hard gelatin cap contains... Agent: Butzel LongIPDocketing Dept

20090162431 - Sustained release formulations containing acetaminophen and tramadol: The present invention provides a pharmaceutical dosage form for sustained release of a combination of acetaminophen and tramadol or its salts. The dosage form has an immediate release portion and a sustained release portion. The immediate release portion has about 16%-75% of the drugs. The sustained release portion includes: a.... Agent: Joseph A. Fuchs Rockey, Depke & Lyons, LLC

20090162432 - Stable laquinimod preparations: The subject invention provides a pharmaceutical composition comprising N-ethyl-N-phenyl-1,2,-dihydro-4-hydroxy-5-chloro-1-methyl-2-oxoquinoline-3-carboxamide or the salt thereof; a pharmaceutically acceptable carrier; and not more than 0.5% w/w relative to N-ethyl-N-phenyl-1,2,-dihydro-4-hydroxy-5-chloro-1-methyl-2-oxoquinoline-3-carboxamide of 2-Chloro-6-(1-ethyl-N-methyl-2-oxoindoline-3-carboxamido)benzoic acid,1H,3H-spiro[5-chloro-1-methylquinoline-2,4-dione-3,3′-[1]ethylindolin-[2]-one], or 5-Chloro-N-ethyl-3-hydroxy-1-methyl-2,4-dioxo-N-phenyl-1,2,3,4-tetrahydro-quinoline-3-carboxamide.... Agent: Cooper & Dunham, LLP

20090162433 - Method of treatment: The invention provides the use of darifenacin, or a pharmaceutically acceptable derivative thereof, in the manufacture of a medicament for the reduction of urgency in patients suffering from overactive bladder.... Agent: Novartis Corporate Intellectual Property

20090162434 - Mesalazine tablet: Disclosed are mesalazine tablets and a method for their preparation. The mesalazine tablets comprise a tablet core, a first coating layer, and a second coating layer. The tablet core comprises mesalazine; the first coating layer comprises a cellulose derivative and/or povidone, and the second coating layer comprises methacrylic acid/methyl methacrylate... Agent: Leydig Voit & Mayer, Ltd

20090162435 - Manufacture of tablet: The present invention features a method of manufacturing a tablet containing a pharmaceutically active agent by the steps of: (a) adding a powder containing a pharmaceutically-acceptable carrier to a die cavity; (b) injecting a liquid drug composition containing the pharmaceutically active agent into the die cavity such that the liquid... Agent: Philip S. Johnson Johnson & Johnson

20090162438 - Compositions and methods for joining non-conjoined lumens: Disclosed are compositions, methods, and kits for joining together non-conjoined lumens in a patient's body including vascular lumens. More particularly, in various aspects, this invention provides compositions, methods, and kits for joining such non-conjoined lumens, including small lumens typically requiring microsurgical technique... Agent: Foley & Lardner LLP

20090162436 - Compositions and methods for repair of tissues: Biomaterials providing sustained release of growth factor for repair of tissues such as bone and cartilage are disclosed. The biomaterials comprise a proteoglycan derived from domain I of perlecan and a growth factor, and, optionally, collagen.... Agent: Ratnerprestia

20090162437 - Modified self-assembling peptides: The present invention provides a self-assembling peptide comprising: (a) a first amino acid domain that mediates self-assembly, wherein the domain comprises alternating hydrophobic and hydrophilic amino acids that are complementary and structurally compatible and self-assemble into a macroscopic structure when present in unmodified form; and (b) a second amino acid... Agent: Choate, Hall & Stewart LLP

20090162439 - Silk fibroin coating: The present invention is directed to compositions and methods for preventing or inhibiting biofilm formation on a solid substrate comprising an antimicrobial agent and a biofilm-degrading enzyme embedded in a matrix material.... Agent: Viksnins Harris & Padys Pllp

20090162446 - Absorbent article having a stable skin care composition: The present invention relates to an absorbent article having a stable skin care composition disposed on its skin-contacting surface. The skin care composition is readily transferable to the skin via normal contact, wearer motion, and/or body heat. Importantly, the skin care composition contains at least one skin care ingredient imparting... Agent: The Procter & Gamble Company Global Legal Department - Ip

20090162445 - Composition for repair of defects in osseous tissues: Tissue repair compositions, particularly bone repair compositions, containing demineralized bone fragments and homogenized connective tissues. The compositions can be used in the form of an injectable gel, an injectable paste, a paste, a putty, or a rehydratable freeze-dried form.... Agent: Morgan Lewis & Bockius LLP

20090162443 - Compositions and methods for reducing or preventing water loss from the skin: Moisturizing compositions comprising microspheres for the purpose of preventing or reducing moisture loss from the skin.... Agent: Schering-plough Corporation Patent Department (k-6-1, 1990)

20090162442 - Multi-phasic, nano-structured compositions containing a combination of a fibrate and a statin: The present invention discloses a pharmaceutical formulation containing a multi-phasic pharmaceutical composition in an oral dosage form. The multi-phasic pharmaceutical composition contains: (a) a fibrate, or a pharmaceutically acceptable salt, ester, hydrate, or prodrug thereof; (b) a statin, or a pharmaceutically acceptable salt, ester, hydrate, or prodrug thereof; (c) a... Agent: Cooley Godward Kronish LLP Attn: Patent Group

20090162441 - Pulmonary delivery in treating disorders of the central nervous system: A method for treating a disorder of the central nervous system includes administering to the respiratory tract of a patient a drug which is delivered to the pulmonary system, for instance to the alveoli or the deep lung. The drug is administered at a dose which is at least about... Agent: Elmore Patent Law Group, PC

20090162444 - Raloxifene composition: A pharmaceutical composition comprising raloxifene or a pharmaceutically acceptable salt thereof, a mixed cellulose excipient, and a disintegrant can be conveniently made.... Agent: SynthonIPInc

20090162440 - Sodium alginate microsphere vascular embolus containing water-soluble drug and preparation and application thereof: The present disclosure relates to a kind of sodium alginate microsphere vascular embolus that contains water-soluble drug and preparation and application thereof. The embolus preparation falls into dry microsphere type and wet one that are made of degradable materials. The drug carrier can be sodium alginate, human serum albumin, chitosan... Agent: Thomas, Kayden, Horstemeyer & Risley, LLP

20090162448 - Metal carbonate particles and methods of making thereof: Silver-containing particles, and methods of making silver-containing particles are disclosed.... Agent: Fish & Richardson PC

20090162447 - Spherically shaped substances: A particle having a rounded shape and characterized by a substantially smooth surface is disclosed. The particle can be made of a food substance (e.g., nutritional substance or nutraceutical substance), a pharmaceutical (pharmaceutically active ingredient or pharmaceutically acceptable carrier) or a cosmetic substance.... Agent: Martin D. Moynihan D/b/a Prtsi, Inc.

20090162449 - Stable oral benzimidazole compositions and process of preparation thereof: The present invention relates to stable oral compositions of one or more benzimidazole compounds and processes for their preparation. Also provided are methods for treating various gastrointestinal disorders.... Agent: Ranbaxy Inc.

20090162450 - Pharmaceutical composition: Provided herein is a pharmaceutical composition comprising an antagonist, an agonist, a seal coat, and a sequestering polymer, wherein the antagonist, agonist, seal coat and at least one sequestering polymer are all components of a single unit, and wherein the seal coat forms a layer physically separating the antagonist from... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20090162451 - Pharmaceutical compositions: Provided herein is a pharmaceutical composition comprising an antagonist, an agonist, a seal coat, and a sequestering polymer, wherein the antagonist, agonist, seal coat and at least one sequestering polymer are all components of a single unit, and wherein the seal coat forms a layer physically separating the antagonist from... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20090162452 - Eb matrix production from animal tissue and its use for tissue repair: A method of forming and preserving a bioremodelable, biopolymer scaffold material by subjecting animal tissue to chemical and mechanical processing. In addition to skin tissue, another source of EBM is a blood vessel. EBM may be used for hernia repair, colon, rectal, vaginal and or urethral prolapse treatment; pelvic floor... Agent: Fish & Richardson PC

20090162453 - Composition for preventing harmful organisms: wherein, in the formula, A1, A2, A3 and A4 independently represent a carbon atom, a nitrogen atom or an oxidized nitrogen atom, G1 and G2 independently represent an oxygen atom or a sulfur atom; R1 and R2 independently represent a hydrogen atom or a C1 to C4 alkyl group; Xs... Agent: Buchanan, Ingersoll & Rooney PC

20090162454 - Compositions and methods for effecting nad+ levels using a nicotinamide phosphoribosyl tranferase inhibitor: The present invention relates to methods for decreasing cellular DNA repair in a target patient; decreasing cellular NAD+ biosynthesis in a target patient; increasing efficiency of radiation therapy in a target patient; modulating nicotinamide phosphoribosyl transferase activity in a patient; or sensitizing a patient to a DNA damaging therapy. The... Agent: Wilmerhale/boston

20090162455 - Feed for fish: A fish feed comprises carvacrol and/or salvia extract (provided that where the fish feed comprises carvacrol and not salvia extract the lipid content of the fish feed is at least 15 wt %). The salvia extract may be selected from extract of Salvia officinalis and extract of Salvia lavandulifolia. The... Agent: Pillsbury Winthrop Shaw Pittman, LLP

20090162456 - Composition and method for prevention and treatment of alzheimer's disease: This invention presented is a composition and method for prevention and treatment of Alzheimer's disease, the composition comprising monacolins, anti-inflammation agents and anti-oxidant compounds is made by the method of the invention. The composition of the invention has effect on prevention and treatment of Alzheimer's disease without noticeable side effects... Agent: Roger H. Chu

20090162457 - Resveratrol and/or grape leaf extract as i. a. endurance improver, anti-aging agent, muscle strength improver: To provide an endurance improver, anti-fatigue agent and anti-aging agent having an ingredient taken for long years as a food, having high safety, easily available, and excellent in processability. An endurance improver, anti-fatigue agent, muscle strength improver, motor performance enhancer and anti-aging agent containing resveratrol and/or grape leaf extract as... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20090162458 - Compositions and methods for inducing the expression of heat shock proteins: A nutritional composition comprising at least an effective amount of geranylgeranylacetone or derivative of geranygeranylacetone and/or paeoniflorin or derivative of paeoniflorin and an effective amount of Schisandrin B, wherein the ingredients act substantially simultaneously, via differing mechanism, to enhance the expression of heat shock protein in cells, particularly heat shock... Agent: Torys LLP

20090162459 - Combination therapy for treatment of patients with neurological disorders and cerebral infarction: The present invention provides compositions and methods of treating a patient having a condition selected from the group of cerebral stroke, heart stroke, neurodegenerative diseases, brain or nervous system trauma, or neuroplasticity wherein the composition comprises: (i) at least 4, 5, 6, 7, 8, 9, 10, 11, 12, 13 or... Agent: Marshall, Gerstein & Borun LLP

20090155164 - Human c-fms antigen binding proteins: Antigen binding proteins that bind to human c-fms protein are provided. Nucleic acids encoding the antigen binding protein, vectors, and cells encoding the same are also provided. The antigen binding proteins can inhibit binding of c-fms to CSF-1, reduce monocyte migration into tumors, and reduce the accumulation of tumor-associated macrophages.... Agent: Amgen Inc. Law Department

20090155165 - Anti-igf-i receptor antibody: Antibodies, humanized antibodies, resurfaced antibodies, antibody fragments, derivatized antibodies, and conjugates of these molecules with cytotoxic agents, which specifically bind to and inhibit insulin-like growth factor-I receptor, antagonize the effects of IGF-I and are substantially devoid of agonist activity toward the insulin-like growth factor-I receptor. These molecules can be conjugated... Agent: Sughrue Mion, PLLC

20090155166 - Methods and compositions for f-18 labeling of proteins, peptides and other molecules: The present application discloses compositions and methods of synthesis and use of F-18 labeled molecules of use, for example, in PET imaging techniques. The labeled molecules may be peptides or proteins, although other types of molecules may be labeled by the described methods. Preferably, the F-18 may be conjugated to... Agent: Immunomedics, Inc.

20090155167 - Automated method: The present invention provides an automated method for the preparation of 99mTc radiopharmaceutical compositions, together with disposable cassettes for use in the method. The use of an automated synthesizer apparatus in the preparation of 99mTc radiopharmaceuticals is also described. Also described is the use of kits for the preparation of... Agent: Ge Healthcare, Inc.

20090155168 - In vivo imaging compounds: The invention relates to a compound of formula (I) having use for in vivo imaging of the NR2B subtype of the NMDA receptor.... Agent: Ge Healthcare, Inc.

20090155170 - Annexin derivatives suitable for pretargeting in therapy and diagnosis: The present invention provides methods and compositions for the treatment and diagnosis of diseases such as neoplastic diseases, neurodegenerative diseases, cardiovascular diseases, autoimmune diseases, and inflammatory diseases. The methods are based on the concept of pretargeting and include the administration of complexes comprising a recognizable compound A coupled to annexins,... Agent: Foley And Lardner LLP Suite 500

20090155169 - Glyco-molecular imaging method for grade classification of liver fibrosis and its glyco-molecular imaging agent thereof: The invention discloses one glyco-molecular imaging method for grade classification of liver fibrosis and its glyco-molecular imaging agent. The agent combining with glyco-molecular imaging method for liver targeting could be used to differentiate the grade of liver fibrosis and follow-up evaluation of the therapeutic effect.... Agent: Michael Lin

20090155172 - Antibodies to magmas and uses thereof: The present invention relates to isolated and purified Magmas protein, isolated and purified nucleic acids encoding Magmas protein, and antibodies to Magmas protein, which interacts with granulocyte macrophage colony stimulating factor (GM-CSF). More specifically, the invention relates to uses of such anti-Magmas antibodies. The invention further relates to a method... Agent: Mary Short

20090155176 - Compositions and methods for treatment of diabetic retinopathy: The present invention provides compounds and methods for the treatment of diabetic retinopathy. In particular, LFA-1 antagonists are described herein to be used in the treatment of diabetic retinopathy. One aspect of the invention provides for diagnosis of diabetic retinopathy and administration of a LFA-1 antagonist, after the patient is... Agent: Wilson Sonsini Goodrich & Rosati

20090155178 - Lipidated glycosaminoglycan particles and their use in drug and gene delivery for diagnosis and therapy: Lipidated glycosaminoglycan particles, prepared by reacting a glycosaminoglycan with at least one lipid to cross-link the carboxylic acid groups in the glycosaminoglycan with a primary amine in the lipid, are used to encapsulate drugs for use in the treatment of pathological conditions in an animal.... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20090155173 - Persistent luminescence nanoparticles used in the form of a diagnosis agent for in vivo optical imaging: The invention relates to using persistent luminescence nanoparticles, functionalised if necessary, in the form of an diagnosis agent for an in vivo optical imaging. Said nanoparticles are preferably consist of a compound selected from a group comprising (1) silicates, aluminates, aluminosilicates, germanates, titanates, oxysulphides, phosphates and vanadates, wherein said compounds... Agent: Foley And Lardner LLP Suite 500

20090155177 - Phthalocyanine dyes and their preparation and use: e

20090155174 - Rna interference mediating small rna molecules: Double-stranded RNA (dsRNA) induces sequence-specific post-transcriptional gene silencing in many organisms by a process known as RNA interference (RNAi). Using a Drosophila in vitro system, we demonstrate that 19-23 nt short RNA fragments are the sequence-specific mediators of RNAi. The short interfering RNAs (siRNAs) are generated by an RNase III-like... Agent: Rothwell, Figg, Ernst & Manbeck, P.C.

20090155175 - Simultaneous transluminal coronary sinus application of cells in conjunction with device resynchronization therapy: Method and instrumentation for repairing tissue of a heart in a patient's body and implantation of biventricular stimulation. Adult stem cells that have the capability to repair tissue of the selected organ are recovered by harvesting from the patient's body from the same site as the implant of the device... Agent: Hanley, Flight & Zimmerman, LLC

20090155171 - Visualizing agent comprising a janus green b and visualizing method by using the same: The present invention relates to a visualizing agent comprising a Janus Green B(JGB), and a visualizing method by using the same. More specifically, the method comprising A method of visualizing the intravascular threadlike structure (Bonghan duct) floating inside a lymphatic vessel comprising injecting JGB into the lymphatic tissue to be... Agent: LexyoumeIPGroup, LLC

20090155179 - Kinetic biomarker for quantification of lymphoproliferation, clonal expansion, recruitment and trafficking in lymphoid tissues and of the in vivo actions of antigens and modulating thereon: The methods of the present invention allow for the measurement of proliferation, clonal expansion trafficking and/or recruitment of lymphocytes into lymphoid tissue in an in vivo setting. Proliferation, clonal expansion, recruitment and/or trafficking of lymphocytes are measured by using stable isotopes to label newly synthesized DNA, isolating the newly-labeled DNA,... Agent: Morgan, Lewis & Bockius, LLP

20090155180 - Methods and targets for identifying compounds for regulating rhinovirus infection: The present invention provides methods for identifying genes, expression regulators, receptors, protein product receptors, and proteins that may regulate rhinovirus infections. The genes identified may be used as markers for disease onset and progression and to measure efficacy of a therapeutic. The present invention also provides methods to screen agents... Agent: The Procter & Gamble Company Global Legal Department - Ip

20090155181 - Compositions useful for reducing toxicity associated with gadolinium-based contrast agents: The invention relates to compositions comprising a gadolinium-based contrast agent and a derivatized cyclodextrin. Further provided are methods for reducing the toxicity associated with gadolinium-based contrast agents.... Agent: Merchant & Gould PC

20090155184 - Magnetic resonance imaging method: The present invention relates to a magnetic resonance imaging (MRI) method, in particular to a MRI method enabling early detection of myocardial ischemia.... Agent: Ge Healthcare, Inc.

20090155182 - Optical in vivo imaging contrast agents and methods of use: Provided is an optical in vivo contrast agent comprising a fluorescent polymeric microsphere, wherein the microsphere is impregnated with a dye having an excitation and emission spectrum compatible with in vivo imaging, and wherein the microsphere is coated with a block copolymer.... Agent: Invitrogen Corporation C/o Intellevate

20090155183 - Sensors for the detection of diols and carbohydrates: The systems and methods disclosed herein include a sensor particle for detecting the presence of a chelatable analyte, such as glucose, wherein the sensor comprises a chromophore and a fluorescent component, such as a quantum dot. The sensor particle further comprises moieties that bind both a clelatable analyte and chromophore... Agent: Ropes & Gray LLP

20090155185 - Medicaments for inhalation comprising an anticholinergic and a betamimetic: e

20090155186 - Compositions and methods for treating inflammatory conditions: The present invention relates to compositions containing signal transduction modulator compounds, to methods for treating or preventing inflammation, or promoting healthy joints, using the compounds and to kits for the same.... Agent: Choate, Hall & Stewart LLP

20090155187 - Drug for inhibiting vascular intimal hyperplasia: [wherein each of R1, R2 and R3 is independently a hydrogen atom or a C1-6 alkyl group, X is a halogen atom, cyano or a hydrogen atom, Y is a halogen atom, trifluoromethyl or a hydrogen atom, and A is a C1-8 alkylene which may be substituted with a hydroxyl... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20090155188 - mouth environment with oral composition: A solid oral composition for providing a mouthwash efficacious effect comprising a non-hygroscopic base, carbamide peroxide, a bacterial immobilizing and sulfur sequestration agent, and an optional antioxidant enzyme.... Agent: James Sonntag James Sonntag, Patent Attorney

20090155189 - Preparations, methods and kits useful for the treatment of cough: The invention relates to a respiratory preparation providing cough relief in a human comprising: a thickening agent; a benefit agent. Additionally, the invention relates to a method of providing cough relief in a human comprising: the steps of administering to a human a respiratory preparation comprising: a thickening agent; a... Agent: The Procter & Gamble Company Global Legal Department - Ip

20090155190 - Tooth whitening compositions and delivery systems therefor: Stain-removing oral compositions, such as gum compositions, are herein provided. The gum compositions include a film-forming agent, such as a fatty acid salt, in combination with an abrasive and a chelating agent. The fatty acid salt may be a salt derived from a hydroxy fatty acid. The chelating agent may... Agent: Hoffmann & Baron, LLP

20090155191 - Use of chlorhexidine in the prevention of root caries: Topical application of a solution of the antimicrobial chlorhexidine to teeth, particularly including exposed root surfaces, prevents the destruction of exposed cementum and associated exposed enamel at the cementum-enamel junction on tooth root surfaces (root caries) and the inflammation of the gingival tissue. In a method of use, a topical... Agent: Rohm & Monsanto, PLC

20090155192 - Antibacterial 5,5'-disubstituted 3,3' dialkoxy-2,2'-dihydroxy-1,1'-biphenyl: Also included in the invention are toothpastes or tooth gels that include at least one humectant: at least one abrasive compound; and an antibacterially effective amount of the compound represented by the structure of formula (I). Also provided are methods of inhibiting bacterial growth in the oral cavity of an... Agent: Colgate-palmolive Company

20090155195 - Capsules: The present invention related to (micro-or nano-) capsules that have two different functional groups on the outer shell of the particles that allow deposition onto the textile surfaces (i.e. exhibit substantivity) and subsequent covalent bonding of the particles onto the textile (i.e. are reactive towards the fiber).... Agent: Joann Villamizar Ciba Corporation/patent Department

20090155194 - Enhanced photostability of avobenzone in the presence of zinc oxide using phosphate-based emulsifiers: The photostability of avobenzone in a sunscreen composition in the presence of zinc oxide is stabilized against photodegradation using phosphate-based emulsifiers.... Agent: Schering-plough Corporation Patent Department (k-6-1, 1990)

20090155193 - Topical bioadhesive formulations: The present invention relates to topical bioadhesive formulations comprising low viscosity, non-liquid crystalline, mixtures of: a) at least one neutral diacyl lipid and/or at least one tocopherol; b) at least one phospholipid; c) at least one biocompatible oxygen containing, low viscosity organic solvent; wherein at least one bioactive agent is... Agent: Nixon Peabody, LLP

20090155196 - Cosmetic preparation: A cosmetic preparation comprising an aqueous solution of a water-soluble iron salt dimer, said aqueous solution containing magnesium ion and calcium ion.... Agent: Sughrue Mion, PLLC

20090155197 - Goniochromic indicator for skin sealant: A skin sealant composition having a film former like cyanoacrylate and a goniochromic dye or pigment is provided. The addition of mica/metal oxide powders to the sealant formulation makes it possible to see where it has been applied, due to the mica/metal oxide's goniochromic (e.g. irridescent or pearlescent) appearance, and... Agent: Kimberly-clark Worldwide, Inc. Catherine E. Wolf

20090155198 - Process for treating hair fibers using polysiloxane/polyurea: A process for treating hair fibers comprising: applying to the hair fibers at least one cosmetic composition comprising, in a cosmetically acceptable medium, at least one polysiloxane/polyurea block copolymer; and subsequently or simultaneously heating the hair fibers at a temperature ranging from 50 to 280° C.... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20090155199 - Apparatus and methods for pain relief using ultrasound energized polymers: Method and device to create energized polymers that can be used for pain relief, comprised of an ultrasound system that ultrasonically energize polymers that can then be used to provide an analgesic effect. Ultrasound waves are delivered to a polymer through direct contact, through a coupling medium, or without contact... Agent: Bacoustics, LLC

20090155201 - Alkylated poly(allylamine) polymers and methods of use: The invention relates to a method for removing bile salts from a patient in need thereof and compositions useful in the method. The method comprises administering to the patient a therapeutically effective amount of a salt of an alkylated and crosslinked polymer. The alkylated and crosslinked polymer salt comprises the... Agent: Hamilton, Brook, Smith & Reynolds, P.C.

20090155200 - Methods of promoting cartilage healing or cartilage integration: The present invention provides methods of promoting cartilage healing or integration that include reducing the effective concentration of lubricin found in the extracellular matrix that is in contact with cartilaginous tissue.... Agent: Clark & Elbing LLP

20090155202 - Dna-binding polymers: Methods and compositions are provided for forming complexes between dsDNA and novel DNA-binding polymers comprising N-terminal thiophene-containing moieties which exhibit selectivity for T-A base pairs. By appropriate choice of target sequences and DNA-binding polymers, complexes comprising polymer-DNA are obtained with high association constants. The formation of complexes can be used... Agent: Foley & Lardner LLP

20090155205 - Human antibodies that bind human tnfa: Human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor α (hTNFα) are disclosed. These antibodies have high affinity for hTNFα (e.g., Kd=10−8 M or less), a slow off rate for hTNFα dissociation (e.g., Koff=10−3 sec−1 or less) and neutralize hTNFα activity in vitro and in... Agent: Lahive & Cockfield, LLP/abbott Floor 30, Suite 3000

20090155204 - Methods for treating disorders involving monocytes: Methods for treating disorders involving monocytic activity by administering IL-15 antagonists that induce apoptosis of monocytes are disclosed.... Agent: Lahive & Cockfield, LLP Floor 30, Suite 3000

20090155206 - Methods, compositions and articles of manufacture for contributing to the treatment of cancers: Methods, compositions and articles of manufacture for contributing to the treatment of cancers, including solid tumors, are disclosed. The methods, compositions and articles of manufacture can utilize an endothelin B agonist (ETB) to enhance the delivery and resulting efficacy of a chemotherapeutic agent.... Agent: K&l Gates LLP

20090155203 - Thrombopoietin mimetics: Invented are non-peptide TPO mimetics. Also invented are novel processes and intermediates used in the preparation of the presently invented compounds. Also invented is a method of treating thrombocytopenia, in a mammal, including a human, in need thereof which comprises administering to such mammal an effective amount of a selected... Agent: Glaxosmithkline Corporate Intellectual Property- Uw2220

20090155207 - Use of immunomodulatory compounds for the treatment of transverse myelitis, multiple sclerosis, and other disorders: Methods of treating, preventing or managing transverse myelitis, multiple sclerosis, and/or other disorders are disclosed. The methods encompass the administration of an immunomodulatory compound provided herein, such as 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl-piperidine-2,6-dione or 1,3-dioxo-2-(2,6-dioxopiperidin-3-yl)-4-aminoisoindoline. Further described are methods of treatment using the immunomodulatory compounds in combination with a second active agent. Pharmaceutical compositions... Agent: Jones Day

20090155208 - Methods and agents for modulating an immune response: This invention is directed to the targeting of proteins or peptides of interest to an autophagosome, for their presentation on a major histocompatibility complex (MHC) class II molecule and methods of use thereof. Nucleic acids, vectors comprising the same, and compositions for targeting proteins or peptides of interest to an... Agent: Fox Rothschild LLP Princeton Pike Corporate Center

20090155209 - Novel macrocyclic inhibitors of hepatitis c virus replication: The embodiments provide compounds of the general Formula I, as well as compositions, including pharmaceutical compositions, comprising a subject compound. The embodiments further provide treatment methods, including methods of treating a hepatitis C virus infection and methods of treating liver fibrosis, the methods generally involving administering to an individual in... Agent: Knobbe Martens Olson & Bear LLP

20090155211 - Methods and compositions for the treatment of autoimmune disorders using clofarabine: This invention relates to methods of treating or preventing an autoimmune disorder comprising the administration of clofarabine or a pharmaceutically acceptable salt, hydrate, solvate, clathrate, prodrug or metabolite thereof to a patient in need of such treatment. The invention further relates to methods of treating or preventing an autoimmune disorder... Agent: Genzyme Corporation Legal Department

20090155210 - Oximyl hcv serine protease inhibitors: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned... Agent: Elmore Patent Law Group, PC

20090155212 - Immunostimulatory nucleic acids and cancer medicament combination therapy for the treatment of cancer: The invention involves administration of an immunostimulatory nucleic acid in combination with a cancer medicament for the treatment or prevention of cancer in subjects. The combination of drugs are administered in synergistic amounts or in various dosages or at various time schedules. The invention also relates to kits and compositions... Agent: Wolf Greenfield & Sacks, P.C.

20090155215 - Engineered enzymatically active bacteriophage and methods for dispersing biofilms: The present invention is directed to engineered enzymatically active bacteriophages that are both capable of killing the bacteria by lysis and dispersing the bacterial biofilm because they have been also engineered to express biofilm-degrading enzymes, particularly dispersin B (DspB), an enzyme that hydrolyzes β-1,6-N-acetyl-D-glucosamine, a crucial adhesion molecule needed for... Agent: Ronald I. Eisenstein

20090155213 - Lactobacillus acidophilus nucleic acids and uses thereof: Lactobacillus acidophilus NCFM nucleic acid molecules, polypeptides, fragments and variants thereof are provided in the current invention. In addition, fusion proteins, antigenic peptides, and antibodies are encompassed. The invention also provides recombinant expression vectors containing a nucleic acid molecule of the invention and cells comprising the expression vectors. Methods for... Agent: Alston & Bird LLP

20090155214 - Novel bacteria and method for controlling plant disease using the same: An object of the present invention is to provide a means for imparting resistance against pathogenic fungal, pathogenic bacterial, or pathogenic viral disease to agriculturally useful plants. The present invention relates to a bacterium belonging to the genus Azospirillum or the genus Herbaspirillum capable of imparting resistance against pathogenic fungal,... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20090155229 - Chondrocyte-based implant for the delivery of therapeutic agents: The present invention relates in general to chondrocyte based explants and implants of genetically engineered chondrocytes and in particular, to the delivery of peptides, proteins and RNAi molecules to a mammalian subject using a genetically modified chondrocyte-based mass. In one embodiment the genetically modified chondrocyte-based mass is provided as a... Agent: Winston & Strawn LLP Patent Department

20090155231 - Compositions and methods for treatment of neoplastic disease: The present invention comprises the use of sickle cells or sickle cell precursors loaded with a therapeutic agent that localizes in tumors and induces a tumoricidal response.... Agent: Central Coast Patent Agency, Inc

20090155233 - Method for treating tumor using irradiated tumor cell expressing human hepatitis b surface antigen and a pharmaceutical composition comprising the tumor cell: The present invention relates to a method for treating a tumor in mammals comprising administering tumor cells in a therapeutically effective amount, in which the tumor cells lose their proliferative function by irradiation, are genetically manipulated to express hepatitis B surface antigen and are the same as the tumor to... Agent: Nixon Peabody LLP

20090155232 - Neonatal human hepatocytes immortalized using tert and methods of their use: The present invention relates to the discovery of immortalized neonatal human hepatocytes that exhibit phenotypic features of human hepatic progenitor cells. The invention is also directed to a method of obtaining telomerase-immortalized neonatal human hepatocytes that exhibit phenotypic features of human hepatic progenitor cells. Furthermore, the instant invention describes methods... Agent: Lahive & Cockfield, LLP Floor 30, Suite 3000

20090155230 - Novel genes and markers in essential arterial hypertension: The present invention relates to previously unknown disease associations between various genes, loci and biomarkers and essential hypertension. The detection of these biomarkers provides novel in vitro methods and test kits which can be used as an aid when making risk assessment, molecular diagnosis or prognosis of HT or a... Agent: Birch Stewart Kolasch & Birch

20090155216 - Grafting material and agent for improvement in bone quality: The present invention has an object to provide a transplant material allowing systemic bone substance improvement to be realized by cell transplant. The present invention teaches to use a transplant material comprising a cell selected from the group consisting of an embryonic stem cell, a mesenchymal stem cell, an osteoblast... Agent: Oliff & Berridge, PLC

20090155217 - Novel e. coli o157:h7 bacteriophage and uses thereof: The present invention is directed to isolated bacteriophage having strong lytic activity against strains of E. coli O157:H7, and methods of using that bacteriophage, and/or progeny or derivatives derived therefrom, to control the growth of E. coli O157:H7 in various settings.... Agent: Hunton & Williams LLP Intellectual Property Department

20090155221 - Bone augmentation utilizing muscle-derived progenitor compositions, and treatments thereof: The present invention provides muscle-derived progenitor cells that show long-term survival following transplantation into body tissues and which can augment non-soft tissue following introduction (e.g. via injection, transplantation, or implantation) into a site of non-soft tissue (e.g. bone). Also provided are methods of isolating muscle-derived progenitor cells, and methods of... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.c

20090155222 - Cell culture: There is provided a method of retarding differentiation of a biological cell, the method comprising culturing the cell in the presence of an inhibitor of E-cadherin activity. The method is particularly advantageous in retarding the differentiation of stem or progenitor cells, and allows suspension culture of such cells in a... Agent: Bose Mckinney & Evans LLP

20090155223 - Cell-based compositions and methods for treating conditions of the nervous system: Disclosed herein are cell-based compositions for the treatment of conditions of the nervous system and methods for their use. In one embodiment, a cell-based composition comprises glial-restricted progenitors (GRPs) genetically modified to express a targeting ligand on their cell surface. Methods for the preparation of such cell-based compositions are disclosed.... Agent: Edwards Angell Palmer & Dodge LLP

20090155227 - Combination growth factor therapy and cell therapy for treatment of acute and chronic heart disease: Acute and chronic heart disease is treated using a rational, multi-tier approach. A patient is pretreated with growth factor proteins or gene therapy, followed by the administration of adult stem cells. The progress of treatment is continuously monitored by echo-cardiogram with growth factor treatment and/or stem cell administration adjusted according... Agent: Ernest D. Buff Ernest D. Buff & Associates, LLC

20090155218 - Compositions and methods for growth of embryonic stem cells: The present invention relates to methods, compositions, and kits for maintenance of the undifferentiated state and/or pluripotency in stem cells, including embryonic stem (ES) cells. It also relates to stem cells that have been maintained in an undifferentiated state. The present invention provides these aspects using culture medium enriched with... Agent: Latimer, Mayberry & MatthewsIPLaw, LLP

20090155228 - Compounds, kits and methods for conferring cytoprotection: hABCG2, a member of the ATP-Binding Cassette transporters has been identified as a protective pump against endogenous and exogenous toxic agents. ABCG2 was shown to be expressed at high levels in stem cells, and variably regulated during cell differentiation. It is demonstrated herein that functional ABCG2 is expressed in human... Agent: Frommer Lawrence & Haug

20090155224 - Dimethyl amino ethyl ether psoralens and methods for their production and use: Water-soluble dimethyl amino ethyl ether psoralens useful in the treatment of proliferative skin disorders, microbial infections and diseases, disorders of the blood and bone marrow of mammals and in microbiocidal compositions for sterilization of blood and blood products and surgical implants and inhibition of microbial growth in industrial applications are... Agent: University Of Medicine And Dentistry Office Of Patents And Licensing

20090155219 - Methods for damaging cells using effector functions of anti-gfra1 antibodies: The present invention relates to the use of cytoxicity based on the effector function of anti-GFRA1 antibodies. Specifically, the present invention provides methods and pharmaceutical compositions that comprise an anti-GFRA1 antibody as an active ingredient for damaging GFRA1-expressing cells using antibody effector function. Since GFRA1 is strongly expressed in breast,... Agent: Townsend And Townsend And Crew, LLP

20090155226 - Regenerative dot cells: Methods and compositions are provided for the isolation, culture and use of highly regenerative somatic mammalian cells. The cells are very small, and have an undefined nuclear structure. The cells may be isolated from fetal or adult tissues, and are found in tissue including, without limitation, fetal dermal tissue, blood,... Agent: Stanford University Office Of Technology Licensing Bozicevic, Field & Francis LLP

20090155220 - Use of bone-marrow derived stem cells to treat ischemia: Disclosed are cellular compositions and methods for preventing, treating or reducing the severity of tissue ischemia, particularly limb ischemia in a mammal. One inventive method includes administering a therapeutically effective amount of a cellular composition comprising a novel isolated multi-potent human bone marrow-derived stem cell (BMSC) having undetectable or negligible... Agent: Edwards Angell Palmer & Dodge LLP

20090155225 - Uses and isolation of very small of embryonic-like (vsel) stem cells: The presently disclosed subject matter provides populations of stem cells that are purified from bone marrow, peripheral blood, and/or other sources. Also provided are methods of using the stem cells for treating tissue and/or organ damage in a subject.... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.c

20090155235 - Aggregates with increased deformability, comprising at least three amphipats, for improved transport through semi-permeable barriers and for the non-invasive drug application in vivo, especially through the skin: The invention describes combinations of at least three amphipatic substances forming aggregate suspensions in a polar liquid. Judicious choice of system components, which differ at least 2-times to 10-times in solubility, ensures said aggregates to have extended, unusually adaptable surfaces. This is probably due to simultaneous action on said aggregates... Agent: Wilson Sonsini Goodrich & Rosati

20090155234 - Detection of mutations in a gene associated with resistance to viral infection, mx1: A method for detecting a mutation related to the gene encoding MxA. This and other disclosed mutations correlate with resistance of humans to viral infection including hepatitis C. Also provided is a therapeutic agent consisting of a protein or polypeptide encoded by the wild-type and mutated genes, or a polynucleotide... Agent: Davis Wright Tremaine, LLP/seattle

20090155236 - Peptide sequence for modulation of delta protein kinase c: A peptide identified from the annexin V protein sequence and having the ability to modulate the activity of delta protein kinase C (PKC) is described. The peptide and variants thereof bind to delta PKC and are effective to regulate delta PKC mediated cellular responses. In particular the annexin V peptide... Agent: Perkins Coie LLP

20090155237 - Compositions and methods for bone strengthening: The invention relates to methods of increasing bone strength in an animal, preferably a mammal. In one aspect, the methods provided by the invention involve administering to the animal strontium and a phytase enzyme. In another aspect, methods are provided for treating or preventing osteoporosis in a subject, the method... Agent: Nixon Peabody LLP - Patent Group

20090155238 - Xylanases, nucleic acids encoding them and methods for making and using them: The invention relates to enzymes having xylanase, mannanase and/or glucanase activity, e.g., catalyzing hydrolysis of internal β-1,4-xylosidic linkages or endo-β-1,4-ghicanase linkages; and/or degrading a linear polysaccharide beta-1,4-xylan into xylose. Thus, the invention provides methods and processes for breaking down hemicellulose, which is a major component of the cell wall of... Agent: Verenium C/o Mofo S.d.

20090155239 - Novel protease, microorganism producing the same, and application thereof: e

20090155240 - Dichloroacetate in combination with clinically high levels of cardioprotective or hemodynamic drugs: The present invention provides compositions and methods for using cardioprotective or hemodynamic drugs in combination with dichloroacetate enabling usage of cardioprotective or hemodynamic drugs at concentrations higher than used in normal clinical practice without increasing deleterious side effects normally associated with the cardioprotective or hemodynamic drug, thereby conferring added clinical... Agent: Pillsbury Winthrop Shaw Pittman LLP

20090155242 - Mammalian genes; related reagents and methods: Nucleic acids encoding mammalian, e.g., primate or rodent, genes, purified proteins and fragments thereof. Antibodies, both polyclonal and monoclonal, are also provided. Methods of using the compositions for both diagnostic and therapeutic utilities are provided.... Agent: Dnax Research Inc. Legal Department

20090155244 - Methods and compositions for poxvirus a35r protein: The present invention provides methods and compositions for modulating an immune response in a subject, comprising administering to the subject an effective amount of an A35R protein or active fragment thereof of vaccinia virus or other poxvirus.... Agent: Myers Bigel Sibley & Sajovec

20090155243 - Non-human model of autoimmune disease: The invention is directed to a method of producing a non-human mammal having one or more pathological characteristics of retinal degeneration and/or age-related macular degeneration. In particular, the invention provides a method of producing a non-human mammal having age-related macular degeneration (AMD). The invention is also directed to non-human animals... Agent: Hamilton, Brook, Smith & Reynolds, P.C.

20090155241 - Prophylactic/therapeutic agent for cancer: A compound or its salt that inhibits the activity of a protein having the same or substantially the same amino acid sequence as the amino acid sequence represented by SEQ ID NO: 1; a compound or its salt that inhibits the expression of a gene for the protein; an antisense... Agent: Foley And Lardner LLP Suite 500

20090155245 - Treatment for organ regeneration with combination of drug and biologics: Combination therapies of drugs and biologics for treatment of acute and chronic organ degeneration are disclosed. More specifically, the use of morphogens, stem cells, and anti-inflammatories or inhibitors for the renin-angiotensin-aldosterone system (RAAS) for the treatment of acute and chronic renal disease is disclosed.... Agent: Philip S. Johnson Johnson & Johnson

20090155254 - Affinity regions: The present invention provides a method for selecting from a collection of IgIV molecules, at least one IgIV molecule comprising an affinity region that is capable of interacting with a misfolded protein and/or with an epitope of a cross-β structure and/or with an epitope of a protein comprising a cross-β... Agent: Traskbritt, P.C.

20090155253 - Anti-cd20 antibodies and fusion proteins therof and methods of use: The present invention provides humanized, chimeric and human anti-CD20 antibodies and CD20 antibody fusion proteins that bind to a human B cell marker, referred to as CD20, which is useful for the treatment and diagnosis of B-cell disorders, such as B-cell malignancies and autoimmune diseases, and methods of treatment and... Agent: Rossi, Kimms & Mcdowell LLP.

20090155246 - Antibodies specific for soluble amyloid beta peptide protofibrils and uses thereof: The invention pertains to the development of antibodies that specifically bind amyloid beta protein (Abeta) in its protofibril conformation. The invention also comprises methods of using anti-Abeta protofibril antibodies to diagnose or treat Alzheimer's disease, Down's syndrome Lewybody dementia, vascular dementia, and other neurodegenerative disorders. Furthermore, the invention pertains to... Agent: Clark & Elbing LLP

20090155248 - Antibodies to mt-sp1 serine protease: This invention provides a novel membrane-type serine protease (designated MT-SP1) elevated expression of which is associated with cancer. In one embodiment, this invention provides a method obtaining a prognosis or of detecting or staging a cancer in an organism. The method involves providing a biological sample from the organism and... Agent: Wilson Sonsini Goodrich & Rosati

20090155255 - Cd23 binding molecules and methods of use thereof: The invention is based, at least in part, on the development of multivalent and stabilized forms of CD23 binding molecules and methods of use thereof for the treatment of immune cell disorders, including leukemias or lymphomas such as CLL.... Agent: Lahive & Cockfield, LLP / Biogen Idec Floor 30, Suite 3000

20090155252 - Chimeric anti-vegf-d antibodies and humanized anti-vegf-d antibodies and methods of using same: The present invention relates to materials and methods for modulating angiogenesis and lymphangiogenesis. The compositions of the invention provide chimeric and/or humanized VEGF-D antibody substances, antibodies, polypeptides and fragments thereof useful for modulating angiogenesis and lymphangiogenesis in a subject.... Agent: Marshall, Gerstein & Borun LLP

20090155263 - Compositions and methods for the treatment of immune related diseases: The present invention relates to compositions containing novel proteins and methods of using those compositions for the diagnosis and treatment of immune related diseases.... Agent: Goodwin Procter LLP Attn: Patent Administrator

20090155262 - Cytotoxicity mediation of cells evidencing surface expression of cd63: This invention relates to the diagnosis and treatment of cancerous diseases, particularly to the mediation of cytotoxicity of tumor cells; and most particularly to the use of cancerous disease modifying antibodies (CDMAB), optionally in combination with one or more chemotherapeutic agents, as a means for initiating the cytotoxic response. The... Agent: Mchale & Slavin, P.A.

20090155259 - Extending time to disease progression or survival in cancer patients: The present application describes extending time to disease progression or survival in a cancer patient, where the patient's cancer displays HER activation, by treating the patient with a HER dimerization inhibitor, such as pertuzumab.... Agent: Genentech, Inc.

20090155249 - Humanized antibody igg1: The present invention is related to chimeric and humanized antibody and to methods and compositions for the therapeutic and diagnostic use in the treatment of amyloidosis, a group of disorders and abnormalities associated with amyloid protein such as Alzheimer's disease.... Agent: Jones Day

20090155257 - Immunoglobulin variants and uses thereof: The invention provides humanized and chimeric anti-CD20 antibodies for treatment of CD20 positive malignancies and autoimmune diseases.... Agent: Morrison & Foerster LLP

20090155256 - Immunotherapy regimes dependent on apoe status: The invention provides methods of immunotherapy of Alzheimer's and similar diseases in which the regime administered to a patient depends on the ApoE genotype of the patient.... Agent: Townsend And Townsend And Crew, LLP

20090155265 - Method for treating multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione in combination with antibodies: Methods of treating, preventing and/or managing cancer as well as and diseases and disorders associated with, or characterized by, undesired angiogenesis are disclosed. Specific methods encompass the administration of an immunomodulatory compound alone or in combination with a second active ingredient. The invention further relates to methods of reducing or... Agent: Jones Day

20090155261 - Methods and compositions for treatment and diagnosis of encephalitis or epilepsy: This invention provides methods of diagnosing or determining a cause of an autoimmune encephalitis or an epilepsy in a subject and of diagnosing a tumor in a subject, comprising the step of testing a biological sample of the subject for an antibody to an NR1 subunit of the NMDA receptor.... Agent: Pearl Cohen Zedek Latzer, LLP

20090155247 - Methods of using death receptor agonists and egfr inhibitors: Methods for using death receptor ligands, such as Apo-2 ligand/TRAIL polypeptides or death receptor antibodies, and EGFR inhibitors to treat pathological conditions such as cancer are provided. Embodiments of the invention include methods of using Apo2L/TRAIL or death receptor antibodies such as DR5 antibodies and DR4 antibodies in combination with... Agent: Genentech, Inc.

20090155250 - Monoclonal antibodies against orthopoxviruses: The present invention relates to monoclonal antibodies that bind or neutralize Orthopoxviruses. The invention provides such antibodies, fragments of such antibodies retaining B5 or A33 binding ability, fully human antibodies retaining B5 or A33 binding ability, and pharmaceutical compositions including such antibodies. The invention further provides for isolated nucleic acids... Agent: Knobbe, Martens, Olson & Bear, LLP

20090155264 - Novel composition and methods for the treatment of psoriasis: The present invention relates to compositions containing a novel protein and methods of using those compositions for the diagnosis and treatment of psoriasis.... Agent: Goodwin Procter LLP Attn: Patent Administrator

20090155258 - Peptide-based passive immunization therapy for treatment of atherosclerosis: The present invention relates to passive immunization for treating or preventing atherosclerosis using an isolated human antibody directed towards at least one oxidized fragment of apolipoprotein B in the manufacture of a pharmaceutical composition for therapeutical or prophylactical treatment of atherosclerosis by means of passive immunization, as well as method... Agent: Gauthier & Connors, LLP

20090155251 - Polypeptide compounds for inhibiting angiogenesis and tumor growth: In certain embodiments, this present invention provides polypeptide compositions, and methods for inhibiting Ephrin B2 or EphB4 activity. In other embodiments, the present invention provides methods and compositions for treating cancer or for treating angiogenesis-associated diseases.... Agent: Ropes & Gray LLP

20090155260 - Use of thymosin alpha 1 for the treatment of immunological diseases: It is described the use of thymosin alpha 1 for preparing a medicament useful for the prevention or treatment of graft-versus-host disease or graft rejection reactions in organ transplantation, in a mammal subject, in which the cells, tissues or organs for transplant is selected from the group comprising: stem cells,... Agent: Lucas & Mercanti, LLP

20090155270 - Caspase inhibitors, especially caspase 3 inhibitors, for the treatment of influenza: The invention relates to the use of at least one caspase inhibitor, in particular a caspase-3 inhibitor, for preparing a pharmaceutical composition for the prophylaxis or therapy of a viral infection, in particular an infection with an RNA negative-strand virus, preferably an influenza infection, and to a test system for... Agent: Mayer & Williams PC

20090155268 - Growth factor binding constructs materials and methods: The present invention provides materials and methods for antagonizing the function of vascular endothelial growth factor receptors, platelet derived growth factor receptors and other receptors. Soluble binding constructs able to bind vascular endothelial growth factors, platelet derived growth factors, and other ligands are provided.... Agent: Marshall, Gerstein & Borun LLP

20090155269 - Growth factor binding constructs materials and methods: The invention relates to fusion proteins comprising a stress protein fused with an engineered antibody or fragment that binds to mesothelin, or a stress protein fused with a biotin-binding protein in combination with a biotinylated engineered antibody or fragment that binds to mesothelin. The invention also relates to fusion proteins... Agent: Edwards Angell Palmer & Dodge LLP

20090155271 - Il-17a and il-17f antagonists and methods of using the same: The present invention relates antagonists of IL-17A and IL-17F. The antagonists of the invention are based on IL-17RC alone or on both IL-17RC and IL-17RA (“IL-17RC/IL-17RA”). Such antagonists serve to block, inhibit, reduce, antagonize or neutralize the activity of IL-17F, IL-17A, or both IL-17A and IL-17F. IL-17A and IL-17F are... Agent: Townsend And Townsend And Crew LLP

20090155266 - Methods and compositions relating to vascular endothelial growth factor and th2 mediated inflammatory diseases: The present invention includes compositions and methods for the treatment of a Th2 mediated inflammatory disease, relating to inhibiting a VEGF. The invention further includes methods to identify new compounds for the treatment of a Th2 mediated inflammatory disease, including, but not limited to, asthma and the like. This is... Agent: Cooley Godward Kronish LLP Attn: Patent Group

20090155267 - Molecule and chimeric molecules thereof: The present invention relates generally to the fields of proteins, diagnostics, therapeutics and nutrition. More particularly, the present invention provides an isolated protein molecule which comprises a C-type lectin or an EGF-like domain such as amphiregulin, CD209L, Langerin, L-selectin or chimeric molecules thereof comprising at least a portion of the... Agent: Seed Intellectual Property Law Group PLLC

20090155274 - Human anti-ngf neutralizing antibodies as selective ngf pathway inhibitors: This invention provides antibodies that interact with or bind to human nerve growth factor (NGF) and neutralize the function of NGF thereby. The invention also provides pharmaceutical compositions of said antibodies and methods for neutralizing NGF function, and particularly for treating NGF-related disorders (e.g., chronic pain) by administering a pharmaceutically... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20090155273 - Remedies for inflammatory bowel diseases: Antibodies against AILIM (also called ICOS and 8F4) were found to significantly suppress the onset of inflammatory bowel diseases (especially Crohn's disease and colitis (ulcerative colitis and such)), and exhibit a significant therapeutic effect against inflammatory bowel diseases.... Agent: Fish & Richardson PC

20090155272 - Targeted pharmaceuticals and ligands: The disclosure pertains to pharmaceuticals, more specifically, to targeted diagnostic and therapeutic formulations and ligands thereof. Such methods and composition comprise antigens that are post-translationally modified compared to antigens found on a normal cell phenotype. Also provided are ligands that bind to such post-translationally modified antigens.... Agent: Buchanan, Ingersoll & Rooney LLP

20090155275 - Multispecific epitope binding proteins and uses thereof: The present invention relates to multispecific epitope binding proteins, methods of making, and uses thereof in the prevention, management, treatment or diagnosis of acute or chronic diseases.... Agent: Medimmune, LLC Jonathan Klein-evans

20090155276 - Novel dkkl-1 splice product modulators for cancer diagnosis and therapy: The present invention relates to novel sequences for use in detection, diagnosis and treatment of diseases, including cancer. The invention provides novel splice products of human DKKL-1 gene. The present invention provides methods of using polynucleotides having the novel splice products of the human DKKL-1 sequences, their corresponding gene products... Agent: Novartis Vaccines And Diagnostics Inc.

20090155282 - Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof: The present invention relates to novel antibodies, particularly antibodies directed against deletion mutants of epidermal growth factor receptor and particularly to the type III deletion mutant, EGFRvIII. The invention also relates to human monoclonal antibodies directed against deletion mutants of epidermal growth factor receptor and particularly to EGFRvIII. Diagnostic and... Agent: Knobbe Martens Olson & Bear LLP

20090155278 - Claudins as markers for early detection, diagnosis, prognosis and as targets of therapy for breast and metastatic brain or bone cancer: Methods of diagnosis, prognosis, and treatment of breast cancer, and of metastatic brain cancer, are provided The diagnostic and prognostic methods involve the immunohistochemical detection of the level of expression of the proteins claudin 1, 3, 4, and 7 in tissue or cell samples. Claudins 1 and 7 are underexpressed... Agent: Whitham, Curtis & Christofferson & Cook, P.C.

20090155280 - Immunoglobulin cleavage fragments as disease indicators and compositions for detecting and binding such: The invention relates to antibody compositions and use of the composition to detect disease processes associated with elaboration of proteases. The reagents are directed to assessing an IgG breakdown product that is the result of such proteolytic cleavage. The invention further relates to the use of a therapeutic immunospecific for... Agent: Philip S. Johnson Johnson & Johnson

20090155281 - Methods of using antibodies that bind both bcma and taci: Molecules that interfere with the binding of a tumor necrosis factor receptor with its ligand, such as a soluble receptor or an anti-receptor antibody, have proven usefulness in both basic research and as therapeutics. The present invention provides antibodies that bind two tumor necrosis factor receptor family members: the transmembrane... Agent: Zymogenetics, Inc. Intellectual Property Department

20090155279 - Pseudomonas aeruginosa outer membrane protein pa5158: An object of the present invention is to provide a protein or peptide antigen and an antibody against it, for use in the diagnosis, prevention, or treatment of diseases associated with Pseudomonas aeruginosa. According to the present invention, there is provided a protein or peptide derived from Pseudomonas aeruginosa outer... Agent: Wenderoth, Lind & Ponack, L.L.P.

20090155277 - Use of immunesuppressant receptor:

20090155283 - Noncompetitive domain antibody formats that bind interleukin 1 receptor type 1: The invention relates to dAb monomers that bind IL-1R1 and inhibit binding of IL-1 (e.g., IL-1α and/or IL-1β) to the receptor but do not inhibit binding of IL-1ra to IL-1R1, and to ligands comprising such dAb monomers. The invention relates to protease resistand dAb monomers, and to ligands comprising protease... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220

20090155284 - Hgf-sf monoclonal antibody combinations: The present invention provides a combination of anti-HGF/SF antibodies that specifically bind HGF/SF and inhibits HGF/SF activity. The present invention further provides a combination of anti-HGF/SF antibodies comprising three or more anti-HGF/SF antibodies selected from the group consisting of: antibody #1 produced from hybridoma 1C10-F1-A11, antibody #4 produced from hybridoma... Agent: National Institute Of Health C/o Ballard Spahr Andrews & Ingersoll, LLP

20090155285 - Tgf-beta binding antibodies: The present invention provides very high affinity antibodies, or antigen-binding fragments thereof, that neutralize mature human TGF-β1, TGF-β2, and TGF-β3. The antibodies of the invention are useful for treating cell proliferative disorders in a mammal.... Agent: Eli Lilly & Company

20090155288 - Methods of identifying combinations of antibodies with an improved anti-tumor activity and compositions and methods using the antibodies: A method of identifying a combination of antibodies with a combined improved anti tumor activity is provided. The method comprising identifying at least two anti RTK antibodies capable of inducing synergistic endocytosis of the RTK in a cell expressing the RTK, thereby identifying the combination of antibodies with the combined... Agent: Martin D. Moynihan D/b/a Prtsi, Inc.

20090155287 - Modified vaccinia virus strains for use in diagnostic and therapeutic methods: Modified viruses and methods for preparing the modified viruses are provided. Vaccines that contain the viruses are provided. The viruses can be used in methods of treatment of diseases, such as proliferative and inflammatory disorders, including cancer, and as anti-tumor and/or antiangiogenic agents. The viruses also can be used in... Agent: Bell, Boyd & Lloyd LLP

20090155286 - Type i interferon blocking agents for prevention and treatment of psoriasis: The discovery of plasmacytoid dendritic cell precursors (PDC) as crucial effector cells with high production of type I interferons (IFNs) in early psoriasis development has led to the present invention that blocking of type I IFNs can be used for prevention and therapy of psoriasis. The invention relates to the... Agent: Goodwin Procter LLP Attn: Patent Administrator

20090155290 - Antigen: The present invention relates to a novel method for the delivery of agents to tumour cells. In particular it relates to a method for the specific delivery of agents to the interior of tumour cells. Uses of the method are also described.... Agent: Marshall, Gerstein & Borun LLP

20090155289 - Furin-cleavable peptide linkers for drug-ligand conjugates: Disclosed are certain peptide linkers for conjugating drugs to ligands, and the resulting drug-linker-ligand molecules and compositions thereof. The conjugated molecules useful for the targeted delivery of drugs to the desired cells, and allow for the intracellular release of the drug in cases where the targeted antigen is internalized via... Agent: M. Elisa Lane Panacea Pharmaceuticals, Inc.

20090155291 - Method of increasing immunological effect: A method of increasing immunological effect in a patient by administering an effective amount of a primary cell derived biologic to the patient, inducing immune production, blocking immune destruction, and increasing immunological effect in the patient. Methods of treating an immune target, treating a tumor, immune prophylaxis, and preventing tumor... Agent: Kohn & Associates, PLLC

20090155292 - Compositions and methods for the prevention and treatment of autoimmune conditions: The methods include selectively reducing or expanding T cells according to the antigenic specificity of the T cells. Therefore, the present invention can be used to reduce or eliminate pathogenic T cells that recognize autoantigens, such as beta cell specific T cells. As such, the present invention can be used... Agent: Fulbright & Jaworski L.L.P.

20090155293 - Modified defensins and their use: This disclosure provides modified antimicrobial agents, for example modified defensin polypeptides. In one embodiment, compositions including a modified arginine residue, such as an ADP-ribosylated and/or ribosylated alpha defensin polypeptide, are provided. Also provided are methods of modulating an immune response using the modified defensin polypeptides. In one embodiment, a method... Agent: Klarquist Sparkman, LLP

20090155294 - Hcv vaccines: Disclosed are methods and compositions for inducing immune responses against Hepatitis C virus (HCV). The compositions comprise one or more epitope from a hotspot epitope. In certain embodiments, an HCV vaccine comprising at least two epitopes, each from a different hotspot epitope, is provided.... Agent: Fulbright & Jaworski L.L.P.

20090155296 - Mutants of lysine decarboxylase, vaccines for periodontitis, and methods of use: The present invention is directed to mutants of lysine decarboxylase, nucleic acids encoding the mutants, and vaccines comprising the mutants for inhibiting and reducing the development of periodontal diseases, including gingivitis and chronic periodontitis. The vaccine composition comprises a recombinant lysine decarboxylase mutant which is based on a native version... Agent: Dunlap Codding, P.C.

20090155295 - Vaccine: A polypeptide derived from the periplasmic space of Yersinia pestis or a fragment or a variant of said polypeptide for use as a medicament is described. Pharmaceutical compositions comprising such polypeptides, such as OppA from Yersinia pestis, are also described and claimed. In a preferred embodiments the pharmaceutical composition further... Agent: John S. Pratt, Esq Kilpatrick Stockton, LLP

20090155298 - Matrix metalloproteinase 11 vaccine: Compositions comprising matrix metalloproteinase 11 (MMP-11) or stromelysin-3 (ST-3) or the nucleic acid en->coding the MMP-11 for use in vaccines for treating tumors and cancers, which overexpress MMP-11, are described. In particular embodiments, the compositions comprise a nucleic acid encoding a fusion polypeptide that includes the catalytically inactivated MMP-11 linked... Agent: Merck And Co., Inc

20090155297 - Methods and compositions for inducing an immune response against multiple antigens: m

20090155299 - Antibodies for the detection of bacillus anthracis and vaccine against b. anthracis infections: The present invention relates to conjugates of oligosaccharides of formula 1, wherein R is a linker to a carrier protein and optionally comprises up to three further saccharides, 5 and which are useful for vaccination, methods of synthesis of such conjugates, antibodies against this antigen, hybridoma producing monoclonal antibodies against... Agent: Wenderoth, Lind & Ponack, L.L.P.

20090155300 - Basidiomycetes, basidiomycetes extract composition, health foods, and immunopotentiators: e

20090155302 - Antigen arrays for treatment of allergic eosinophilic diseases: The present invention is related to the fields of molecular biology, virology, immunology and medicine. The invention provides a composition comprising an ordered and repetitive antigen or antigenic determinant array, and in particular an array comprising a protein or peptide of IL-5, IL-13 or eotaxin. More specifically, the invention provides... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20090155303 - Cpg single strand deoxynucleotides for use as adjuvant: The present invention provides an adjuvant, which includes at least one single strand deoxynucleotide containing a CpG dinucleotide. The single strand deoxynucleotide comprises one or more CpG dinucleotides. When used in combination with rabies vaccine, HBV vaccine or other vaccines, the adjuvant can significantly improve the immune effect of the... Agent: Knobbe Martens Olson & Bear LLP

20090155301 - Pseudoinfectious flavivirus and uses thereof: The present invention discloses a replication-deficient pseudoinfective virus belonging to the Flaviviridae family that lack the capsid gene, where the replication-deficient pseudoinfective virus propagates only in cells expressing the capsid or capsid, prM and envelope protein of the flavivirus. The present also discloses the method of producing such viruses on... Agent: Benjamin Aaron Adler Adler & Associates

20090155304 - Modified cyanovirin-n polypeptide: This disclosure relates to a modified version of cyanovirin-N protein and a transformed Lactobacillus bacterium that is capable of recombinantly expressing this modified protein. Further disclosed are polynucleotide sequence encoding the modified cyanovirin-N protein, expression cassette that allows the expression of the modified protein, and method of make and use... Agent: Townsend And Townsend And Crew, LLP

20090155305 - Manufacture of vaccines that contain both hepatitis b virus surface antigen and surfactant: When preparing HBsAg for use in a combination vaccine, it is known to add a non-ionic detergent after the HBsAg has been purified. Adding detergents after purification of HBsAg is not optimal, however, as it requires a separate processing step during manufacture. Thus the invention uses them during HBsAg purification.... Agent: Novartis Vaccines And Diagnostics Inc.

20090155307 - Immunostimulatory nucleic acid oil-in-water formulations and related methods of use: The invention involves methods and compositions of an immunostimulatory nucleic acid in oil-in-water emulsions for topical delivery. The compositions can be used to stimulate immune responses, particularly useful in the prevention and/or treatment of infectious disease and cancer.... Agent: Wolf Greenfield & Sacks, P.C.

20090155306 - Pamps, pathogen associated molecular patterns: A method for identifying a polypeptide which acts as an adjuvant in a host organism. The invention further provides adjuvant compositions comprising said polypeptides and optionally further comprising an antigen.... Agent: Novartis Vaccines And Diagnostics Inc.

20090155309 - Novel vaccine: The invention relates to the use of a non-live influenza virus antigen preparation, particularly a split influenza virus preparation, in the manufacture of a vaccine formulation for a one-dose intranasal vaccination against influenza, wherein the one-dose vaccination meets international regulatory requirements for influenza vaccines. Further provided are methods for the... Agent: Glaxosmithkline

20090155308 - Powerful vaccine composition comprising lipopeptide and poly i:c as an adjuvant: The present invention relates to an adjuvant comprising a lipopeptide and poly I:C. When the adjuvant of the present invention is used, the level of antigen specific antibody induction is synergistically increased and Th1 type immune response is also induced. Therefore, the adjuvant of the present invention can be very... Agent: The Nath Law Group

20090155310 - Hn epitope recognized by avian immune system and antigenic variant newcastle disease viruses carrying changes in the epitope: The present invention relates to an epitope of HN protein in Newcastle disease virus which can be recognized by an avian immune system and an antibody against the epitope, a method for detecting a Newcastle disease virus by using the antibody, and an antigenic variant of Newcastle disease virus carrying... Agent: LexyoumeIPGroup, LLC

20090155311 - Indoleamine 2,3-dioxygenase pathways in the generation of regulatory t cells: The present invention provides methods for the control of the generation of regulatory T cells (Tregs) and uses thereof.... Agent: Mueting, Raasch & Gebhardt, P.A.

20090155312 - Viral variants detection and application: The present invention relates generally to viral variants exhibiting reduced sensitivity to particular agents and/or reduced interactivity with immunological reagents. More particularly, the present invention is directed to hepatitis B virus (HBV) variants exhibiting complete or partial resistance to nucleoside or nucleotide analogs and/or reduced interactivity with antibodies to viral... Agent: Scully Scott Murphy & Presser, PC

20090155313 - Vaccine against salmonid rickettsial septicaemia based on arthrobacter cells: A vaccine based on live Arthrobacter cells is useful in preventing piscirickettsiosis in fish.... Agent: Womble Carlyle Sandridge & Rice, PLLC

20090155314 - Dermal filler: Improved dermal filler formulation comprising a hyaluronic acid and a botulinum toxin.... Agent: Allergan, Inc.

20090155315 - Pharmaceutical product: A pharmaceutical and pharmaceutical-like product is provided. The product provides a plurality of components having active agents that are delivered in a single delivery entity or vehicle. The product allows for selective control of the release rates of each of the active agents while still being delivered in a single... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220

20090155321 - Compositions with encapsulated coloring agents and method to impart a healthy skin appearance: A cosmetic composition and method of imparting a healthy appearance to skin is provided which includes using a composition formed with about 0.1 to about 20% by weight of the composition of beads, from about 1 to about 80% by weight of the beads of a first coloring agent incorporated... Agent: Unilever Patent Group

20090155317 - Cosmetic or demopharmaceutical composition comprising enkephalin-derived peptides to reduce and/or eliminate facial wrinkles: c

20090155319 - Method for producing cosmetic and/or dermatological powder: A cosmetic or dermatological powder, which comprises (i) from 61 to 99.99% by weight is relative to the total weight of the powder of at least one starch modified by a combination of esterification and heat-moisture treatment, (ii) from 0.01 to 29.99% by weight is relative to the total weight... Agent: Merchant & Gould PC

20090155320 - Method for producing hydroxyapatite particles: This invention relates generally to a preparation of bone repair compositions, and more special refers to a novel technology in preparing a matrix building polymer i.e. collagen with inclusions of hydroxyapatite particles as biomaterial for medical applications. In this composition that consists of hydroxyapatite particles embedded in a matrix at... Agent: Demont & Breyer, LLC

20090155316 - Oral wash: An oral wash comprising an aqueous dispersion of transition metal fineparticles such as platinum colloid. The wash is capable of conveniently and quickly eliminating active oxygen species which causes damages of mucosa in the oral cavity, periodontium, and the like.... Agent: Greenblum & Bernstein, P.L.C

20090155318 - Process to form nano-sized materials, the compositions and uses thereof: Various embodiments of the invention include systems and methods of generating nano-sized salt particles. These methods include generation of a supersaturated solution of a salt MX by mixing of salts MY and NX in which the solubility of MX is lower than that of MY, NX or NY. In some... Agent: Peters Verny , L.L.P.

20090155322 - Self-tanning effects: A cosmetic composition and method is herein described for sunless tanning to impart a glow/shiny effect on skin. The composition includes a sunless tanning agent and coated beads incorporating tan colored pigment. A colorant which imparts a color other than tan to the beads is distributed within the coating. The... Agent: Unilever Patent Group

20090155323 - Skin cosmetic composition: A skin cosmetic composition comprising: a hydrogel particle comprising a non-crosslinked hydrogel containing an oil component therein dispersed in an aqueous medium; a hydrogel particle comprising a non-crosslinked hydrogel containing an oil component therein; and a process for preparing a hydrogel particle comprising the steps of discharging an oil component-emulsified... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20090155325 - Formulation and products for promoting skin cleanliness and health: The present disclosure generally relates to a formulation. More particularly, the formulation may be applied to skin and/or used in combination with a personal care product to improve absorbance and leakage control of the personal care product, and to promote a more positive feel and comfort through improved skin cleanliness... Agent: Christopher M. Goff (27839) Armstrong Teasdale LLP

20090155326 - Layered drug delivery polymer monofilament fibers: The present invention is directed generally to a layered polymeric monofilament fiber drug delivery device, where each layer of the device can contain a different polymer, drug, additive, or any combination or mixture thereof. The layered nature of the current monofilament polymeric monofilament device provides the capability to modulate the... Agent: Kauth , Pomeroy , Peck & Bailey ,llp

20090155324 - Skin treatment system: A skin treatment system includes a flexible panel having an outer surface and an inner surface. The flexible panel may be configured to surround at least a portion of a user's appendage. The skin treatment system may also include at least one skin treatment insert having an inner surface and... Agent: Holland & Knight LLP

20090155327 - Self-indicating wipe for removing bacteria from a surface: A wipe that includes a bacteriostatic agent that contains cations having an affinity for the negatively charged cell walls of bacteria is provided. The affinity of the bacteriostatic agent for the bacteria allows the wipe to capture bacteria, thereby removing them from a surface and also inhibiting their spread to... Agent: Dority & Manning, P.A.

20090155328 - Films comprising antimicrobial and fungistatic agents: A process for producing a film having incorporated or applied thereon or therein an antimicrobial agent and a liquid additive is provided wherein the film comprises a liquid absorbent layer and an impermeable layer are provided. The films can be used for producing a tubular casing or shrinkbag such as... Agent: E I Du Pont De Nemours And Company Legal Patent Records Center

20090155329 - Novel e. coli bacteriophage and uses thereof: The present invention is directed to isolated bacteriophage having strong lytic activity against strains of E. coli, and methods of using that bacteriophage, and/or progeny or derivatives derived therefrom, to control the growth of E. coli in various settings.... Agent: Hunton & Williams LLP Intellectual Property Department

20090155331 - Injectable nanoparticulate olanzapine formulations: Described are injectable formulations of particulate olanzapine that produce a prolonged duration of action upon administration, and methods of making and using such formulations. The injectable formulations comprise particulate olanzapine.... Agent: Fox Rothschild, LLP Elan Pharma International Limited

20090155330 - Vaccine delivery via microneedle arrays: A microprojection array is provided, comprising an approximately planar base and a plurality of microprojections, wherein the array comprises a vaccine and a polymeric material. The array may have multiple layers. The vaccine may be placed in only one layer. In another embodiment of the invention, a method of preventing... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.c

20090155333 - Dermis-derived cells for tissue engineering applications: Methods for inducing differentiation of dermis-derived cells to serve as a source of chondrocytes and associated methods of use in forming tissue engineered constructs. One example of a method is a method for inducing differentiation of cells into chondrocytes comprising providing aggrecan sensitive isolated dermis cells and seeding the cells... Agent: Baker Botts, LLP

20090155334 - Implant for tissue engineering: The invention provides a process for the production of a monolithic implant for use in tissue engineering, the process comprising the steps of plasticising at least one biocompatible material into a paste, extruding the paste through a die, and drying the extruded material to eliminate an aqueous and/or non-aqueous component.... Agent: Hunton & Williams LLP Intellectual Property Department

20090155336 - Neuromodulatory methods for treating pulmonary disorders: A method for treating a pulmonary disorder in a subject includes inserting a therapy delivery device into a vessel of the subject, advancing the therapy delivery device to a point adjacent an intraluminal target site of the autonomic nervous system, and activating the therapy delivery device to delivery a therapy... Agent: Tarolli, Sundheim, Covell & Tummino L.L.P.

20090155335 - Non-leaching non-fouling antimicrobial coatings: Compositions containing one or more types of membrane-targeting antimicrobial agents immobilized on a substrate with activity in relevant biological environments, and methods of making and using thereof, are described herein. The antimicrobial agents retain their activity in the presence of blood proteins and/or in vivo due to improved molecular structures... Agent: Pabst Patent Group LLP

20090155332 - Replacement bone tissue: Bone replacement tissue suitable for bone grafting procedures, said bone replacement tissue being grown in a host until suitable for translocation into a desired position in a patient, and methods for manufacturing said bone replacement tissue.... Agent: Kohn & Associates, PLLC

20090155337 - Method and agent for in-situ stabilization of vascular tissue: A method for stabilizing an extra cellular matrix layer in the vascular system of the body is disclosed herein. The method can comprise placing a vascular catheter adjacent to the extra cellular matrix layer, delivering a solution containing a bioflavonoid to the extra cellular matrix layer with the vascular catheter,... Agent: Knobbe Martens Olson & Bear LLP

20090155338 - Chronotherapeutic ocular delivery system comprising a combination of prostaglandin and a beta-blocker for treating primary glaucoma: Chronotherapeutic delivery system for treating primary open-angle glaucoma, comprising a delivery system incorporating pharmaceutical products for delivery to an eye in the treatment of primary open-angle glaucoma (POAG), comprising: (a) a biocompatible erodible material incorporating a therapeutically-effective amount of a prostaglandin analogue, and (b) a reservoir containing a therapeutically-effective amount... Agent: Wiggin And Dana LLP Attention: Patent Docketing

20090155339 - Biocompatible antimicrobial filament material: r

20090155340 - Method of cell storage in a delivery system: Cell storage and delivery systems and methods for storing and delivering viable cells to a mammal are disclosed. The cell storage and delivery systems include a biodegradable and/or bioabsorbable fibrous matrix physically associated with viable cells to contain and release the cells at a controlled rate. The biodegradable and/or bioabsorbable... Agent: Hoffmann & Baron, LLP

20090155341 - Medical device and a method for applying a biochemically active material on one or more body parts: A medical device having a sleeve-shaped elastic body which is rolled up to form an annular structure and may be rolled down to annularly contacting one or more body parts, such as limbs, a biochemically active material, such as a disinfecting material, added substantially to a portion of the sleeve-shaped... Agent: Martin D. Moynihan D/b/a Prtsi, Inc.

20090155342 - Mineral technologies (mt) for acute hemostasis and for the treatment of acute wounds and chronic ulcers: Compositions comprising clay minerals and methods for their use in promoting hemostasis are provided. The compositions comprise clay minerals such as bentonite, and facilitate blood clotting when applied to a hemorrhaging wound. Electrospun or electrosprayed materials (e.g. bandages, micron beads, etc.) which include clay minerals, and methods for the treatment... Agent: Venable LLP

20090155343 - Tamsulosin-containing transdermal patch: A tamsulosin-containing transdermal patch. A transdermal patch comprising a backing-layer and an adhesive layer on the backing-layer, characterized in that the adhesive layer contains an acrylic adhesive, further contains tamsulosin as an active ingredient in an amount of 0.1 to 20% by mass of the total mass of the adhesive... Agent: Oliff & Berridge, PLC

20090155350 - Chlamydia antigens and protein vaccine: The present invention provides vaccines for immunizing a host, including humans, against disease caused by infection by a strain of Chlamydia, specifically C. pneumoniae. The vaccine and method employ a full-length, 5′-truncated or 3′-truncated 76 kDa protein of a strain of Chlamydia pneumoniae. Modifications are possible within the scope of... Agent: Smart & Biggar P.o. Box 2999, Station D

20090155347 - Cosmetic composition for stimulating the synthesis of proteins of the basement membrane: Cosmetic composition which can be applied topically, comprising at least one compound of the general formula (I) in which R1 is H, C1-C20-alkyl, cycloalkyl or aryl-C1-C4-alkyl, n is 1-4, X is —O—, —NH— or —NR2— and R2H or C1-C20-alkyl; and at least one compound corresponding to the above formula (I)... Agent: Birch Stewart Kolasch & Birch

20090155348 - Detoxified recombinant botulinum neurotoxin: The present invention relates to the isolation of polypeptides derived from the Clostridium botulinum neurotoxin and the use thereof as immunogens for the production of vaccines and antitoxins, as well as research and drug development applications. Clostridium botulinum is responsible for food bone botulism, a severe and often deadly disease.... Agent: Medlen & Carroll, LLP

20090155345 - Methods for affecting liposome composition ultrasound irradiation: The present invention provides methods for loading of agents and substances into per-formed liposomes, preferably a suspension of pre-formed liposomes as well as to methods for the controlled quantum (step-wise) release of agents and substances from liposomes. One of the principle features of the methods of the invention is to... Agent: Brooks Kushman P.C.

20090155349 - Methods of treating influenza viral infections: wherein R1 and R2 each independently represents a hydrogen, a lower alkyl, a lower acyl, an alkylene, or —OR1 and —OR2 each independently represents an unsubstituted or substituted amino acid residue or pharmaceutically acceptable salt thereof; R3, R4, R5, R6, R10, R11, R12 and R13 each independently represents a hydrogen,... Agent: Darby & Darby P.C.

20090155344 - Preparation and application of biodegradable-material-made microsphere vascular embolus containing liposome-encapsulated cytokines: The present invention discloses preparation and application of a kind of biodegradable-material-made microsphere vascular embolus that contains liposome-encapsulated cytokines. The present invention is technologically characterized by encapsulation of liposome-wrapped immunocytokines such as IL-2, TNF and interferon by sodium polysaccharide or gelatin, which is extracted from natural alga and is good... Agent: Thomas, Kayden, Horstemeyer & Risley, LLP

20090155346 - Preparation of powders containing colloidal particles: The invention discloses a method for preparing a powder from an aqueous liquid which comprises colloidal particles. The method is based on the use of dense-phase extraction media, i.e. near-critical or supercritical fluids. The powder obtained through the method can be reconstituted with an appropriate aqueous liquid to yield a... Agent: Young & Thompson

20090155352 - Microemulsion containing indolocarbazole compound and dosage forms containing the same: The invention described herein provides a pharmaceutical composition and oral dosage forms containing the same, having high concentrations of solubilized indolocarbazole compounds as the active ingredient in microemulsion form. The invention also provides a process for increasing the solubilized concentration of indolocarbazole compounds such as lestaurtinib using the addition of... Agent: Ross J. Oehler Cephalon, Inc.

20090155353 - Microemulsions for pharmaceutical compositions: The invention provides microemulsion pharmaceutical compositions comprising pharmaceutical actives which are hydrotropes that facilitate formation of microemulsions. The invention further provides methods of making the compositions and utilization of the compositions in liquid fill soft shell capsules including capsules having shells of non-animal derived materials (e.g. non-ADRM).... Agent: Wyeth Patent Law Group

20090155351 - Solid vaccine formulation: The invention relates to a solid vaccine formulation adapted for mucosal administration comprising at least one antigen as active substance, wherein the formulation comprises a lyophilisate of a suspension comprising an oxygen-containing metal salt, the antigen(s) and one or more excipients selected from (i) saccharides, (ii) sugar alcohols, and (iii)... Agent: Birch Stewart Kolasch & Birch

20090155354 - Dispensing encapsulated liquids into body cavities: Body tissue or cavities are treated by inserting a membrane module containing a substance for treating a condition of the cavity or tissue. The substance is enclosed in a membrane that melts, dissolves, or dissipates in the environment of the cavity such as a vagina to release the substance into... Agent: Marvin E. Jacobs, Esq.

20090155355 - Particles in a capsule: The invention relates to a capsule containing a heterogeneous mixture of active agents in the form of particles suspended in a liquid matrix and optionally active ingredients in the liquid matrix; the liquid matrix occupying less than the total internal volume of the capsule. The present invention further describes a... Agent: Torys LLP

20090155356 - Thixotropic oil based vehicle for pharmaceutical compositions: The present invention relates to a novel thixotropic oily vehicle comprising between about 0.2% to about 5% (w/w) of a colloidal silica and between about 0.2% to about 5% (w/w) of a hydrophilic polymer in an edible oil. The interaction between the hydrophylic polymer and the colloidal silica in the... Agent: Hoffmann-la Roche Inc. Patent Law Department

20090155357 - Alcohol resistant pharmaceutical formulations: The present invention provides alcohol resistant oral dosage pharmaceutical forms and methods of using such oral dosage forms to avoid dose dumping if the dosage form is taken together with alcohol.... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20090155358 - Pharmaceutical compositions of short-acting hypnotic agents in modified-release forms and the procedures to prepare the mentioned formulation: This application refers to a modified-release pharmaceutical composition containing, as the active agent, a short-acting hypnotic agent or a pharmaceutically acceptable salt thereof, comprising two sustained-release pharmaceutical entities, differentiated from each other by a different release rate of the active agent wherein the release of the active agent from one... Agent: Patent Central LLC Stephan A. Pendorf

20090155359 - Granulated particles, tablets and method for producing granulated particles: The present invention relates to granulated particles including a poorly water soluble drug (A) and a diluent (B) and characterized in that a volume average particle size of the particles of the poorly water soluble drug (A) and the particles of the diluent (B) is within the range of 0.01... Agent: Merchant & Gould PC

20090155360 - Orally disintegrating tablets comprising diphenhydramine: The compositions of the present invention comprise a therapeutically effective amount of particles consisting of diphenhydramine or pharmaceutically acceptable salts thereof, optionally in combination with another drug such as pseudoephedrine, or phenylephrine and hydrocodone, in combination with rapidly-dispersing microgranules comprising a disintegrant and a sugar alcohol and/or a saccharide. These... Agent: Cooley Godward Kronish LLP Attn: Patent Group

20090155361 - Tablet with multiple drug-containing sections: A tablet which is either a two-layer tablet comprising a layer A and a layer B or a three-layer tablet comprising a layer A, a layer B and a layer C in that order, wherein the layer B is a medicinal additive layer, the layer A and the layer C... Agent: Sughrue Mion, PLLC

20090155362 - Method of cross-linking hyaluronic acid with divinulsulfone: The present invention relates to methods of producing a homogenous hydrogel comprising hyaluronic acid, or salt thereof, crosslinked with divinylsulfone (DVS), said method comprising the steps of (a) providing an alkaline solution of hyaluronic acid, or salt thereof; (b) adding DVS to the solution of step (a), whereby the hyaluronic... Agent: Novozymes North America, Inc.

20090155363 - Methods for oral administration of active drugs: The present invention relates to methods that facilitate the oral administration of active drugs to a patient. Specifically, the methods of the present invention may utilize compositions comprising an active drug and a gelling agent that provides an easily consumable gel dosage form and the active drug is homogenously mixed... Agent: Don J. Pelto Sheppard, Mullin, Richter & Hampton LLP

20090155364 - Transdiscal administration of anti-tnfalpha antibodies and growth differentiation factors: The present invention relates to injecting a high specificity cytokine antagonist into a diseased intervertebral disc.... Agent: Hamilton, Brook, Smith & Reynolds, P.C.

20090155365 - Method for remotely controlling a sol-gel transition of hydrogels and method for delivering a drug using the same: The present invention relates to a method for remotely controlling a sol-gel transition of hydrogels and a method for delivering a drug using the same. More specifically, the invention relates to a method of remotely controlling a sol-gel transition of polyethylene glycol (PEG)-containing hydrogels—three-dimensional networks of crosslinked polymer chains—by X-ray... Agent: Harness, Dickey & Pierce, P.L.C

20090155366 - Osteoinductive materials: The present invention concerns improved osteoinductive materials comprising matrix materials and morphogenetic roteins, wherein depending on the subject matter the proteins may be dimeric or monomeric proteins. The osteoinductive materials according to the present invention have improved properties. The invention further concerns methods for producing the respective improved osteoinductive materials.... Agent: Rothwell, Figg, Ernst & Manbeck, P.C.

20090155367 - Occlusion of fallopian tubes: The present invention provides a method for inducing Fallopian tube blockage as a means for female contraception. The method comprises contacting the inner surface tissue of a Fallopian tube with a silver nitrate bearing substrate, delivering an amount of silver nitrate to the tissue sufficient to induce blockage of the... Agent: Olson & Cepuritis, Ltd.

20090155368 - Pharmaceutical compositions: The present invention relates to crosslinked polyamine particles and/or pharmaceutical compositions comprising, at least in part, crosslinked polyamine particles and aggregates of such particles (including cured aggregates of crosslinked polyamine particles). The compositions may be in the form of tablets comprising, for example, particles larger than 500 μm, and used... Agent: Jones Day

20090155369 - Pharmaceutical composition containing levodopa, entacapone and carbidopa: The present invention refers to a solid pharmaceutical composition of entacapone, levodopa and carbidopa or pharmaceutically acceptable salts thereof characterized in that entacapone is in the form of granules and it is added separately to levodopa and carbidopa. In addition, this invention provides the process for its preparation.... Agent: Moore & Van Allen PLLC

20090155371 - Compositions comprising solid particles entrapped in collapsed polymeric microspheres, and methods of making the same: The present invention relates to topical compositions containing solid particles that are stabilized via entrapment by microspheres. Each of the microspheres contains a collapsed polymeric shell that has entrapped therein one or more solid particles. The solid particles are preferably formed of zinc oxide or titanium dioxide or both, which... Agent: Mimi Yang

20090155372 - Method of manufacturing modified release dosage forms: In one embodiment a dosage form comprises at least one active ingredient and a molded matrix which comprises 10-100% of a material having a melting point of less than about 100 degrees C. selected from the stamp consisting of thermoplastic polyalkylene oxides, low melting hydrophobic materials, thermoplastic polymers, thermoplastic starches... Agent: Philip S. Johnson Johnson & Johnson

20090155370 - Methods and compositions for selectively removing potassium ion from the gastrointestinal tract of a mammal: The present invention provides methods and compositions for the treatment of ion imbalances using core-shell composites and compositions comprising such core-shell composites. In particular, the invention provides core-shell particles and compositions comprising potassium binding polymers, and core-shell particles and compositions comprising sodium binding polymers, and in each case, pharmaceutical compositions... Agent: Senniger Powers LLP

20090155373 - Cosmetic compositions and method which impart a healthy appearance to skin: A cosmetic product and method of imparting a healthy appearance to skin is provided which includes using a composition formed with about 0.1 to about 20% by weight of the composition of beads, from about 1 to about 80% by weight of the beads of a coloring agent incorporated within... Agent: Unilever Patent Group

20090155374 - Nanoparticles for protein drug delivery: The invention discloses the nanoparticles composed of chitosan, poly-glutamic acid, and at least one protein drug or bioactive agent characterized with a positive surface charge and their enhanced permeability for paracellular protein drug and bioactive agent delivery.... Agent: Hosheng Tu

20090155375 - Compositions comprising a lipid and copolymer of styrene and maleic acid: A composition comprising a lipid and copolymer of styrene and maleic acid, wherein the copolymer of styrene and maleic acid is non-alternating, and wherein the polymer and lipid are in the form of macromolecular assemblies.... Agent: Smith, Gambrell & Russell

20090155376 - Protein hydrolysate with antidiabetic effect: The present invention provides compositions (blood sugar increase inhibitors) that have an action of lowering the blood sugar level of a subject in a hyperglycemic condition and are for use in lowering the blood sugar level of such a subject. Moreover, the present invention provides compositions for use in preventing... Agent: Knobbe Martens Olson & Bear LLP

20090155377 - Synergistic phytoceutical compositions: Phytoceutical compositions for the prevention and treatment of circulatory disorders, feminine endocrine disorders, and dermal disorders. A specific combination of extracts of plants is taught, as well as principles for varying the formulations based on categorizing plants into one of three groups, Energy, Bio-Intelligence, and Organization and selecting several plants... Agent: Baker & Mckenzie LLP

20090155378 - Osteoinductive demineralized cancellous bone: An osteoinductive demineralized bone matrix, corresponding osteoimplants, and methods for making the osteoinductive demineralized bone matrix are disclosed. The osteoinductive demineralized bone matrix may be prepared by providing demineralized bone and altering the collagenous structure of the bone. The osteoinductive demineralized bone matrix may also be prepared by providing demineralized... Agent: Dorsey & Whitney LLP Intellectual Property Department

20090155379 - Nutritional composition for facilitating muscle pumps: A composition for providing a method for creating and prolonging muscle pumps, providing a transducer effect for nitric oxide, increasing nutrient delivery and promoting increased vascular response in individuals. The composition of the present invention comprises citrulline, aspartic acid and creatine. In addition, the nutritional composition may also comprise L-arginine,... Agent: Iovate Health Science Research Inc.

20090155380 - Non-medicinal food additive for animals, supplemented foods containing same and method for improving animal growth: c

20090155381 - Method of treatment or prevention of age-related macular degeneration: A method of treatment and/or prevention of age-related macular degeneration (AMD) wherein, in a first step, the need for treatment or susceptibility to AMD is determined for an individual and, in a second step, a medication comprising lutein and/or zeaxanthin and/or certain antioxidants (or a mixture thereof) is tailored to... Agent: Nixon & Vanderhye, PC

20090155382 - Methods and compositions for heavy metal detoxification: Compositions and methods for enhancing heavy metal detoxification are described. The compositions and methods described provide enhanced activity of key detoxification systems including that the induction of phase II detoxification enzymes, such as glutathione S-transferases (GSTs), and NADPH quinone reductase (NQO1) activity.... Agent: Mcdermott Will & Emery LLP

20090155383 - Personal care compositions comprising undecyl sulfates: A personal care composition utilizing undecyl sulfates and/or ethoxylated undecyl sulfates (undeceth sulfates).... Agent: The Procter & Gamble Company Global Legal Department - Ip

20090155384 - Methods and compositions for the sustained release of chromium: Provided herein are compositions for the administration of chromium that include at least two components: a hydrophilic chromium complex and a lipophilic chromium complex, and methods of using the same. Also provided are compositions for the administration of chromium that include a first “fast-acting” chromium complex and a second “slow-acting”... Agent: Knobbe Martens Olson & Bear LLP

20090155385 - Methods of reducing or eliminating salmonella in reptiles and/or their eggs: A method for reducing or eliminating Salmonella in reptiles and/or reptile eggs through the use of at least one N,N-dihalo-5,5-dialkylhydantoin in which each of the alkyl groups is independently selected from those containing in the range of from 1 to about 6 carbon atoms.... Agent: Albemarle Corporation Patent Department

20090155386 - Method for treating agricultural products of vegetable origin and the side-products and/or derivatives obtained by treatment: The present invention relates to a method to reduce the micro-biological load on agricultural raw materials, in which the agricultural raw materials are treated with an electrolysed saline solution, because of which the number of micro-organisms is reduced. With this method it will be possible to disinfect agricultural raw materials... Agent: Clark & Elbing LLP

20090155387 - Stable pharmaceutical composition comprising beta-lactam antibiotic and ion-chelating agent: A pharmaceutical composition comprising: at least one β-lactam antibiotic and at least one ion-chelating agent; wherein when said pharmaceutical composition is used as an anti-microbial drug, it optionally comprises further at least one aminoglycoside antibiotic.... Agent: Matthias Scholl

20090155388 - Weight phyto-nutraceutical synergistic composition: A Phytoceutical composition for the prevention and treatment of weight disorders and symptoms is provided. A specific combination of extracts of plants and nutraceuticals is provided, based on categorizing plants and nutraceuticals into one of three groups, Energy, Bio-Intelligence, and Organization. Such combinations have synergistic effects, with minimal side effects.... Agent: Jose Olalde Rangel

20090155389 - Selective serotonin receptor inverse agonists as therapeutics for disease: Disclosed herein are pharmaceutical compositions comprising an inverse serotonin receptor agonist or a serotonin receptor antagonist and an anti-psychotic agent. Disclosed herein are also methods of treating psychotic disorders using the disclosed pharmaceutical compositions.... Agent: Duane Morris LLP - San Diego

20090155390 - Composition and method of treating temporary and permanent hearing loss: A composition for treating permanent and temporary hearing loss includes components that function through different biological mechanisms to provide an additive effect that is equal to or greater than a sum of the effect of the individual components. The composition includes a biologically effective amount of at least one scavenger... Agent: Honigman Miller Schwartz & Cohn LLP

20090155391 - Hydroxycitric acid salt composition and method of use for reducing body weight: Disclosed is a hydroxycitric acid salt composition comprising a mixture of calcium and potassium salts of hydroxycitric acid, preferably in a defined proportion. The HCA salts are prepared by a process that includes treating an aqueous extract of Garcinia cambogia or Garcinia indica fruit with a liquid quaternizing agent such... Agent: Conley Rose, P.C. David A. Rose

20090155392 - Methods and systems for sublingual guarana administration: Embodiments of the present invention relate generally to methods and systems for the sublingual and buccal administration of herbal supplements, and more particularly, to the sublingual and buccal administration of Guaraná, which allows for considerably reducing the therapeutic dose, with the additional advantage of increasing the quickness of the beneficial... Agent: Kirton And Mcconkie

20090155393 - Method for prolonging the life of animals: A method for increasing the longevity of an old animal comprising administering to the animal a composition comprising one or more antioxidants in a total antioxidant amount sufficient to increase the longevity of the animal.... Agent: Colgate-palmolive Company

20090155394 - Method for admixing plant essential oils to coatings for the purpose of repelling insects: The Federal EPA has consistently limited the use of known toxicants (insecticides) to preclude their admixture into paints and coatings by contractors or homeowners for the purpose of repelling or killing insects on the dried or cured coating. The current invention is a method to repel, rather than kill, insects,... Agent: Butler, Snow, O'mara, Stevens & Cannada PLLC

20090155395 - Sf303t, anti-inflammatory and anti-acne agent: The present invention provides a composition comprising Rehmanniae radix, Paeonia suffruticosa, Saposhnikovia divaricata, Schizonepeta multifida, Saphora flavescens, Paeonia lactiflora, Dictamnus dasycarpus, Mentha arvensis, Rheum palmatum, Xanthium sibiricum, Campsis grandiflora and Glycyrrhizae radix for treating or prophylaxis of acne and inflammation related to skin disorders.... Agent: Wpat, PC Intellectual Property Attorneys

20090155396 - Use of a novel phytonutrient rich bioactive concentrate (ri--activetm) for the prevention and treatment of cardiovascular disease, diabetes and other health disorders: The present invention is generally related to the use of a novel composition containing a concentrate of the bioactives, micronutrients and antioxidants present in the unsaponifiable fraction of rice bran oil or rice germ oil, in the prevention and treatment of health disorders. This invention extends to the therapeutic usefulness... Agent: Kartik Natarajan

20090155397 - Demucilaged flax sprouts and their by-product as well as production and application thereof: The present invention relates to demucilaged flax sprouts derived from flaxseeds freed of their mucilage. The flax sprouts according to the invention are easily digestible and can be utilized in different fields, e.g. in food industry, therapy and hus-handry. The invention also relates to the production process and applications of... Agent: Birch Stewart Kolasch & Birch

20090155398 - Jucara and acai fruit-based dietary supplements: The present invention relates to stable, palatable, freeze-dried, fruit-based dietary supplements. Specifically, the inventions relates to compositions of Açai fruit and Jucara fruit with high antioxidant capability and cyclooxygenase-inhibitory activity, and their uses. The invention further provides for methods of making stable, palatable, freeze-dried, fruit-based dietary supplements from Açai fruit... Agent: Greenberg Traurig LLP (la)

20090148382 - Technetium- and rhenium-bis(heteroaryl) complexes, and methods of use thereof: One aspect of the invention relates to complexes of technetium (Tc) and rhenium (Re) with various heteroaromatic ligands, e.g., quinolinyl and isoquinolinyl ligands, and their use in fluorescence and radioimaging for a variety of clinical diagnostic applications, as well as radiopharmaceuticals for therapeutic applications. Another aspect of the invention relates... Agent: Foley & Lardner LLP

20090148383 - Anticoagulation agent and uses thereof: The present invention provides an anticoagulant agent including a first element capable of inhibiting coagulation and a second element capable of targeting an activated platelet wherein upon administration of element directs the first element to the activated platelet. Also provided is a probe for detecting a blood vessel abnormality including... Agent: Clark & Elbing LLP

20090148384 - Functionalized, solid polymer nanoparticles comprising epothilones: The present invention describes polymer nanoparticles with a cationic surface potential, in which both hydrophobic and hydrophilic pharmaceutically active substances can be encapsulated. The hydrophilic and thus water-soluble substances are encapsulated in the particle core by co-precipitation through ionic complexing with a charged polymer. Both therapeutic agents and diagnostic agents... Agent: Millen, White, Zelano & Branigan, P.C.

20090148387 - Ultrasmall superparamagnetic iron oxide nanoparticles and uses thereof: The present invention provides a biomimetic contrast agent comprising an amine-functionalized iron (II) oxide/iron(III) oxide nanoparticle core a targeting ligand attached to the nanoparticle core via a linker and an inert outer layer of a hydrophilic polymer conjugated to the targeting ligand and imaging methods using the biomimetic contrast agents.... Agent: Benjamin Aaron Adler Adler & Associates

20090148385 - Ultrasound contrast agents for molecular imaging: A new type of contrast agent is described, which comprises matrix particles with a plurality of metal nanoparticles as well as the method of imaging therewith. A plurality of metal nanoparticles are encapsulated in a non-proteinaceous biocompatible or biodegradable matrix particle and/or attached to a non-proteinaceous biocompatible or biodegradable matrix... Agent: Philips Intellectual Property & Standards

20090148386 - Enzyme substrate comprising a functional dye and associated technology and methods: Enzyme substrates and associated technology of the present invention are provided. An enzyme substrate of the invention may comprise a biologically functional fluorescent dye and an enzyme-specific substrate moiety attached in such a way that the functionality of the functional dye is diminished. An enzymatic reaction may cleave at least... Agent: Wilson Sonsini Goodrich & Rosati

20090148388 - Isoindoline compounds and methods of making and using the same: The invention encompasses isoindoline compounds, pharmaceutical compositions comprising them, and methods of their use for the treatment, prevention or management of various diseases and disorders. Examples include, but are not limited to, cancer, inflammatory bowel disease and myelodysplastic syndrome.... Agent: Jones Day

20090148389 - Induction of mucosal tolerance to antigens: Induction of tolerance to antigens by mucosal, preferably oral, delivery of the antigen in combination with an immunomodulating compound producing micro-organism is disclosed. More specifically, Foxp3+ and/or IL-10 and/or TGF-β producing regulatory T-cells are induced which are capable of suppressing undesired immune responses toward an antigen. The antigen is preferably... Agent: Knobbe Martens Olson & Bear LLP

20090148390 - Jucara and acai fruit-based dietary supplements: The present invention relates to stable, palatable, freeze-dried, fruit-based dietary supplements. Specifically, the inventions relates to compositions of Açai fruit and Jucara fruit with high antioxidant capability and cyclooxygenase-inhibitory activity, and their uses. The invention further provides for methods of making stable, palatable, freeze-dried, fruit-based dietary supplements from Açai fruit... Agent: Greenberg Traurig LLP (la)

20090148392 - Compositions containing benefit agents pre-emulsified using colloidal cationic particles: A cleansing or a surface-conditioning composition comprising a mixture of (i) and (ii) in water: i) a surfactant selected from the group consisting of anionic, non-ionic, zwitterionic, cationic, and mixtures thereof; and ii) a hydrophobic benefit agent in a particulate form having a mean particle size in the range of... Agent: Marshall, Gerstein & Borun LLP

20090148391 - Synergistic active preparations comprising diphenylmethane derivatives and further skin and/or hair lightening and/or senile keratosis reducing compounds: b) a skin- and/or hair lightening and/or senile keratosis-reducing amount of one or more compounds selected from the group consisting of (i) chelating agents, (ii) phenolic derivatives, plant extracts with an amount of phenolic derivatives and (iii) organic acid derivatives as well as uses thereof.... Agent: Connolly Bove Lodge & Hutz LLP

20090148393 - Multistep cosmetic compositions: The present invention relates to a system of cosmetic and dermatological compositions and methods for treating and improving the aesthetic appearance of a biological surface by altering the optical properties of the biological surface, thereby resulting in a natural, flawless appearance. The compositions of the invention may be topically applied... Agent: Avon Products, Inc.

20090148394 - Treatment of chronic ulcerous skin lesions: The invention provides a method of treating a wound (for example, a chronic ulcerous skin lesion) in a human or non-human mammal (particularly a human). The wound is contacted with a topical hydrogel composition comprising a hydrophilic polymer carrying multiple pendant sulphonyl groups, optionally with multiple pendant carboxylic groups, on... Agent: Ronald I. Eisenstein Nixon Peabody LLP

20090148395 - Biomedical foam articles: The present invention relates to biomedical foam articles for the wound sector which are formed by spraying a polymeric dispersion onto a wound. The polymeric dispersion being sprayed onto a wound surface forms a three-dimensional body which conforms to the spatial shape of the wound and which, as well as... Agent: Baker Donelson Bearman, Caldwell & Berkowitz, PC

20090148396 - Biocompatible biodegradable fumagillin analog conjugates: Fumagillin analog polymer conjugates, methods of making fumagillin analog polymer conjugates, compositions comprising a polymer conjugate of a fumagillin analog, and methods for treating cancer, or treating angiogenic diseases comprising administering to a subject in need thereof an effective amount of a polymer conjugate of a fumagillin analog, are described.... Agent: Wilmerhale/boston

20090148397 - Compositions and methods of treatment with proanthocyanidin polymer antidiarrheal compositions: Pharmaceutical compositions containing a proanthocyanidin polymer composition which are useful for the treatment and prevention of secretory diarrhea are provided. The invention specifically relates to pharmaceutical formulations of a proanthocyanidin polymer composition which has been isolated from a Croton spp. or a Calophyllum spp. In particular, the invention relates to... Agent: King & Spalding

20090148398 - naturally occurring volatile attractant: A bait composition for the control of fire ants based on fact that an ant pyrazine attractant contained therein will attract foraging fire ants and the fire ants will be stimulated by the phagostimulant to eat the bait and distribute active ingredients also contained therein throughout the colony. Furthermore, the... Agent: Usda, Ars, Ott

20090148399 - Controlled release attractant for gravid female mosquitoes: One or a combination of known chemical cues that attract pregnant female mosquitoes to an egg-laying site are embedded in a biodegradable carrier that releases the compound at a generally constant rate for up to a year or longer. The compound is useful for attracting large numbers of mosquito vectors... Agent: James R. Bette

20090148400 - Composition of tumour-associated peptides and related anti-cancer vaccine: The present invention relates to immunotherapeutic peptides and their use in immunotherapy, in particular the immunotherapy of cancer. The present invention discloses tumour-associated T-helper cell peptide epitopes, alone or in combination with other tumour-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions which stimulate anti-tumour immune responses. In... Agent: Baker Donelson Bearman, Caldwell & Berkowitz, PC

20090148404 - Compositions and methods for eliminating undesired subpopulations of t cells in patients with immunological defects related to autoimmunity and organ or hematopoietic stem cell transplantation: The present invention relates generally to methods for stimulating T cells, and more particularly, to methods to eliminate undesired (e.g., autoreactive, alloreactive, pathogenic) subpopulations of T cells from a mixed population of T cells, thereby restoring the normal immune repertoire of said T cells. The present invention also relates to... Agent: Invitrogen Corporation C/o Intellevate

20090148405 - Induction of dendritic cell development with macrophage-colony stimulating factor (m-csf) receptor ligands: A method of inducing dendritic cell (DC) development by administering Macrophage-Colony Stimulating Factor Receptor Ligand is provided. M-CSF receptor ligands induce DCs to differentiate into subtypes, for example plasmacytoid DCs and conventional DCs. Induction with an M-CSF receptor ligand can be achieved in vitro from hematopoietic precursors, such as bone... Agent: Law Office Of Salvatore Arrigo

20090148403 - Interleukin-9 antagonist muteins and their pharmacological methods of use: This invention relates to IL-9 muteins that inhibit the activity of wild-type IL-9, multimers and Fc-fusion constructs of IL-9 proteins, and an efficient method to purify IL-9 proteins produced by eukaryotic cells. Related formulations, dosages and methods of administration thereof for therapeutic purposes are also provided. More particularly, these IL-9... Agent: Lisa A. Haile, J.d., Ph.d. Dla Piper US LLP

20090148401 - Methods and compositions for needleless delivery of binding partners: The present invention relates, in part, to methods and compositions for needleless delivery of macromolecules to a subject. In one aspect, the methods and compositions involve administering to the subject a delivery construct comprising a carrier construct non-covalently bound to a binding partner, wherein the carrier construct comprises a receptor-binding... Agent: Jones Day

20090148402 - Therapy of non-malignant diseases or disorders with anti-erbb2 antibodies: The present application describes treatment of non-malignant indications, such as psoriasis, endometriosis, scleroderma, vascular diseases or disorders, respiratory disease, colon polyps or fibroadenoma, with anti-ErbB2 antibodies (e.g. rhuMAb 2C4).... Agent: Goodwin Procter LLP Attn: Patent Administrator

20090148406 - Stable aqueous systems comprising proteins: An aqueous system comprises a protein and one or more stabilising agents, characterised in that (i) the one or more stabilising agents have ionisable groups capable of exchanging protons with the protein and with the ionised products of water dissociation; (ii) the ionisable groups include first groups that are positively... Agent: Elmore Patent Law Group, PC

20090148407 - Novel macrocyclic inhibitors of hepatitis c virus replication: The embodiments provide compounds of the general Formulae (I) through general Formula (VIII), as well as compositions, including pharmaceutical compositions, comprising a subject compound. The embodiments further provide treatment methods, including methods of treating a hepatitis C virus infection and methods of treating liver fibrosis, the methods generally involving administering... Agent: Knobbe Martens Olson & Bear LLP

20090148409 - Canine probiotic bifidobacteria globosum: According to the invention there is provided a strain of lactic acid bacteria of the species Bifidobacteria globosum obtainable by isolation from resected and washed canine gastrointestinal tract having a probiotic activity in animals. Methods of use and compositions comprising the Bifidobacteria globosum of the present invention are also provided.... Agent: The Procter & Gamble Company Global Legal Department - Ip

20090148410 - Canine probiotic bifidobacteria pseudolongum: According to the invention there is provided a strain of lactic acid bacteria of the species Bifidobacteria pseudolongum obtainable by isolation from resected and washed canine gastrointestinal tract having a probiotic activity in animals. Methods of use and compositions comprising the Bifidobacteria pseudolongum of the present invention are also provided.... Agent: The Procter & Gamble Company Global Legal Department - Ip

20090148408 - Lactobacilli expressing biologically active polypeptides and uses thereof: The present invention relates to Lactobacillus species recombinantly altered to express a biologically active protein. The invention also related to methods of providing the bacteria to the vagina.... Agent: Townsend And Townsend And Crew, LLP

20090148411 - Viral vector-based gene therapy methods and compositions: Disclosed are improved VP2-modified recombinant adeno-associated viral (rAAV) vectors, expression systems, and rAAV virions that are fully virulent, yet lack functional VP2 protein expression. Also disclosed are pharmaceutical compositions, virus particles, host cells, and pharmaceutical formulations that comprise these modified vectors useful in the expression of therapeutic proteins, polypeptides, peptides,... Agent: Haynes And Boone, LLPIPSection

20090148424 - Reversibly immortalized mammalian liver cells and use thereof: The present invention provides a reversibly immortalized mammalian liver cell line, especially CYNK-1 (deposited with International Patent Organism Depository, National Institute of Advanced Industrial Science and Technology, address: AIST Tsukuba Central 6, 1-1, Higashi 1-Chome, Tsukuba-shi, Ibaraki-ken, 305-8566 Japan, deposited date: Mar. 10, 2004, accession number: FERM BP-08657) comprising an... Agent: The Nath Law Group

20090148425 - Therapeutic method for blood coagulation disorder: The present invention provides agents for treating blood coagulation abnormalities, which contain as an active ingredient a lentiviral vector carrying a blood coagulation factor gene operably linked to a promoter which induces platelet-specific expression. Agents for treating hemophilia A or hemophilia B are provided by application of the gene encoding... Agent: Clark & Elbing LLP

20090148412 - Methods of using a cholesterol-lowering preparation, food supplement and foodstuff: The present invention relates to cholesterol-lowering preparations, in particular to a bacterial preparation for use as a medicament for lowering of the blood cholesterol level. The present invention provides inter alia a preparation of Rhodospirillum spp. and/or Phaeospirillum with cholesterol-lowering effects, food supplements and foodstuffs comprising said preparation and methods... Agent: Weingarten, Schurgin, Gagnebin & Lebovici LLP

20090148413 - Method for treatment of irritable bowel syndrome: A composition and method for treatment for bowel disorders is described. The composition consists of three parts. The first part is a highly purified, insoluble, chemically unmodified fiber from plants which is mixed with an aqueous solution such as water. The second part of the composition is a commercially available... Agent: David G. Moore Strasburger & Price, LLP

20090148414 - Novel composition to improve gut health and animal performance and methods of making the same: The present invention relates to compositions comprising at least about 8% β-glucans and/or at least about 8% α-fucans, which has a prebiotic effect and act as a replacement for in-feed antibiotics. The present invention also relates to extraction methods to obtain such extracts and various uses for the compositions comprising... Agent: Chalker Flores, LLP

20090148416 - Angiogenically induced transplants and methods for their use and manufacture: Angiogenically induced transplants and methods for their use and manufacture are disclosed. The angiogenic potential of the transplants is increased by contacting the transplants with donor mesenchymal cells such as hair follicle dermal papilla stem cells. Methods for treating disorders and diseases, such as disorders of the skin and angiopathies,... Agent: Stemedica Cell Technologies, Inc

20090148417 - Carbon nanotubes serving as stem cell scaffold: The present invention relates to a scaffold for transplanting a stem cell comprising a carbon nanotube without cytotoxicity, and a composition for stem cell therapy comprising (a) a stem cell; and (b) a carbon nanotube serving as a stem cell scaffold without cytotoxicity. The scaffold for transplanting stem cells comprising... Agent: Buchanan, Ingersoll & Rooney PC

20090148421 - Compositions comprising vascular and myocyte progenitor cells and methods of their use: The invention provides compositions of adult cardiac vascular progenitor cells (VPCs) and adult cardiac myocyte progenitor cells (MPCs) useful for the treatment of various cardiac conditions. The invention also encompasses methods of generating a biological bypass, repairing damaged myocardium, and treating or preventing hypertensive cardiomyopathy and heart failure with the... Agent: Cooley Godward Kronish LLP Attn: Patent Group

20090148423 - Endothelial progenitor cells and methods of use thereof: Endothelial progenitor cells immunoreactive for VEGFR-2 or Tie-2, and CD45 are provided. Optionally the cell is immunoreactive with CD14. The cells are capable of differentiating in vivo into an endothelial cell or a smooth muscle cells. The cultures integrate well after transplantation into adult vasculature.... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.c

20090148422 - Methods of proliferating stem cells: The invention relates to methods of proliferating stem cells. More particularly, the invention relates to the use of glycosaminoglycans or proteoglycans to promote the growth of stem cells in ex vivo culture, while preserving their multipotentiality.... Agent: Seed Intellectual Property Law Group PLLC

20090148418 - Skeletal site-specific characterization of orofacial and illiac crest human bone marrow stromal cells in same individuals: The present invention relates to methods and compositions useful for the detection, enrichment, and use of orofacial-derived bone marrow stromal cells. In one aspect, the invention relates to the use of characteristics specific to orofacial-derived bone marrow stromal cells to distinguish orofacial-derived bone marrow stromal cells from other cells.... Agent: Drinker Biddle & Reath Attn: Intellectual Property Group

20090148420 - Stem cells: Stem cells obtained through in vitro culture with heparan sulphate are described.... Agent: Seed Intellectual Property Law Group PLLC

20090148415 - Treatment for chronic myocardial infarct: A method of treating chronic post-myocardial infarction including helical needle transendocardial delivery of autologous bone marrow (ABM) mononuclear cells around regions of hypo or akinesia in chronic post-myocardial infarction (MI) patients. The treatment is safe and improves ejection fraction (EF).... Agent: Crockett & Crockett

20090148419 - Use of adipose tissue derived mesenchymal stem cells for the treatment of graft versus host disease: The present invention relates to the use of a particular type of adipose tissue derived mesenchymal stem cells (AD-MSCs), which exert immunosuppressive properties, in the manufacture of a pharmaceutical composition for the prevention and treatment of the graft-versus-host disease (GVHD) produced after allogeneic hematopoietic stem cell transplantation.... Agent: Moore & Van Allen PLLC

20090148426 - Composition for life extension and method of extending the life: The present invention relates to a composition for life extension, comprising reduced coenzyme Q10 as an active ingredient, as well as relates to a method of extending a life span using the composition comprising reduced coenzyme Q10 as an active ingredient. In the present invention, it has been found that... Agent: Sughrue Mion, PLLC

20090148427 - Platelet glycoprotein ib alpha fusion polypeptides and methods of use thereof: The present invention provides compositions and methods for treating or preventing vascular-associated disorders.... Agent: Ivor R. Elrifi Mintz, Levin, Cohn, Ferris,

20090148428 - Glycine n-methyltransferase (gnmt) animal model and use thereof: The present invention is a new type of Glycine N-methyltransferase (GNMT) knockout mice model. This model can be applied to screen drug, test of treatment and search for diagnostic marker of hepatocellular carcinoma (HCC), glycogen storage disease, liver dysplasia, fatty liver and other liver disease.... Agent: Wpat, PC Intellectual Property Attorneys

20090148429 - Debriding composition from bromelain and methods of production thereof: The present invention relates to a debriding composition obtained from bromelain and to methods of producing same. Particularly, the present invention relates to a debriding composition obtained from bromelain comprising proteolytic enzymes having molecular weights of about 23 kDa, being essentially devoid of bromelain inhibitors, and to pharmaceutical compositions comprising... Agent: Winston & Strawn LLP Patent Department

20090148430 - Human obesity susceptibilty gene encoding potassium ion channels and uses thereof: The present invention more particularly discloses the identification of human obesity susceptibility genes, which can be used for the diagnosis, prevention and treatment of obesity ant associated disorders, as well as for the screening of therapeutically active drugs. The invention more specifically discloses certain alleles of potassium voltage-gated channel (E.CNA)... Agent: Occhiuti Rohlicek & Tsao, LLP

20090148431 - Modulating the production of neurons and/or oligodendrocytes from white matter progenitor cells: The present invention relates to a method of modulating production of neurons and/or oligodendrocytes from neural progenitor cells of human white matter and to a method of treating a subject for a condition modulated by underproduction of oligodendrocytes from human white matter. Both of these methods involve administering an agonist... Agent: Nixon Peabody LLP - Patent Group

20090148432 - Compositions for inhibiting atherosclerosis: The present invention relates to compositions and methods for the reduction of atherosclerotic plaques and the decrease in the level of total serum cholesterol, triglycerides, serum LDL cholesterol, and serum HDL cholesterol.... Agent: Baker Botts L.L.P.

20090148433 - Metallo-protein and tocotrienol (mp-t3) compositions and uses thereof: Metallo-proteins including but not limited to lactoferrin (LF), transferrin (TF) and ovotransferrin (OTF) (all members of transferrin family), ceruloplasmin (CP) and metallo-thionein (MT) were found to stabilize and enhance the bio-functional activity of tocotrienol (T3), T3 mixtures or derivates. The synergism between MP and T3 also promote the intestinal transfer... Agent: Knobbe Martens Olson & Bear LLP

20090148434 - Antibody compositions and methods: Provided are concentrated preparations comprising single immunoglobulin variable domain polypeptides that bind target antigen with high affinity and are soluble at high concentration, without aggregation or precipitation, providing, for example, for increased storage stability and the ability to administer higher therapeutic doses.... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220

20090148435 - Antibody purification by cation exchange chromatography: A method for purifying an antibody by cation exchange chromatography is described in which a high pH wash step is used to remove of contaminants prior to eluting the desired antibody using an elution buffer with increased conductivity.... Agent: Genentech, Inc.

20090148436 - Antibody to gdf8 and uses thereof: The disclosure provides novel molecules related to growth and differentiation factor-8 (GDF8), in particular epitopes specific to GDF8 and other specific antagonists of GDF8 in particular anti-GDF8 antibodies or antigen binding protein or fragment thereof which may inhibit GDF8 activity and signal in vitro and/or in vivo. The disclosure also... Agent: Wyeth Patent Law Group

20090148437 - Polypeptides, antibody variable domains & antagonists: The present invention relates to polypeptides e.g. protease resistant polypeptides, immunoglobulin (antibody) single variable domains e.g. which are protease resistant and also to vascular endothelial growth factor (VEGF) antagonists comprising these. The invention further relates to uses, formulations, and compositions comprising such polypeptides e.g. for delivery to the eye.... Agent: Glaxosmithkline Corporate Intellectual Property - Uw2220

20090148441 - Anti-cancer antibodies with reduced complement fixation: The invention provides modified antibodies directed against GD2 that have diminished complement fixation relative to antibody-dependent, cell-mediated cytotoxicity, which is maintained. The modified antibodies of the invention may be used in the treatment of tumors such as neuroblastoma, glioblastoma, melanoma, small-cell lung carcinoma, B-cell lymphoma, renal carcinoma, retinoblastoma, and other... Agent: Goodwin Procter LLP Patent Administrator

20090148440 - Antibodies against interleukin-22 binding protein and its uses for the treatment of metabolic disorders: The present invention relates to antibodies and antigen-binding fragments that bind to interleukin-22 binding protein, in particular, human interleukin-22 binding protein (IL-22 BP), and are involved in regulating interleukin-22-associated biological responses. The invention also relates to methods of using the antibodies and antigen-binding fragments to treat disorders associated with interleukin-22.... Agent: EagleIPLimited

20090148438 - Binding moieties based on shark ignar domains: The present invention relates to immunoglobulin new antigen receptors (IgNARs) from fish and uses thereof. In particular, the present invention relates to modified IgNAR variable domains and to domains from members of the immunoglobulin superfamily that have been modified to include structural features derived from IgNAR variable domains.... Agent: J. Mitchell Jones Medlen & Carroll

20090148442 - Combination of blys inhibition and anti-cd 20 agents for treatment of autoimmune disease: The invention relates to novel combination therapies involving BLyS or BLyS/APRIL inhibition and anti-CD20 agents for the treatment of autoimmune diseases. One preferred method is where the BLyS antagonist is a Fc-fusion protein which can be a TACI-Fc-fusion protein comprising the extracellular domain of TACI or a functional fragment thereof,... Agent: Alston & Bird LLP

20090148443 - Humanized antibodies and compositions for binding sphingosine-1-phosphate: The present invention relates to anti-S1P agents, particularly humanized monoclonal antibodies (and antigen binding fragments thereof) specifically reactive with S1P, compositions containing such antibodies (or fragments), and the use of such antibodies (or fragments), for example, to treat diseases and conditions associated with aberrant levels of S1P.... Agent: Biotechnology Law Group 12707 High Bluff Drive

20090148446 - Method and composition for treatment of renal failure with antibodies and their equivalents as partial or complete replacement for dialysis: A method for treating renal failure associated with advanced stage renal disease includes administering a soluble cytokine receptor to one or more of tumor necrosis factor alpha, interferon gamma or interleukin 6; or antibodies to one or more of interleukin 6 or interleuking 1 beta. The method can be used... Agent: Houston Eliseeva

20090148439 - Methods for diagnosis and treatment of epithelial-derived cancers: The present invention relates to the use of a polypeptide (CD27L) for diagnosis of epithelial-related cancers, in particular kidney cancer e.g. renal cell cancer and colorectal cancer, e.g. colon cancers, as well as in methods of treatment of such cancers.... Agent: Klauber & Jackson

20090148445 - Methods of sensitizing cancer to therapy-induced cytotoxicity: The present application demonstrates that Salinosporamide A can be used to sensitize cancer cells to cancer therapy. Furthermore, the present application demonstrates that Salinosporamide A acts as a therapeutic agent to kill or inhibit cancer cells after sensitization of the cells by an antibody or other chemosensitizing reagents. The cancer... Agent: Townsend And Townsend And Crew, LLP

20090148444 - Pharmaceutical composition for treating immune diseases: An antibody against AILIM (alternatively called JTT-1 antigen, JTT-2 antigen, ICOS and 8F4) was found to have a significant therapeutic effect on arthrosis, for example, rheumatoid arthritis and osteoarthritis, graft versus host disease, graft immune rejection, inflammation (hepatitis and inflammatory bowel diseases), diseased condition accompanied by the excessive production of... Agent: Fish & Richardson PC

20090148447 - Binding peptides having a c-terminally disposed specific binding domain: Specific binding peptides having a general schematized structure of an optional N-terminal hinge region joined to an immunoglobulin-derived constant sub-region comprising a CH2 region and a CH3 region, followed by a PIMS linker peptide and at least one specific binding domain are provided, along with encoding nucleic acids, vectors and... Agent: Marshall, Gerstein & Borun LLP

20090148448 - Methods and compositions for modulating and detecting wisp activity: Methods and compositions for use in modulating the activity(s) of WISP-1 polypeptide are provided. WISP-1 antagonists include anti-WISP-1 antibodies, WISP-1 immunoadhesins and WISP-1 variants (and fusion proteins thereof) which inhibit or neutralize induction or secretion of HAS2, HA, CD44 or RHAMM by native human WISP-1 polypeptide in at least one... Agent: Genentech, Inc.

20090148449 - Antibodies against cd38 for treatment of multiple myeloma: Isolated human monoclonal antibodies which bind to human CD38, and related antibody-based compositions and molecules, are disclosed. Also disclosed are pharmaceutical compositions comprising the human antibodies, and therapeutic and diagnostic methods for using the human antibodies.... Agent: Lahive & Cockfield, LLP Floor 30, Suite 3000

20090148450 - Atf4 as a therapeutic target in alzheimers disease and other neurological disorders: The present invention relates to methods and compositions for treating Alzheimer's Disease and other neurological disorders by inhibiting expression and/or activity of ATF4. It further provides for diagnostic methods and reagents as well as assays to identify agents for the treatment of Alzheimer's Disease and other ATF4-related conditions.... Agent: Baker Botts L.L.P.

20090148455 - Anti-rantes antibodies and methods of use thereof: The invention relates to fully human monoclonal antibodies, and fragments thereof, that bind to the chemokine Regulated upon Activation, Normal T-cell Expressed, and Secreted (RANTES, CCL5), thereby modulating the interaction between RANTES and one of more of its receptors, such as, e.g., CCR1, CCR3, CCR4 and CCR5, and/or modulating the... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.c

20090148456 - Canine rankl and methods for preparing and using the same: The present invention provides isolated nucleic acid molecules that encode a substantial part of canine RANKL polypeptide, including the extracellular domains of that polypeptide, the polypeptide and fragments thereof. Vectors and host cells encoding and expressing canine RANKL polypeptide are provided, as well as antibodies that bind to RANKL and... Agent: Schering-plough Corporation Patent Department (k-6-1, 1990)

20090148452 - Composition for treating cancer adapted for intra-tumoral administration and uses thereof: A composition is adapted for intra-tumoral administration of a subject suffering from cancer, whereby administration of the composition to the subject induces IMC differentiation by neutralizing a factor implicated in a DC differentiation defect.... Agent: Ip Group Of Dla Piper US LLP

20090148457 - Hepatocyte growth factor receptor antagonists and uses thereof: Hepatocyte growth factor (HGF) receptor antagonists are provided. The HGF receptor antagonists include HGF receptor antibodies and fragments thereof. The HGF receptor antagonists can be employed to block binding of HGF to HGF receptors or substantially inhibit HGF receptor activation. The HGF receptor antagonists may be included in pharmaceutical compositions,... Agent: Genentech, Inc.

20090148453 - Monoclonal antibodies against hmgb1: In various embodiments, the present invention is drawn to antibodies or antigen-binding fragments thereof that bind to a vertebrate high mobility group box (HMGB) polypeptide, methods of detecting and/or identifying an agent that binds to an HMGB polypeptide, methods of treating a condition in a subject characterized by activation of... Agent: Hamilton, Brook, Smith & Reynolds, P.C.

20090148454 - Peptide domain required for interaction between the envelope of a virus pertaining to the herv-w interference group and an hasct receptor: The invention relates to a peptide domain required for interaction between the envelope of a virus pertaining to the HERV-W interference group and a hASCT receptor, comprising an N end point and a C end point. Said peptide domain is defined, at the N end point thereof, by a pattern... Agent: Oliff & Berridge, PLC

20090148451 - Therapeutic anti-cytomegalovirus compounds: The present invention provides synthetic compounds, antibodies that recognize and bind to these compounds, polynucleotides that encode these compounds, and immune effector cells raised in response to presentation of these epitopes. The invention further provides methods for inducing an immune response and administering immunotherapy to a subject by delivering the... Agent: Genzyme Corporation Legal Department

20090148458 - Coagulation factor iii polymorphisms associated with prediction of subject outcome and response to therapy: The invention provides methods and kits for obtaining a prognosis for a subject having or at risk of developing an inflammatory condition or hypertension. The method generally comprises determining a coagulation factor III genotype(s) of a subject for one or more SNPs, comparing the determined genotype with known genotypes for... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20090148459 - Prevention or treatment of cancer using integrin alphavbeta3 antagonists in combination with other agents: The present invention relates to methods and compositions designed for the treatment, management or prevention of cancer. The methods of the invention comprise the administration of an effective amount of one or more antagonists of Integrin αVβ3 alone or in combination with the administration of an effective amount of one... Agent: Medimmune, LLC Jonathan Klein-evans

20090148461 - Anti fgf23 antibody and a pharmaceutical composition comprising the same: To provide an antibody against FGF23 and a pharmaceutical composition such as a preventive or therapeutic agent which can prevent or treat by suppressing an action of FGF23 by using the antibody. An antibody or its functional fragment against human FGF23 produced by hybridoma C10 (Accession No. FERM BP-10772).... Agent: Foley And Lardner LLP Suite 500

20090148460 - Exosome ligands, their preparation and uses: The present invention relates to exosome-specific ligands and compositions comprising the same. The invention also relates to methods of generating said ligands and compositions, to methods of using said ligands or compositions, e.g., to block the exosome pathway or to detect and/or characterize exosomes in a sample or subject, as... Agent: Nixon & Vanderhye, PC

20090148463 - Ivig modulation of chemokines for treatment of multiple sclerosis, alzheimer's disease, and parkinson's disease: The present invention provides methods for providing a prognosis of treatment of diseases associated with inflammatory disease of the brain, including MS, e.g., relapsing-remitting multiple sclerosis (RRMS), Alzheimer's disease, and Parkinson's disease using molecular markers that are shown to be overexpressed or underexpressed in patients treated with intravenous immunoglobulins (IVIG).... Agent: Baxter Healthcare Corporation

20090148462 - Methods and compositions for use in treatment of patients with autoantibody positive disease: The present invention relates to methods and compositions for use in treatment of patients with autoantibody positive disease. In a specific embodiment, the present invention relates to a method of treating a patient that has an ANA titer of 1:80 or greater and/or greater than or equal to 30 IU/ml... Agent: Leydig, Voit & Mayer Ltd.

20090148464 - Preventive or therapeutic agent containing anti thioredoxin antibody polypeptide as an active ingredient for disorders: The present invention provides a preventive or therapeutic agent being effective for disorders induced by macrophage migration inhibitory factor and vascular system disorders, and having fewer side effects. In particular, the present agent is characterized by containing anti TRX antibody polypeptide as an active ingredient to inhibit adherence of leukocyte... Agent: Law Offices Of Albert Wai-kit Chan, PLLC

20090148465 - Mutants of the p4 protein of nontypable haemophilus influenzae with reduced enzymatic activity: A P4 variant protein that has reduced enzymatic activity and that induces antibody to wild-type P4 protein and/or has good bactericidal activity against non-typable H. influenzae (NTHi) is useful as an active component in an immunogenic composition for humans. Methods of using these proteins, and compositions containing them in combination... Agent: Howson & Howson LLP

20090148466 - Process for the preparation of hypoallergenic mosaic antigens: A process for the preparation of an hypoallergenic mosaic antigen derived from an allergen is disclosed whereby a) in a first step the allergen is split into at least two parts and the IgE reactivity of each part is determined and b) in a second step those parts of the... Agent: Smith Patent Consulting Consulting, LLC

20090148467 - Herpes simplex virus combined subunit vaccines and methods of use thereof: This invention provides vaccines comprising two or more recombinant Herpes Simplex Virus (HSV) proteins selected from a gD protein, a gC protein and a gE protein; and methods of impeding immune evasion by HSV thereby vaccinating a subject against HSV and treating, suppressing, inhibiting, and/or reducing an incidence of an... Agent: Pearl Cohen Zedek Latzer, LLP

20090148468 - Rapid, efficient purification of hsv-specific t-lymphocytes and hsv antigens identified via same: Described is a method of identifying an immunologically active antigen of a virus that attacks skin, as well as a method of enriching a population of lymphocytes for T lymphocytes that are specific to a virus that attacks skin. Also provided are HSV antigens and epitopes that are useful for... Agent: Karen S. Canady Canady & Lortz LLP

20090148469 - Multicomponent meningococcal vaccine: A composition is provided comprising N. meningitidis outer membrane vesicles, wherein said outer membrane vesicles are enriched with at least one antigenic component. The composition is suitable for use in vaccines and for treatment of infection, particularly meningococcal infection, demonstrating a broad spectrum of protection. A number of preferred antigenic... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20090148470 - Protein-based streptococcus pneumoniae vaccines: The present invention is primarily directed to a method for preventing infection of a mammalian subject with S. pneumoniae, wherein said method comprises administering to said subject an effective amount of one or more S. pneumoniae cell wall and/or cell membrane proteins and/or immunogenically-active fragments, derivatives or modifications thereof, wherein... Agent: Winston & Strawn LLP Patent Department

20090148472 - Identification of protective antigenic determinants of porcine reproductive and respiratory syndrome virus and uses thereof: The invention relates to a polypeptide of a protective antigenic determinant (PAD polypeptide) of porcine reproductive and respiratory syndrome virus (PRRSV) and nucleic acids encoding a PAD polypeptide. The PAD polypeptide and nucleic acids encoding a PAD polypeptide are useful in the development of antibodies directed to PAD, vaccines effective... Agent: Mckee, Voorhees & Sease, P.L.C

20090148471 - Molecular vaccine linking an endoplasmic reticulum chaperone polypeptide to an antigen: This invention provides compositions and methods for inducing and enhancing immune responses, such as antigen-specific cytotoxic T lymphocyte (CTL) responses, using chimeric molecules comprising endoplasmic reticulum chaperone polypeptides and antigenic peptides. In particular, the invention provides compositions and methods for enhancing immune responses induced by polypeptides made in vivo by... Agent: Foley Hoag, LLP (w/jhv)

20090148473 - Microbial vaccine and vaccine vector: The present invention includes cold-adapted, acid-fast bacterium for use as a vaccine and a vaccine vector. In preferred embodiments, the cold-adapted, acid-fast bacterium is a Mycobacteria, for example, Mycobacteria shottsii.... Agent: Mueting, Raasch & Gebhardt, P.A.

20090148475 - Identification of protective antigenic determinants of porcine reproductive and respiratory syndrome virus and uses thereof: The invention relates to a polypeptide of a protective antigenic determinant (PAD polypeptide) of porcine reproductive and respiratory syndrome virus (PRRSV) and nucleic acids encoding a PAD polypeptide. The PAD polypeptide and nucleic acids encoding a PAD polypeptide are useful in the development of antibodies directed to PAD, vaccines effective... Agent: Mckee, Voorhees & Sease, P.L.C

20090148474 - Porcine reproductive and respiratory syndrome isolates and methods of use: A method of predicting the virulence of a new or uncharacterized PRRS virus isolate is provided wherein the isolate is injected into swine and allowed to replicate for a period of from about 3-15 days. During this period, the rate of virus growth and/or the magnitude of viremia is determined,... Agent: Michael P. Morris Boehringer Ingelheim Usa Corporation

20090148476 - Chemodenervating pharmaceutical as anti-inflammatory agent: Pharmaceutical application of a chemodenervating agent, particularly botulinum toxin, reduces inflammatory response and serves as an anti-inflammatory agent without systemic side effects and with long duration action, on the order of 12-24 weeks. In one embodiment, the effective dosage for allergy provoked inflammation reduction is an order of magnitude less... Agent: Milbank, Tweed, Hadley & Mccloy LLP

20090148477 - Adenoviral vector-based malaria vaccines: The invention provides adenoviral vectors comprising an adenoviral genome comprising heterologous antigen-encoding nucleic acid sequences, such as Plasmodium nucleic acid sequences, operably linked to promoters. The invention further provides a method of inducing an immune response against malaria in a mammal comprising administering the adenoviral vectors to the mammal.... Agent: Leydig Voit & Mayer, Ltd

20090148478 - Combinations of tumor-associated antigens in compositions for various types of cancers: Disclosed herein are methods and compositions for inducing an immune response against various combinations of tumor-associated antigens, which can promote effective immunologic intervention in pathogenic processes. Embodiments of the invention disclosed herein are directed to the use of effective combinations of TuAAs for the immunotherapy of patients with various types... Agent: Davis Wright Tremaine LLP/mankind Corporation

20090148479 - Methods of modulating an immune response using immunostimulatory sequences and compositions for use therein: The invention provides methods of modulating an immune response to a second antigen which entail administration of a first antigen and an immunostimulatory polynucleotide. Modulation of the immune response is generally manifested as stimulation of a Th1 response.... Agent: Morrison & Foerster LLP

20090148480 - Sustained release preparation: The invention provides a preparation which shows a satisfactory gastric residence time, has such a size that allows for easy ingestion, can quickly disintegrate after expelled from the stomach, and can be prepared readily in an industrial scale. A gastric retentive preparation having a gastric resident layer and a drug... Agent: Sughrue Mion, PLLC

20090148481 - Method of formulating zinc oxide powder blends for balanced uva/uvb attenuation: Disclosed is a composition that comprises an effective proportion of a first metal oxide powder having a primary particle size and a secondary particle size selected for the first metal oxide powder to attenuate UVA and an effective proportion of a second metal oxide powder having a secondary particle size... Agent: Thompson Hine L.L.P. Intellectual Property Group

20090148482 - Device, system, and method comprising microencapsulated proton donor for release of nitric oxide from a polymer: A device, comprising an NO eluting polymer is provided. Said device is furthermore provided with microencapsulated liquid (101), such as water or water containing liquid in micro-capsules (101), which water or water containing liquid after breakage of said micro capsules, initiates elution of NO from said device. Furthermore, a manufacturing... Agent: Inskeep Intellectual Property Group, Inc

20090148483 - Olfactory patch: An olfactory patch comprises a well 6 formed by a reservoir layer 2, the well sandwiched between a barrier layer 3 and a permeable layer 4. The permeable layer defines a pathway for olfactory fluid flow from the well 6 (A, FIG. 1). The flow of the olfactory may be... Agent: Dr Asrar Rashid

20090148484 - Stably-dispersing composite of metal nanoparticle and inorganic clay and method for producing the same: A stably-dispersed composite of metal nanoparticles and inorganic clay and a method for producing the composite, in which interlayered charges of the clay are replaced with the metal ions, which are then reduced to metal particles by a reducing agent. The metal particles will not aggregate together and can be... Agent: Pai Patent & Trademark Law Firm

20090148488 - Bioactive coating for medical devices: A medical device (and method for making same) comprising a passivating coating comprising keratin.... Agent: Vinson & Elkins, L.L.P.

20090148486 - Compositions and methods for treating pulp inflammations caused by infection or trauma: The present disclosed subject matter relates to methods and compositions for restoring a diseased or damaged tooth such that infection is inhibited or eliminated and pulp regeneration is facilitated. The disclosed subject matter also includes a composition comprising a physiologically acceptable matrix seeded with pulp cells. The matrix can be... Agent: Wilmerhale/columbia University

20090148485 - Controlled release devices and structural elements for use in their manufacture: A structural element (2), suitable for use in the manufacture of a release device for intraruminal administration of an active agent to a ruminant animal, is of a compacted material, which material comprises a mixture of powdered iron, graphite and optionally copper, the graphite being present in the mixture in... Agent: Townsend And Townsend And Crew, LLP

20090148487 - Moldable biomaterial for bone regeneration: The present invention is directed to a moldable biomaterial comprising a particulate solid porous material and a biodegradable paste material. The paste material and the particulate solid porous material form a matrix usable for the replacement or augmentation of bone. In various embodiments the matrix has a high structural integrity,... Agent: Leydig Voit & Mayer, Ltd

20090148489 - Bioabsorbable material: A bioabsorbable material suitable for implanting within a human body, the material including fibers of a composite of a synthetic bioabsorbable polymer such as poly-lactic acid, and a particulate bioactive filler such as calcium phosphate powder. The fibers are discontinuous with non-uniform cross-sections and non-uniform cross-sectional areas. The surface topography... Agent: Smith-hill And Bedell, P.C.

20090148491 - Dual-targeted drug carriers: The present invention relates to implantable medical devices containing surface-treated, dual-targeted drug carriers for treating vascular diseases.... Agent: Squire, Sanders & Dempsey LLP

20090148494 - Egfr inhibitors promote axon regeneration: Compositions and methods for promoting neural regeneration in a patient determined to have a lesion in a mature CNS neuron are disclosed. The method comprises the step of contacting the neuron with an EGFR inhibitor sufficient to promote regeneration of the neuron.... Agent: David S. Resnick

20090148492 - Method of making a vascular closure device: A method of making a biocompatible, implantable medical device, including a vascular closure device is disclosed. The method includes forming a biocompatible polymer into at least one fiber and randomly orienting the at least one fiber into a fibrous structure having at least one interstitial spaces. Polymeric materials may be... Agent: Philip S. Johnson Johnson & Johnson

20090148493 - Methods and devices for enhanced biocompatibility: The present invention is directed to devices with enhanced biocompatibility and methods for generating and utilizing such devices. The present invention is further directed to enhanced biocompatibility utilizing oligonucleotide functionalization. In one aspect, a device for implantation and/or prolonged exposure to the body tissues includes a functionalized surface. The functionalized... Agent: Bio Tex, Inc.

20090148490 - Preparation of therapeutic foam: A device is described for facilitating the preparation of therapeutic foam e.g. for the treatment of varicose veins. A pressurised vial contains a sclerosant liquid, e.g., polidocanol solution, and a sterile gas which is readily absorbed by the body, e.g., carbon dioxide, oxygen or a mixture of these gases. The... Agent: Nixon & Vanderhye, PC

20090148497 - Antibiotic microspheres for treatment and prevention of osteomyelitis and enhancement of bone regrowth: A method of treating or preventing infection at a surgical site comprising a bony defect and an implanted metal device is disclosed. Biodegradable microspheres are placed at the site and are capable of near-linear controlled release of an antibiotic agent for a predetermined period of time. The microspheres are configured... Agent: Conley Rose, P.C. David A. Rose

20090148496 - Implants with membrane diffusion-controlled release of active ingredient: An implant for implantation in a human or animal body having a structure comprising a) an implant base body; b) a primer layer which is partially or completely applied to the surface of the implant; c) an active ingredient layer consisting of one, two, three or more active ingredients applied... Agent: Bryan Cave Powell Goldstein

20090148495 - Optimum density fibrous matrix: An implantable biodegradable porous fibrous matrix is disclosed, the fibrous matrix being constructed of fibers arranged in a nonwoven array. The density of the nonwoven array is adjusted in the manufacturing process to obtain an optimum density of the array for tissue ingrowth. When implanted, the optimum density fibrous matrix... Agent: Philip S. Johnson Johnson & Johnson

20090148498 - Controlled release implantable dispensing device and method: A dispensing device having a polymer which is combined with a therapeutic agent in the form of a microparticle which is compressed to form a controlled release dispensing device and methods of locally administering a therapeutic agent using said microparticles.... Agent: Hedman & Costigan P.C.

20090148499 - Formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents: Combinations of hydrophilic and hydrophobic entities in a biodegradable sustained release implant are shown to modulate each other's rate of release. Formulations of a therapeutically active agent and modulator provide substantially constant rate of release for an extended period of time.... Agent: Allergan, Inc.

20090148500 - Medicinal implant cartridge: The invention includes a cartridge for use in a device for inserting a medicament within a body cavity of a mammal, the cartridge including a housing, a retractable chamber disposed within the housing and having a lumen having a uniform cross-section sized to contain the medicament therein, a substantially stationary... Agent: Philip S. Johnson Johnson & Johnson

20090148501 - Process for the preparation of aromatized chewing foams for cosmetic products: The invention relates to a process for the preparation of novel aromatized chewing foams for the oral care sector based on polyurethane-polyureas and aromatizing compositions... Agent: Connolly Bove Lodge & Hutz LLP

20090148502 - Compositions and methods for treating lacerations, abrasions, avulsions, burns, ulcers, and cases of excessive bleeding: Described herein are compositions and methods related to wound treatment. Compositions are multi-components admixed in amounts and ratios to meet specific objectives for optimally treating various types of wound injury.... Agent: Foley & Lardner LLP

20090148503 - Topical devices and methods for assisting performance of surgical incision: A flexible topical device for assisting performance of surgical incision comprises a tear-resistant support layer and an adhesive layer disposed thereon. The device can further comprises a tear-resistant reinforcement layer disposed adjacent to the support layer. The device is adhesively attached to a surface of the tissue in which an... Agent: Hai H. Trieu

20090148504 - Transdermal pharmaceutical preparation: A percutaneous administration type pharmaceutical preparation in tape form comprising a flexible backing, which is not permeable by the active ingredient, and an adhesive base layer formed on said flexible backing; said adhesive base layer consisting essentially of an adhesive base material, ingredients, and an active ingredient, wherein said adhesive... Agent: Cheng Law Group, PLLC

20090148507 - Chimeric polypeptides containing chemokine domains: This invention provides a chimeric DNA molecule comprising a sequence encoding a chemokine polypeptide covalently attached to a heterologous polypeptide, the encoded chimeric polypeptide, and uses thereof.... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.c

20090148511 - Composition and method for dermatological treatment: A topical composition for the treatment of acne and other dermatological conditions comprises a liposomal formulation of a retinoid and an antibiotic in which the retinoid is disposed in the lipid phase of the formulation, and the antibiotic is disposed in the aqueous phase. Lincosamides, such as clindamycin, are one... Agent: Gifford, Krass, Sprinkle,anderson & Citkowski, P.c

20090148509 - Encapsulation and deaggregation of polyene antibiotics using poly(ethylene glycol)-phospholipid micelles: Amphotericin B (or other hydrophobic compound) is encapsulated in a deaggregated form in micelles of monomethoxy poly(ethylene glycol)-phospholipid (as specifically exemplified, the phospholipid is 1,2 di-stearoyl-sn-glycero-3-phosphatidyl ethanolamine) formed by solvent evaporation. Advantageously, the hydration of the dried drug-polymer film is carried at between about 25° C. and about 80° C.... Agent: Greenlee Winner And Sullivan P C

20090148510 - Gpcr crystalization method using an antibody: An antibody that specifically binds a three dimensional epitope on the IC3 loop of a GPCR is provided. The antibody may be employed in a method that comprises: contacting a GPCR with a monovalent version of the antibody binding conditions to form a complex; and crystallizing the complex.... Agent: Stanford University Office Of Technology Licensing Bozicevic, Field & Francis LLP

20090148506 - Liposomal formulations comprising secondary and tertiary amines and methods for preparing thereof: Provided herein are liposomal compositions comprising a therapeutic agent having a protonatable amino group and a secondary or tertiary amine, and methods for encapsulating such therapeutic agents. In one aspect, the present invention relates to liposomal formulations comprising irinotecan in a triethanolamine solution, and optionally comprising copper gluconate, and methods... Agent: Morrison & Foerster LLP

20090148508 - Methods of compositions for the treatment of ocular diseases: Methods and compositions for the treatment of ocular disease with a cyclin dependent kinase inhibitor are provided.... Agent: Townsend And Townsend And Crew, LLP

20090148505 - Novel antiproliferative factor and methods of use: A novel antiproliferative factor comprising a glycopeptide is disclosed. In specific embodiments, the novel antiproliferative factor is associated with the bladder. Compositions, diagnostic kits and reagents, and methods of using the compounds for identifying and/or treating interstitial cystitis and cancer are disclosed.... Agent: Fulbright & Jaworski, LLP

20090148513 - Compositions and methods for crystallizing antibodies: The present invention relates to a batch crystallization method for crystallizing anti-human TNFalpha (hTNFalpha) antibody and antibody fragments which allows the production of said antibody on an industrial scale; a method of controlling the size of antibody crystals, for example, crystals of anti-hTNFalpha antibody fragments, compositions containing said crystals as... Agent: Abbott Bioresearch

20090148514 - Multipart capsule for staged release of one or more pharmaceutical compositions: A multipart capsule, e.g., a dosage form, is provided which includes a plurality of capsule portions, at least one of which contains a substance to be released into a gastro-intestinal environment and at least one link component interconnecting two adjacent capsule portions. At least one capsule portion is formed from... Agent: Glaxo Smith Kline/finnegan, Henderson LLP

20090148512 - Novel uses of chloramphenicol and analogous thereof: A method for reducing the resistance of an MRSA bacterium to an antibiotic selected from the group consisting of vancomycin and methicillin comprising administering to a patient in need thereof an effective amount of chloramphenicol or analogues thereof. The invention is also directed to chloramphenicol containing pharmaceutical compositions.... Agent: Fox Rothschild LLP Princeton Pike Corporate Center

20090148515 - Two-piece metal capsule for accommodating pharmaceutical preparations for powder inhalers: The invention relates to novel two-piece metal capsules for accommodating pharmaceutical preparations to be used in powder inhalers as well as a method for producing said capsule. The inventive capsules are particularly impermeable to steam and oxygen.... Agent: Michael P. Morris Boehringer Ingelheim Usa Corporation

20090148517 - Melt-extrusion multiparticulates: A unit dose sustained-release oral dosage form containing a plurality of melt-extruded particles, each consisting essentially of a therapeutically active agent, one or more retardants, and an optional water-insoluble binder is disclosed. The particles have a length of from about 0.1 to about 12 mm and can be of varying... Agent: Jones Day

20090148516 - Treated feed supplement capsule for ruminants: A formaldehyde-treated protein capsule for protecting any encapsulated substance from chemical modification in the rumen is generally disclosed. Also, processes for making and using the formaldehyde treated protein capsule arc generally disclosed. The formaldehyde treated capsule can contain substantially no excess formaldehyde on or within the capsule. Also, the protein... Agent: Dority & Manning, P.A.

20090148518 - Pharmaceutical formulations: The present invention is directed to novel pharmaceutically acceptable polymeric compositions suitable for melt extrusion and injection moulding of single or multi-component pharmaceutical dosage forms comprising a plurality of drug substance containing sub-units, being capsule compartments and/or solid sub-units comprising a solid matrix of a polymer which contains a drug... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220

20090148519 - Pulsed-release preparation having improved disintegration properties in vivo: An object of the present invention is to provide a pulsed-release preparation that achieves pulsed-release by coating the exterior of a core that contains a physiologically active substance and a disintegrant, with a controlled-release coating that contains a water-insoluble polymer and an enteric polymer, or a water-insoluble polymer and a... Agent: Nixon & Vanderhye, PC

20090148521 - Solid oral form of a medicinal preparation and a method for the production thereof: A solid oral form of an antibody-based medicinal preparation comprises an effective carrier quantity irrigated with an active form of an antibody aqueous-alcoholic dilution, which is prepared by combining a repeated successive antibody dilution with an external action, and pharmaceutically acceptable additives. The inventive method for producing a solid oral... Agent: Kaplan Gilman & Pergament LLP

20090148520 - Tablet: The present invention can inhibit the occurrence of defective products without increasing the hardness of a tablet even if stress is applied to the tablet on transporting it or packing it by an automatic dispensing machine or when taking it out of the PTP and besides can be put into... Agent: Wenderoth, Lind & Ponack, L.L.P.

20090148522 - Heated roller compaction process for making pharmaceutical compositions: A process for using a heated roller compactor to prepare melt granulated composition of a therapeutic compound, especially a poorly compressible and/or moisture sensitive therapeutic compound, with a granulation excipient.... Agent: Novartis Corporate Intellectual Property

20090148523 - System and process for providing at least one opening in dosage forms: The present invention relates to apparatus, methods, and processes for making solid dosage forms comprising at least one active ingredient, a core and shell configuration, wherein the shell comprises a hardenable material, such as a thermal-gelling polymer, for example gelatin; and the shell is provided with at least one opening.... Agent: Philip S. Johnson Johnson & Johnson

20090148524 - Method of producing solid preparation disintegrating in the oral cavity: It is intended to provide a method of producing a solid preparation disintegrating in the oral cavity characterized by comprising mixing fine subtilaes containing a medicinal ingredient with an additive containing δ-mannitol and tableting the mixture; and a solid preparation disintegrating in the oral cavity produced thereby. This solid preparation... Agent: Wenderoth, Lind & Ponack, L.L.P.

20090148525 - Pharmaceutical formulations of potassium atp channel openers and uses thereof: Provided are immediate or prolonged administration of certain potassium ATP (KATP) channel openers to a subject to achieve novel pharmacodynamic, pharmacokinetic, therapeutic, physiological, metabolic and compositional outcomes in the treatment of diseases or conditions involving KATP channels. Also provided are pharmaceutical formulations, methods of administration and dosing of KATP channel... Agent: Foley & Lardner LLP

20090148526 - Salts of potassium atp channel openers and uses thereof: Provided are immediate or prolonged administration of certain salts of KATP channel openers such as diazoxide to a subject to achieve novel pharmacodynamic, pharmacokinetic, therapeutic, physiological, metabolic and compositional outcomes in the treatment of diseases or conditions involving KATP channels. Also provided are pharmaceutical formulations, methods of administration and dosing... Agent: Foley & Lardner LLP

20090148527 - Intraocular formulation: Biodegradable therapeutic agent incorporating microspheres formulated in a high viscosity carrier suitable for intraocular administration to treat an ocular condition. The formulation can also be used to treat non-ocular conditions such as articular pathologies.... Agent: Allergan, Inc.

20090148529 - Hydrogel suspension and manufacturing process thereof: The present invention relates to a hydrogel suspension which comprises a fine particle and high molecular weight hydroxypropylmethyl cellulose or methylcellulose, which exhibits high transparency and stability; and a manufacturing process thereof.... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20090148528 - Material that progressively liberates an active liquid substance by evaporation, and mosquito repellent bracelet incorporating such a material: A material controllingly releases by evaporation a liquid active substance and comprises a polymer material matrix impregnated with a liquid composition. The liquid composition contains a mixture of the active substance and a solute which reduces the active substance evaporation kinetics by decreasing a vapor pressure. A method for producing... Agent: Bachman & Lapointe, P.C.

20090148530 - Method for prevention and treatment of reflux injury in the aerodigestive tract and laryngopharynx caused by pepsin: A method for treating or preventing disorders, diseases, and symptom of reflux, that is laryngopharyngeal reflux (LPR), in the laryngopharynx caused by pepsin comprises orally administering to the laryngopharynx of a patient an effective amount of cellulose powder. A method for treating or preventing damage to the lining membranes of... Agent: Elliot Furman

20090148531 - Rate-controlled particles: m

20090148532 - Preparation of controlled release skeletal muscle relaxant dosage forms: The present invention is directed to a method of preparing an extended release pharmaceutical composition comprising cyclobenzaprine, comprising coating inert particles with a cyclobenzaprine-containing the drug layering composition and a seal coating composition to form IR beads, then coating the IR beads with an extended release coating to form ER... Agent: Cooley Godward Kronish LLP Attn: Patent Group

20090148533 - Ion binding compositions: The present invention provides methods and compositions for the treatment of ion imbalances. In particular, the invention provides core-shell compositions and pharmaceutical compositions thereof. Methods of use of the core-shell compositions for therapeutic and/or prophylactic benefits are disclosed herein. Examples of these methods include the treatment of phosphate imbalance disorders,... Agent: Senniger Powers LLP (rly)

20090148535 - Method for treating cancer using interference rna: The present application discloses acolloidal nanoparticle that includes a therapeutic nucleic acid species and a targeting protein species attached via a coating on the nanoparticle that facilitates the specific attachment of both species.... Agent: Jhk Law

20090148534 - Process for producing water-soluble hyaluronic acid modification: The present invention provides a water-soluble modified HA practically used as a drug carrier and a production method thereof. The present invention provides: a water-soluble modified hyaluronic acid, the residence time in blood of which is elongated to a practical level, which is produced by introducing a substituent into the... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20090148536 - Traditional chinese medicine composition to treat rheumatoid arthritis and preparation method thereof: The present invention discloses a traditional Chinese medicine composition to treat Rheumatoid Arthritis and its preparation method. The composition is mainly comprised of the following crude drugs: ant, Radix Salviae Miltiorrhizae, Radix Aconiti Preparata, Radix Ginseng, Caulis Spatholobi, and Ramulus Cinnamomi, etc. According to pharmaceutical methods, various clinical acceptable dosage... Agent: Birch Stewart Kolasch & Birch

20090148537 - Medical composition: The present invention relates to a method of preparing a medical composition, including the steps of preparing a treatment composition, and adding at least one viscosity increasing agent to the treatment composition, characterized in that the viscosity increasing agents has a property of increasing or at least maintaining the viscosity... Agent: Knobbe Martens Olson & Bear LLP

20090148538 - Use of adsorbent carbon microspheres to treat pouchitis: Disclosed herein is the use of adsorbent carbon microspheres for the treatment of pouchitis.... Agent: Knobbe Martens Olson & Bear LLP

20090148539 - Methods, compositions, and kits relating to chitinases and chitinase-like molecules and inflammatory disease: The present invention includes compositions and methods for the treatment of inflammatory disease (e.g. asthma, COPD, inflammatory bowel disease, atopic dermatitis, atopy, allergy, allergic rhinitis, scleroderma, and the like), relating to inhibiting a chitinase-like molecule. The invention further includes methods to identify new compounds for the treatment of inflammatory disease,... Agent: Ropes & Gray LLP

20090148540 - Antibacterial composition and method of production: An electrolysis method is described for generating an aqueous solution of copper citrate that has bacteriocidal activity against methicillin resistant Staphylococcus aureus (MRSA) bacteria. Gram positive bacteria are known to be relatively more sensitive to the bacteriocidal activities of copper ions than are Gram negative bacteria. Situations exist in which... Agent: William John Martin

20090148541 - Compositions and methods for the treatment of seborrhea: Methods and compositions are provided for treating dermatological diseases, disorders, and pathologies, including seborrheic dermatitis, in a subject in need thereof. In some embodiments, methods are provided for the treatment of a dermatological disease, disorder, or pathology comprising, topically administering to a subject in need of dermatological treatment a composition... Agent: Jenkins, Wilson, Taylor & Hunt, P. A.

20090148542 - Composition comprising an extract of tiarella polyphylla and tiarellic acid isolated therefrom having antiinflammatory, antiallergic and antiasthmatic activity: The present invention relates to a composition comprising an extract of Tiarella polyphylla, and tiarellic acid isolated therefrom having anti-inflammatory, anti-allergic and anti-asthmatic activity. The extract of Tiarella polyphylla and the tiarellic acid isolated therefrom shows the inhibitory effect on the LTC4 release in vitro test and the suppressive effect... Agent: Ohlandt, Greeley, Ruggiero & Perle, LLP

20090148544 - Cosmetic composition containing an extract from lotus and method of cosmetic care using said composition: e

20090148543 - Method for protecting humans against superficial vasodilator flush syndrome,: Methods for protection of a human from SVFS comprise the administration of a flavonoid compound of the basic structures 2-phenyl-4H-1-benzopyran or 2-phenyl-4-keto-1-benzopyran or glycosides thereof, alone or, optionally, together with one or more of an olive kernel extract, a non-bovine sulfated proteoglycan, bitter willow extract, a D-hexosamine sulfate, S-adenosylmethionine, folic... Agent: Wilmerhale/boston

20090148545 - Methods of use and nutritional compositions of touchi extract: Disclosed is a method and composition for nutritional compositions containing -glucosidase inhibitors, and more specifically Touchi Extract and its uses in the treatment of many disorders. These disorders include diabetes, hyperlipidemia, obesity, Metabolic syndrome/Syndrome X, COPD, malabsorption, Crohn's disease, diarrhea, constipation, irritable bowel syndrome, human immunodeficiency virus, cystic fibrosis, non-alcoholic... Agent: Nestle Healthcare Nutrition

20090148546 - Methods and compounds fo rthe treatment of obesity and obesity-related disorders: In certain embodiments, the invention comprises the use of plant-derived substances to reduce body fat and/or to increase insulin sensitivity in mammals. In certain embodiments, the invention comprises a composition for reducing the amount of fat in the body of a mammal, the composition comprising at least one plant-derived substance... Agent: Adams And Reese LLP

20090142259 - Compositions and methods for the diagnosis and treatment of bladder and urinary tract tumors: The present invention is directed to methods of diagnosing and treating, as well as articles of manufacture useful for diagnosing and treating, bladder and/or urinary tract tumor in mammals.... Agent: Genentech, Inc.

20090142260 - In vivo detection of apoptosis: The invention provides methods and products, such as kits, useful for determining the apoptotic state of cells in an organism, comprising detecting the presence or abundance of at least one caspase affinity labeling agent in the cells of an animal into which at least one caspase affinity labeling agent has... Agent: Viksnins Harris & Padys Pllp

20090142263 - Cytotoxicity mediation of cells evidencing surface expression of trop-2: The present invention relates to a method for producing cancerous disease modifying antibodies using a novel paradigm of screening. By segregating the anti-cancer antibodies using cancer cell cytotoxicity as an end point, the process makes possible the production of anti-cancer antibodies for therapeutic and diagnostic purposes. The antibodies can be... Agent: Mchale & Slavin, P.A.

20090142261 - Ephb3-specific antibody and uses thereof: EphB3-specific antibodies are provided, along with pharmaceutical compositions containing such antibody, kits containing a pharmaceutical composition, and methods of preventing and treating cancer.... Agent: Novartis Vaccines And Diagnostic, Inc.

20090142262 - Method of diagnosing, monitoring, staging, imaging and treating prostate cancer: The present invention provides new methods for detecting, diagnosing, monitoring, staging, prognosticating, imaging and treating prostate cancer.... Agent: Licata & Tyrrell P.C.

20090142264 - 18f-labeled phenoxyphenyl nu-benzyl alkanamid derivatives for positron emission tomography (pet) imaging of peripheral benzodiazepine receptor: The present invention provides novel 18F-labeled phenoxyphenyl N-benzyl alkanamid derivative compounds that are suitable for use as an in vivo imaging agent. A pharmaceutical comprising the compound and a kit for the preparation of the pharmaceutical are also provided. Methods of use and use of claims for novel 18F-labeled phenoxyphenyl... Agent: Ge Healthcare, Inc.

20090142265 - Alpha-fluoroalkyl tetrabenazine and dihydrotetrabenazine imaging agents and probes: wherein R1 is a C1-C10 fluorinated aliphatic radical; R2 is hydrogen or a C1-C10 aliphatic radical; and R3 is hydrogen or a C1-C10 aliphatic radical. The alpha-fluoroalkyl compounds are provided in both racemic and enantiomerically enriched forms and may comprise either or both of fluorine-18 and fluorine 19. The alpha-fluoroalkyl... Agent: General Electric Company Global Research

20090142268 - Chain-end functionalized poly(ethykene oxide) and process for the preparation of a nano-sized transition metal or metal salt using the same: There is provided a novel chain-end functionalized PEO of formulas (I) to (IV) prepared via living anionic polymerization and chain-end functionalization, as well as a simple method of preparing nano-sized transition metal or metal salt particles using the same, which can be readily stabilized even in an aqueous medium. The... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20090142271 - Dendritic cells: The present invention provides systems for isolating, characterizing, and modulating brain dendritic cells. The invention may allow a better understanding of and opportunities to modulate neurodevelopmental processes (such as, for example, neurogenesis) and neurological diseases (such as, for example, Alzheimer's Disease).... Agent: Choate, Hall & Stewart LLP

20090142267 - Fusogenic properties of saposin c and related proteins and peptides for application to tansmembrane drug delivery systems: The present invention comprises a method for delivering pharmaceutical and/or imaging agents within and/or through the dermal, mucosal and other cellular membranes, and across the blood-brain barrier, utilizing a fusogenic protein. The fusogenic protein is associated with a phospholipid membrane, such as a liposome. The liposome may include dioleoylphosphatidylserine, a... Agent: Frost Brown Todd, LLC

20090142269 - Isotoypically-labeled benzothiazole compounds as imaging agents for amyloidogenic proteins: The present invention provides an isolated linezolid impurity, desfluoro linezolid, the preparation thereof and its use as a reference standard.... Agent: Foley And Lardner LLP Suite 500

20090142266 - Peptides derived from maurocalcine used as vectors for intracellular addressing of molecules of interest: Use of a peptide vector for intracellular addressing of a substance of interest, said vector essentially comprising a peptide which is derived from maurocalcine corresponding to the following sequence (I): Z-X1-X2-X3-X4-X5-X6-X7-X8-X9-X10-X11-X12-X13-X14-X15-X16-X17-X18-X19-X20-X21-X22-X23-X24-X25-X26-Z′, wherein X1 and X26 each represent a cysteine, X2 to X25 each represent an amino acid or are absent,... Agent: Alston & Bird LLP

20090142270 - Prevention and treatment of cerebral amyloid angiopathy: The invention provides improved agents and methods for treatment of cerebral amyloid angiopathy (CAA) and methods to effect prophylaxis of CAA. The methods can treat CAA concurrently with Alzheimer's disease or separately. The methods can effect prophylaxis of CAA concurrently with Alzheimer's disease or separately. The methods involve administering antibody... Agent: Townsend And Townsend And Crew, LLP

20090142272 - Pfks as modifiers of the igfr pathway and methods of use: Human PFK genes are identified as modulators of the IGFR pathway, and thus are therapeutic targets for disorders associated with defective IGFR function. Methods for identifying modulators of IGFR, comprising screening for agents that modulate the activity of PFK are provided.... Agent: Mcdonnell Boehnen Hulbert @ Berghoff LLP

20090142273 - Activatable cest mri agent: A chemical exchange saturation transfer (CEST) contrast agent is provided. One embodiment includes a ligand and a functional group linked to the ligand. The functional group has a hydrogen exchange site and is capable of undergoing a change in chemical functionality by enzyme catalysis or reaction with a metabolite to... Agent: Mcdonald Hopkins LLC

20090142276 - Alpha-fluoroalkyl dihydrotetrabenazine imaging agents and probes: wherein R1 is a C1-C10 fluorinated aliphatic radical; R2 is hydrogen or a C1-C10 aliphatic radical; R3 is hydrogen or a C1-C10 aliphatic radical; and R4 is a C1-C10 aliphatic radical, a C3-C10 cycloaliphatic radical, or a C3-C10 aromatic radical. The alpha-fluoroalkyl dihydrotetrabenazine compounds are provided in both racemic and... Agent: General Electric Company Global Research

20090142274 - Intracellular nanosensors and methods for their introduction into cells: The invention provides ion-selective sensors capable of selectively measuring ions, e.g., Na+, K+, Cl−, etc., in the cytosol of a single living cell. The sensor comprises one or more quantum dots or a fluorescent dye, a pH-sensitive dye, and optionally an ion-selective component such as an ionophore. These elements may,... Agent: Ropes & Gray LLP

20090142275 - Wound suture capable of identifying the presence of bacteria: A wound suture containing a solvatochromatic indicator that undergoes a color change in the presence of bacteria often associated with surgical site infection is provided. Such a color change provides a “real time” indication of the onset of infection, which may alert medical staff to apply an appropriate antimicrobial treatment... Agent: Dority & Manning, P.A.

20090142278 - Effervescent compositions comprising phosphonates and methods related thereto: The invention provides effervescent composition comprising a bisphosphonate, an acidic compound, an alkaline effervescing component, and optionally an anti-ulcer agent and methods of treating osteoporosis in a mammal using the effervescent compositions.... Agent: NeifeldIPLaw, P.C.

20090142277 - Treatment of active infections and related compositions: The present invention is directed to the treatment of infections and the associated symptoms of sinusitis, rhinitis and related neurological disorders of the cranial cavity and facial tissue. More specifically, the present invention is directed to aerosols that are used to treat infections and the associated symptoms of sinusitis, rhinitis... Agent: Sheppard, Mullin, Richter & Hampton LLP

20090142279 - Novel m3 muscarinic acetylcholine receptor antagonists: Muscarinic Acetylcholine receptor antagonists and methods of using them are provided.... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220

20090142280 - Protective skin care peptides: The disclosed invention provides tetrapeptides with the amino acid sequence proline-glutamine-glutamate-X (P-Q-E-X), where X can be either lysine (K) or isoleucine (I). These tetrapeptides inhibit ultraviolet light (UV)-induced expression of the pro-inflammatory cytokine interleukin-6 (IL-6) by skin epithelial cells and fibroblasts. Furthermore, the tetrapeptides repress the upregulation of matrix metalloproteinase-1... Agent: Howrey LLP-hn

20090142281 - Composition comprising a coupled enzyme system: The present invention relates to a composition comprising a coupled enzyme system for the rapid and efficient production of hydrogen peroxide by the coupling of a first enzyme system capable of hydrogen peroxide generation, to a second enzyme system which utilizes the non hydrogen peroxide product of the first enzyme... Agent: Frommer Lawrence & Haug

20090142282 - High-solids alcoholic solutions of rosin esters for varnish applications: High-solids solutions of solid rosin esters and lower alcohols can be obtained at rosin ester concentrations above the binary solubility of the rosin ester in the alcohol. Such solutions can be achieved by adding an additional modified rosin or by dissolving a small amount of the alcohol in the rosin... Agent: Jonathan Kendall

20090142283 - Peptide-based antidandruff reagents: Peptide-based antidandruff reagents, formed by coupling a skin-binding peptide with an antidandruff agent, are described. The skin-binding peptide part of the peptide-based antidandruff reagent binds strongly to the skin, thus keeping the antidandruff agent coupled to the skin for a long lasting effect. Hair care compositions comprising the peptide-based antidandruff... Agent: E I Du Pont De Nemours And Company Legal Patent Records Center

20090142284 - Water-based olefin-graft polymer system for multifunctional cosmetic applications: A polymer emulsion for use in a cosmetic composition includes an olefin copolymer; a copolymer of an acidic monomer to include acrylic acid, methacrylic acid or other unsaturated, carboxyl containing monomer; optionally, at least one stabilizing emulsifier; optionally, a resin selected from a group consisting of an acrylic resin and... Agent: Hamilton, Brook, Smith & Reynolds, P.C.

20090142285 - Cosmetic composition comprising ascorbic acid 2-glucoside and ergothioneine: This invention relates to a cosmetic composition allowing the effects of skin aging to be reduced or delayed, comprising as the cosmetically active ingredients ascorbic acid 2-glucoside and ergothioneine. The invention also relates to the use of these cosmetically active ingredients in a cosmetic composition as agents to stimulate DNA... Agent: Foley And Lardner LLP Suite 500

20090142286 - Cosmetic makeup and/or care process: The present invention relates to a cosmetic process for making up and/or caring for keratin material(s), comprising the application, on contact with a keratin material, of at least one cosmetic composition comprising at least one fatty phase and consisting of at least 75% by weight, relative to its total weight,... Agent: Oliff & Berridge, PLC

20090142287 - Emulsified antiperspirant composition and method for making same: Antiperspirant compositions that include a continuous phase employing a water-immiscible liquid and a structurant, and a disperse phase employing a solution of antiperspirant active in water.... Agent: The Procter & Gamble Company Global Legal Department - Ip

20090142290 - Shaving gel products: The present invention comprises a soap-free self-foaming shave gel composition which maintains superior performance attributes while avoiding the harshness and drying associated with soap-based shave preparations. The shave gel composition of the present invention comprises water, a short-chain polyol, a water-soluble sarcosinate salt, and a volatile self-foaming agent.... Agent: The Procter & Gamble Company Global Legal Department - Ip

20090142288 - Hair straightening composition comprising a disaccharide: A hair straightening composition comprising at least one hydroxide ion generator and a disaccharide.... Agent: Unilever Patent Group

20090142289 - Composition containing a hard wax and a pasty compound, and process for the care or making up of the eyelashes: Composition containing an aqueous phase, at least 10% by weight of at least one hard wax, relative to the total weight of the composition, and at least one pasty compound. Also described is a composition containing an aqueous phase, at least one hard wax, at least one pasty compound, and... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20090142291 - Pigmented cosmetic and personal care composition and process for preparing the same: A pigment dispersed in a silicone polymer is combined with at least one cosmetic component or at least one dematologically acceptable and active agent to prepare a wide variety of cosmetic and personal care compositions. The pigment may be dispersed in a polysiloxane, such as an alkylpolysiloxane, to provide a... Agent: Curatolo Sidoti Co., Lpa

20090142292 - Method for the mitigation of symptoms of dry eye: A method for the mitigation of symptoms of dry eye is disclosed. The method involves at least (a) incorporating one or more non-functionalized polymers having one or more hydrophilic moieties into an ophthalmic device that is a polymerization product of a comonomer mixture comprising: (i) a major amount of a... Agent: Bausch & Lomb Incorporated

20090142293 - Polyammonium/polysiloxane copolymers: The invention relates to polyammonium/polysiloxane copolymers, methods for production and use thereof.... Agent: Rankin, Hill & Clark LLP

20090142297 - 5-substituted isoindoline compounds: This invention relates to 5-substituted isoindoline compounds, and pharmaceutically acceptable salts, solvates, stereoisomers, and prodrugs thereof. Methods of use, and pharmaceutical compositions of these compounds are disclosed.... Agent: Jones Day

20090142295 - Anti-connexin compounds and uses thereof: Methods and compositions for modulating the activities of connexins are provided, including, for example, for use for treatment of cardiovascular, vascular, neurological, for wounds and for other indications. These compounds and methods can be used therapeutically, for example, to reduce the severity of adverse effects associated diseases and disorders where... Agent: Duane Morris LLP - San Diego

20090142296 - Method of increasing trafficking of endothelial progenitor cells to ischemia-damaged tissue: This invention provides a method of increasing trafficking of endothelial progenitor cells to ischemia-damaged tissue in a subject comprising administering to the subject an amount of interleukin-8 effective to attract endothelial progenitor cells to the ischemia-damaged tissue.... Agent: Cooper & Dunham, LLP

20090142294 - Parameter selected gm-csf, il-3, il-4, il-5 and chimeras thereof for therapeutic and diagnostic purposes: The present invention relates generally to the fields of proteins, diagnostics, therapeutics and nutrition. More particularly, the present invention provides an isolated protein molecule in or related to the short chain 4 helix bundle superfamily such as GM-CSF, IL-3, IL-4 and IL-5 or chimeric molecules thereof comprising at least a... Agent: Seed Intellectual Property Law Group PLLC

20090142298 - Apolactoferrin compositions and methods for their use in the treatment of viral hepatitis c: The invention refers to medicine, in particular to hepatology and virology, and can be used for treatment, including complete recovery, of patients with viral hepatitis C, including its chronic form. This invention provides a remedy for treating viral hepatitis C, that is, apoprotein lactoferrin in a monomeric form. This invention... Agent: Stemedica Cell Technologies, Inc

20090142299 - Macrocyclic tetrazolyl hepatitis c serine protease inhibitors: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned... Agent: Elmore Patent Law Group, PC

20090142300 - Compositions and methods related to toll-like receptor-3: The invention relates to compositions and methods related to Toll-like receptor (TLR) polypeptides. In some embodiments, the invention relates to managing TLR3 related diseases. In further embodiments, the invention relates to methods of preventing and treating inflammation. In some embodiments, the invention relates to antagonists of TLR3, to amino acid... Agent: Peter G. Carroll Medlen & Carroll, LLP

20090142301 - Novel pharmaceutical composition of interferon gamma or pirfenidone with molecular diagnostics for the improved treatment of interstitial lung diseases: The present invention relates to a novel pharmaceutical composition of compounds having the biological activity of interferon gamma (IFN-γ) or pirfenidone in combination with a diagnostic array of candidate polynucleotides for the improved treatment of all forms of interstitial lung disease, in particular of idiopathic pulmonary fibrosis (IPF).... Agent: Winstead PC

20090142302 - Insulin-like growth factor binding protein 7 for treatment of cancer: Methods of treating a tumor in a subject include identifying a subject having, at risk for, or suspected of having a tumor, and administering to the subject an effective amount of an IGFBP7 agent if the tumor has increased Ras-BRAF-MEK-Erk signaling, is dependent for growth and/or survival upon the Ras-BRAF-MEK-Erk... Agent: Fish & Richardson PC

20090142312 - Methods for promoting wound healing and muscle regeneration with the cell signaling protein nell1: The present invention provides methods for promoting wound healing and treating muscle atrophy in a mammal in need. The method comprises administering to the mammal a Nell1 protein or a Nell1 nucleic acid molecule.... Agent: Ut-battelle, LLC Office Of Intellectual Property

20090142304 - Composition for improving intestinal flora: A composition provided by the present invention for improving intestinal microflora includes 1-kestose as an active ingredient. The present invention further provides a lactic acid bacteria proliferating agent including 1-kestose as an active ingredient, which proliferates Bifidobacterium and lactic acid bacteria simultaneously. According to the present invention, intestinal microflora can... Agent: Wenderoth, Lind & Ponack, L.L.P.

20090142303 - Methods and compositions for dried cellular forms: Methods and compositions of spray drying cellular material are provided that allow preservation of the cellular material. In one aspect, the cellular material is spray dried with a quantity of excipient. In another aspect, the cellular material is spray dried using a cryoprotectant.... Agent: Fish & Richardson PC

20090142314 - Maternal supplement: The use of docosahexaenoic acid in the manufacture of a composition for administration to a pregnant woman for reducing the risk of development of overweight or obesity of the baby in infancy and/or early childhood.... Agent: K&l Gates LLP

20090142313 - Vaginal delivery system: The present invention is related to an intravaginal delivery system for the controlled release of drospirenone and an estrogen, optionally also comprising one or more therapeutically active or a health-promoting substance capable of giving and/or enhancing protection against bacterial and fungal infections, and/or enhancing protection against sexually transmitted diseases. The... Agent: Birch Stewart Kolasch & Birch

20090142315 - Methods for the dietary management of irritable bowel syndrome and carbohydrate malabsorption: The invention relates generally to digestive disorders, and in particular to methods for treating irritable bowel syndrome by increasing carbohydrate absorption by administering a composition containing a Bacillus coagulans bacterium.... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.c

20090142311 - Engineered intervertebral disc tissue: Surgically implantable tissue engineered intervertebral disc tissues that effectively replicate the physicochemical properties of the corresponding in vivo tissues are provided. Methods for producing such tissues can involve culturing the intervertebral disc cells to produce cells surrounded by an extracellular matrix and culturing the cells and matrix on a semipermeable... Agent: Foley & Lardner LLP

20090142309 - Hydroxyphenyl cross-linked macromolecular network and applications thereof: A dihydroxyphenyl cross-linked macromolecular network is provided that is useful in artificial tissue and tissue engineering applications, particularly to provide a synthetic macromolecular network for a wide variety of tissue types. In particular, artificial or synthetic cartilage, vocal cord material, vitreous material, soft tissue material and mitral valve material are... Agent: Pearne & Gordon LLP

20090142310 - Method of treating inflammatory arthropathies with suppressors of cpg oligonucleotides: The present disclosure relates to oligodeoxynucleotides that suppress an immune response. Methods are disclosed for preventing or treating inflammatory arthropathies by administering a therapeutically effective amount of a suppressive oligodeoxynucleotide.... Agent: Klarquist Sparkman, LLP

20090142306 - Methods and systems for treating ischemic tissues: Methods and systems for regenerating damaged tissue rely on direct injection of selected therapeutic cells into a tissue at or near the site of tissue damage. Direct injection is accomplished using an intravascular catheter having a deployable needle, and injection is usually targeted into the adventitial and peri-adventitial tissues surrounding... Agent: Townsend And Townsend And Crew, LLP

20090142308 - Methods for treating autoimmune disease by inducing autoantigen-specific regulatory cd4+ t cells: Described herein are methods and compositions for the treatment and monitoring the progress of autoimmune diseases. In some embodiments, the methods include the stimulation of regulatory T cells specific to autoantigens associated with the autoimmune disease. A specific embodiment relates to diabetes mellitus, and the prevention or delay of loss... Agent: Fish & Richardson PC

20090142305 - Pegylated fibrinogen-based biomatrix: The invention involves methods and materials related to fibrin-based biomatrices.... Agent: Fish & Richardson P.C.

20090142307 - Shape-based approach for scaffoldless tissue engineering: Methods for forming tissue engineered constructs without the use of scaffolds and associated methods of use in tissue replacement. One example of a method may comprise providing a shaped hydrogel negative mold; seeding the mold with cells; allowing the cells to self-assemble in the mold to form a tissue engineered... Agent: Baker Botts, LLP

20090142318 - Method to expand ntreg cells using p70 s6 kinase antagonist: Disclosed in this specification is a method to promote the growth of CD4+CD25Foxp3+ nTreg cells in a culture while treating the culture with a p70 S6 kinase inhibitor. The resulting cells are useful in the treatment of immune-related diseases.... Agent: Hiscock & Barclay, LLP

20090142319 - Method to expand ntreg cells using pi-3k antagonist: Disclosed in this specification is a method to promote the growth of CD4+CD25Foxp3+ nTreg cells in a culture while treating with a PI-3K antagonist. The resulting cells are useful in the treatment of immune-related diseases.... Agent: Hiscock & Barclay, LLP

20090142320 - Method to minimize il-17 production during ntreg cell expansion: Disclosed in this specification is a method to promote the growth of CD4+CD25Foxp3+ nTreg cells in a culture while minimizing the production of IL-17. The resulting cells are useful in the treatment of immune-related diseases.... Agent: Hiscock & Barclay, LLP

20090142317 - Process for reducing effects of graft versus host disease using ex vivo expanded cd4+cd25+ regulatory t cells: Disclosed in this specification is a process for producing ex vivo expanded CD4+CD25+ regulatory T cells. The process includes the steps of extracting a sample that includes peripheral blood mononuclear cells from a human donor. The extracted cells include a certain number of cells which are CD4+CD25+ regulatory T cells.... Agent: Hiscock & Barclay, LLP

20090142316 - Use of dendrimers to stimulate cell growth: The present invention relates to the use of dendrimers with monophosphonic or bisphosphonic terminations in order to stimulate the growth of cell cultures or to activate cells in culture.... Agent: Young & Thompson

20090142322 - Coenzyme q10 production in a recombinant oleaginous yeast: Engineered strains of the oleaginous yeast Yarrowia lipolytica capable of co-producing coenzyme Q10 and at least one ω-3/ω-6 polyunsaturated fatty acid are provided. The strains may also be engineered to co-produce at least one C40 carotenoid. Methods of using the antioxidant products obtained (e.g., biomass and/or pigmented oils) in food... Agent: E I Du Pont De Nemours And Company Legal Patent Records Center

20090142323 - Methods for treating a disorder by regulating gprc6a: A disorder related to a non-genomic androgen response or a metabolic syndrome can be treated, inhibited, and/or prevented by regulating an expression level and/or activity of GPRC6A. Such a method can include identifying an individual with a disorder associated with a non-genomic androgen response or metabolic syndrome; and administering to... Agent: Workman Nydegger 1000 Eagle Gate Tower

20090142324 - Oil-in-water type emulsion containing coenzyme q10 and process for producing the same: To provide an oil-in-water emulsion composition that prevents separation of coenzyme Q10 and creaming during storage, maintains a stable emulsification state over long term exceeding two weeks, and does not impair flavor or taste. The oil phase of the oil-in-water emulsion composition contains coenzyme Q10, and a complex of an... Agent: Brinks Hofer Gilson & Lione

20090142321 - Opthalmic composition: An ophthalmic composition which is prepared by incorporating pyridoxine hydrochloride in combination with chondroitin sulfate and a cellulosic polymer. The composition is reduced or eliminated in eye irritation attributable to pyridoxine hydrochloride.... Agent: Marshall, Gerstein & Borun LLP

20090142325 - Compositions and methods for treating tumour spreading: There is provided a method of prevention or inhibition of uncontrolled proliferation of a cancer comprising administration to a mammal of a therapeutically effective amount of a pharmaceutical composition comprising a cell-permeable fusion protein conjugate comprising a polypeptidic cell-membrane transport moiety and a Clostridium botulinum C3 exotransferase unit or a... Agent: Ogilvy Renault LLP

20090142326 - Glycosidase enzymes: A thermostable glycosidase enzymes derived from various Thermococcus, Staphylothermus and Pyrococcus organisms is disclosed. The enzymes are produced from native or recombinant host cells and can be utilized in the food processing industry, pharmaceutical industry and in the textile industry, detergent industry and in the baking industry.... Agent: Verenium Corporation Intellectual Property Department

20090142327 - Novel class of therapeutic protein based molecules: The present invention provides new compositions and methods for preventing and treating pathogen infection. In particular, the present invention provides compounds having an anchoring domain that anchors the compound to the surface of a target cell, and a therapeutic domain that can act extracellularly to prevent infection of a target... Agent: Fish & Richardson, PC

20090142329 - Interleukin-1 beta converting enzyme like apoptosis protease-3 and 4: Disclosed are human interleukin-1 β converting enzyme like apoptosis proteases-3 and 4 and DNA (RNA) encoding such polypeptides. Also provided is a procedure for producing such polypeptides by recombinant techniques and antibodies and antagonists against such polypeptides. Also provided are methods of using the polypeptides, for example, as an antitumor... Agent: Human Genome Sciences Inc. Intellectual Property Dept.

20090142328 - Uses of antileukoprotease in carcinoma: The present invention provides a method of detecting/monitoring tumor growth and progression in a tissue by measuring the level of antileukoprotease. Also provided is a method of treating an individual having a tumor by administering antileukoprotease to inhibit the activity of stratum corneum chymotryptic enzyme. Specifically, the tumor is an... Agent: Dr. Benjamin Adler Mcgregor & Adler, L.L.P.

20090142330 - Use of inactive-plasmin to treat chronic inflammatory disease and tumors: Methods are provided for the suppression of inflammation or a tumor. The methods can include selecting a subject in need of suppression of inflammation or the tumor and inhibiting plasmin activity in the subject to decrease matrix metalloproteinase production, thereby suppressing the inflammation or tumor. In several examples, an agent... Agent: Klarquist Sparkman, LLP

20090142331 - Method for the production of bio-active substances from the novel actinomycete taxa mar3a, mar3b and mar4 belonging to the family treptomycetaceae: This invention provides a method for the isolation and identification of marine actinomycetes tentatively named MAR3A and MAR3B and the use of these groups as a source of new biologically active compositions including pharmaceuticals. The method includes specifics about where these microorganisms occur and their culture requirements. It also provides... Agent: Dla Piper LLP (us)

20090142333 - Activin-actriia antagonists and uses for promoting bone growth in cancer patients: In certain aspects, the present invention provides compositions and methods for promoting bone growth and increasing bone density, as well as for the treatment of multiple myeloma.... Agent: Ropes & Gray LLP

20090142334 - Detection and modulation of iaps and naip for the diagnosis and treatment of proliferative disease: Disclosed are diagnostic and prognostic kits for the detection and treatment of proliferative diseases such as ovarian cancer, breast cancer, and lymphoma. Also disclosed are cancer therapeutics utilizing IAP antisense nucleic acids, IAP fragments, and antibodies which specifically bind IAP polypeptides.... Agent: Lowrie, Lando & Anastasi, LLP

20090142332 - Identification of biomarkers by serum protein profiling: The present invention relates to methods of determining colorectal cancer status in a subject. The invention further relates to kits for determining colorectal cancer status in a subject. The invention further related to methods of identifying biomarker for determining colorectal cancer status in a subject.... Agent: Edwards Angell Palmer & Dodge LLP

20090142336 - Metabolic regulators and uses thereof: The present invention relates to metabolic regulators that affect metabolic function, for example metabolic regulators that affect muscle mass, muscle regeneration, muscle hypertrophy, fat mass, insulin and glucose sensitivity, angiogenesis and cardiovascular function. In particular, the present invention relates to modulating metabolic function by administering an effective amount of a... Agent: Ronald I. Eisenstein

20090142335 - Methods of diagnosis and treatment of metabolic disorders: The invention features diagnostic methods for metabolic disorders (e.g., diabetes and obesity), methods for screening for compounds useful in the treatment of metabolic disorders, and methods for treatment of metabolic disorders that involve sirtuin2.... Agent: Clark & Elbing LLP

20090142337 - Pharmaceutical combinations of diazole derivatives for cancer treatment: The invention provides a combination comprising (or consisting essentially of) an ancillary compound and a compound of the formula (I): or salts, tautomers, solvates and N-oxides thereof; wherein: R1 is 2,6-dichlorophenyl; R2a and R2b are both hydrogen; and R3 is a group: formula (A) where R4 is C1-4 alkyl. The... Agent: Heslin Rothenberg Farley & Mesiti PC

20090142339 - Humanized anti-ccr2 antibodies and methods of use therefor: The present invention relates to a humanized antibody or functional fragment thereof which binds to a mammalian (e.g., human) CC-chemokine receptor 2 (CCR2) or a portion of the receptor and blocks binding of a ligand to the receptor. The invention further relates to a method of inhibiting the interaction of... Agent: Lowrie, Lando & Anastasi, LLP

20090142338 - Methods and compositions for treating type 1 and type 2 diabetes mellitus and related conditions: Embodiments of the present invention relate to compositions and methods of treating type 1 or type 2 diabetes mellitus or other conditions relating to metabolic dysfunction that may impact insulin secretion or action by administering an islet neogenesis agent in combination with an agent or agents that selectively inhibits, blocks... Agent: Pepper Hamilton LLP

20090142341 - Mutated pseudomonas exotoxins with reduced antigenicity: The invention provides mutated Pseudomonas exotoxins (PE) that have reduced immunogenicity compared to PEs containing the native sequence. The PEs of the invention have one or more individual mutations of positions of the native sequence of PE that reduce antibody binding to one or more PE epitopes. Nucleic acids encoding... Agent: Townsend And Townsend And Crew, LLP

20090142340 - Optimized fc variants and methods for their generation: The present invention relates to optimized Fc variants, methods for their generation, and antibodies and Fc fusions comprising optimized Fc variants.... Agent: Xencor

20090142342 - B7-h4 receptor agonist compositions and methods for treating inflammation and auto-immune diseases: Compositions containing B7-H4 receptor agonists in an amount effective to reduce, inhibit, or mitigate an inflammatory response in an individual and methods for the treatment or prophylaxis of inflammatory disorders and autoimmune diseases or disorders have been developed. It has been discovered that B7-H4 receptor agonists, for example B7-H4 fusion... Agent: Pabst Patent Group LLP

20090142343 - Anti-vegf antibodies: The invention herein provides isolated antibodies that bind to VEGF. The invention further provides methods of making anti-VEGF antibodies, and polynucleotides encoding anti-VEGF antibodies.... Agent: Clark & Elbing LLP

20090142344 - Breast cancer related gene znfn3a1: Objective methods for detecting and diagnosing breast cancer (BRC) are described herein. Also described are methods of treating and preventing breast cancer and breast cancer metastasis as well as methods of assessing the prognosis of a breast cancer subject and the efficacy of a breast cancer therapy. In one embodiment,... Agent: Townsend And Townsend And Crew, LLP

20090142346 - Preventive/remedy for cancer: A human monoclonal antibody against a protein comprising the same or substantially the same amino acid sequence as the amino acid sequence represented by SEQ ID NO: 1 or SEQ ID NO: 3, its partial peptide, or a salt thereof, is useful as an agent for preventing/treating cancer, etc., an... Agent: Edwards Angell Palmer & Dodge LLP

20090142345 - Prophylactic/therapeutic agent for cancer: The present invention provides a safe drug that targets a molecule specifically expressed in cancer cells, and that induces cancer cell growth inhibition. More specifically, the present invention provides a neutralizing antibody against a protein comprising the same or substantially the same amino acid sequence as that shown by SEQ... Agent: Sughrue Mion, PLLC

20090142352 - Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (pcsk9): Antigen binding proteins that interact with Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) are described. Methods of treating hypercholesterolemia and other disorders by administering a pharmaceutically effective amount of an antigen binding protein to PCSK9 are described. Methods of detecting the amount of PCSK9 in a sample using an antigen... Agent: Knobbe Martens Olson & Bear LLP

20090142349 - Cd19 antibodies and their uses: The present disclosure provides isolated monoclonal antibodies, particularly human monoclonal antibodies that specifically bind to CD19 with high affinity. Nucleic acid molecules encoding such CD19 antibodies, expression vectors, host cells and methods for expressing the CD19 antibodies are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the CD19 antibodies... Agent: Baker Botts L.L.P.

20090142351 - Human and rat pgc-3, ppar-gamma coactivations and splice variants thereof: A novel gene PGC-3, and its role in regulating the transcriptional activity of PPARγ in adipose tissue. PGC-3 is highly expressed in human white adipose tissue and has utility in the development of new therapeutic agents for use in the treatment of obesity and other related disorders such as non-insulin... Agent: Ropes & Gray LLP

20090142354 - Human antibodies to human delta like ligand 4: An isolated human antibody or a fragment of a human antibody which specifically binds to human delta-like ligand 4 (hDll4) and blocks hDll4 binding to a Notch receptor. The human anti-hDll4 antibody or antibody fragment binds dimeric hDll4 with an affinity of 75 pM or better, as measured by surface... Agent: Regeneron Pharmaceuticals, Inc

20090142353 - Human tumor necrosis factor receptor tr17: The present invention relates to a novel protein, TR17, which is a member of the tumor necrosis factor (TNF) receptor superfamily. In particular, isolated nucleic acid molecules are provided encoding the human TR17. TR17 polypeptides are also provided as anti TR17 antibodies and vectors, host cells and recombinant methods for... Agent: Human Genome Sciences Inc. Intellectual Property Dept.

20090142348 - Novel gene disruptions, compositions and methods relating thereto: The present invention relates to transgenic animals, as well as compositions and methods relating to the characterization of gene function. Specifically, the present invention provides transgenic mice comprising disruptions in PRO844, PRO1131 or PRO5992 genes. Such in vivo studies and characterizations may provide valuable identification and discovery of therapeutics and/or... Agent: Genentech, Inc.

20090142350 - Pancreatic cancer genes: The present invention provides the art with the DNA coding sequences of polynucleotides that are up-or-down-regulated in cancer and dysplasia. These polynucleotides and encoded proteins or polypeptides can be used in the diagnosis or identification of cancer and dysplasia. Inhibitors of the up-regulated polynucleotides and proteins can decrease the abnormality... Agent: Novartis Vaccines And Diagnostics, Inc. Corporate Intellectual Property-r338

20090142347 - Tissue-nonspecific alkaline phosphatase (tnap): a therapeutic target for arterial calcification: This invention relates generally to the field of mineralization, and specifically to the role of TNAP in regulating the levels of extracellular inorganic pyrophosphate. The invention provides methods for modulating the activity of TNAP activity; methods for screening for modulators of TNAP activity; modulators of TNAP activity; and methods for... Agent: Catalyst Law Group, Apc

20090142355 - Diagnosis and treatment of type 1 diabetes: Methods for the diagnosis and treatment of type 1 diabetes are described. HLA-DQA2 has now been identified as the gene which is primarily responsible for determining whether an individual is susceptible to develop type 1 diabetes. The use of HLA-DQA2 as a target for developing therapeutic and diagnostic targets for... Agent: Rissman Jobse Hendricks & Oliverio, LLP

20090142356 - Pharmaceutical composition of f(ab')2 antibody fragments and a process for the preparation thereof: The present invention is directed to a pharmaceutical composition comprising F(ab′)2 antibody fragments that are preferably free from albumin and of whole antibodies and also substantially free of pyrogens, and an effective amount of a pharmaceutically acceptable carrier. It is also directed to a method for the production of a... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20090142357 - Specific depletion of cd4+ t cells: Specific depletion or modulation of activity of CD4+ T cells is used to treat and/or prevent damage due to ischemia of kidneys, heart, brain. It also has been found to reduce rejection of transplanted organs. The donor, recipient, or isolated organ can be so treated.... Agent: Banner & Witcoff, Ltd.

20090142358 - Human antibodies specific to kdr and uses thereof: The invention provides an antibodies that bind to KDR with an affinity comparable to or higher than human VEGF, and that neutralizes activation of KDR. Antibodies include whole immunoglobulins, monovalent Fabs and single chain antibodies, multivalent single chain antibodies, diabodies, triabodies, and single domain antibodies. The invention further provides nucleic... Agent: Imclon Lerner, David, Littenberg, Krumholz & Mentlik, LLP

20090142359 - Antibody-induced apoptosis: Anti-Her2 antibodies which induce apoptosis in Her2 expressing cells are disclosed. The antibodies are used to “tag” Her2 overexpressing tumors for elimination by the host immune system. Also disclosed are hybridoma cell lines producing the antibodies, methods for treating cancer using the antibodies, and pharmaceutical compositions.... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20090142360 - Use of ferritin to treat iron deficiency disorders: The present inventors have demonstrated the presence of H-ferritin receptors on endothelial cells in culture and on rat brain rat brain microvasculature, identifying H-ferritin as a means for transporting iron across the blood brain barrier. The present invention provides a method for treating an iron deficiency disorder in a patient,... Agent: Buchanan, Ingersoll & Rooney PC

20090142361 - Drug conjugate composition: The invention provides a lyophilized composition comprising a therapeutically effective amount of a conjugate comprising an antibody chemically coupled to a maytansinoid. The invention further provides a method for killing a cell in a human comprising administering to the human the reconstituted composition such that the antibody binds to the... Agent: Leydig Voit & Mayer, Ltd

20090142365 - Compositions and methods for using ca9 protein to stimulate an immune response: Provided are methods for stimulating an immune response to an antigen by administering a composition to an individual in an amount effective to stimulate an immune response to the antigen. The stimulated immune response to the antigen is greater than the immune response stimulated by the antigen in the absence... Agent: Hodgson Russ LLP The Guaranty Building

20090142363 - Cytotoxic t-cell epitope peptide and use thereof: The successful identification of epitope peptides specific to adenovirus belonging to subgroup B and epitope peptides exhibiting specificity to all adenoviruses using hexon proteins which exhibit the highest homology among genes of adenoviruses of various subgroups is herein described. The peptides have a function capable of efficiently inducing adenovirus-specific cytotoxic... Agent: Townsend And Townsend And Crew, LLP

20090142364 - Method for finding novel peptide immunostimulatory adjuvants, compositions and methods of use: The invention describes production of an adjuvant with biological activities related to N-acetylglucosaminyl-β1-4-N-acetylmuramyl-alanyl-D-isoglutamine (GMDP), a commonly used enhancer of the immune response. It was found in the present invention that the drawbacks of GMDP can be avoided by replacing it with a peptide that does not have any direct structural... Agent: Dodds & Associates

20090142362 - Peptide-based vaccine compositions to endogenous cholesteryl ester transfer protein (cetp): Improved vaccine compositions and methods of use thereof are described that elicit production of antibodies in an individual to the individual's own endogenous cholesteryl ester transfer protein (CETP).... Agent: Wolf Greenfield & Sacks, P.C.

20090142366 - Yeast-based vaccines as immunotherapy: Compositions and methods for treating and/or preventing a variety of diseases and conditions that are amenable to immunotherapy and, in one particular embodiment, compositions and methods for treating and/or preventing cancer in an animal are described. Specifically improvements related to the use of a yeast-based vaccine comprising a yeast vehicle... Agent: Sheridan Ross P.C.

20090142368 - Chemically programmable immunity: The present invention is related to methods and compositions that are capable of immediately immunizing a human or animal against any molecule or compound. The present invention comprises an immunity linker molecule with at least two sites; (1) a first binding site that binds to an immune system molecule in... Agent: King & Spalding

20090142367 - Yeast-based vaccines as immunotherapy: Compositions and methods for treating and/or preventing a variety of diseases and conditions that are amenable to immunotherapy and, in one particular embodiment, compositions and methods for treating and/or preventing cancer in an animal are described. Specifically improvements related to the use of a yeast-based vaccine comprising a yeast vehicle... Agent: Sheridan Ross P.C.

20090142370 - Method for preventing skin-cellular aging by using green algae extract and cosmetic composition containing green algae extract: A method for preventing skin-cellular aging by using a green algae extract and a cosmetic composition containing the green algae extract are disclosed. An effective dose of the green algae extract is used to inhibit the activity of Metalloproteinase (MMP) in the fibroblast and to promote of collagens and elastins... Agent: Charles E. Baxley, Esquire

20090142369 - Method for preventing skin-cellular injury by using green algae extract and cosmetic composition containing green algae extract: A method for preventing UV-induced skin-cellular injury by using a green algae extract and a cosmetic composition containing the green algae extract are disclosed. An effective dose of the green algae extract is used to protect fibroblasts from UV-induced apoptosis. The mechanism of the disclosed method is using the green... Agent: Charles E. Baxley, Esquire

20090142371 - Hiv recombinant vaccine: Reagents and methods for making and using HIV recombinant vaccines are disclosed.... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20090142372 - Therapeutic composition for use in the prevention and treatment of bone metastases: The invention is relates to drugs on the basis of antibodies against non-cellular bone matrix proteins, especially BSP, for use in the prevention and treatment of bone metastases. According to the invention, the antibodies are induced in the patient by recombinantly expressing antigenic determinants of bone matrix proteins in Listeria... Agent: Birch Stewart Kolasch & Birch

20090142373 - Immunizing against hiv infection: A virus neutralizing level of antibodies to a primary HIV isolate is generated in a host by a prime-boost administration of antigents. The primary antigen is a DNA molecule encoding an envelop glycoprotein of a primary isolate of HIV-1 while the boosting antigen is either a non-infectious, non-replicating HIV-like particle... Agent: Sim & Mcburney

20090142374 - Composition for immunostimulation: The present invention relates to a composition for immunostimulation useful for promoting IgA and secretory component productions in mucosal tissues, comprising, alone or in combination, a cell of bifidobacterium belonging to Bifidobacterium bifidum or a processed product thereof, wherein the bifidobacterium has an activity to stimulate secretory component production and... Agent: Greenblum & Bernstein, P.L.C

20090142375 - Lipoteichoic acid from lactic acid bacteria and its use to modulate immune responses madiated by gram-negative bacteria, potential pathogenic gram-positive bacteria: The invention relates to a composition for modulating the immune responses induced by Gram negative bacteria, potential pathogenic Gram positive bacteria and/or their derivatives, comprising lipoteichoic acid from lactic acid bacteria as an active ingredient. It also relates to the use of a lipoteichoic acid from lactic acid bacteria as... Agent: K&l Gates LLP

20090142376 - Chlamydia polypeptides and corresponding dna fragments and uses thereof: The present invention provides a method of nucleic acid, including DNA, immunization of a host, including humans, against disease caused by infection by a strain of Chlamydia, specifically C. pneumoniae, employing a vector containing a nucleotide sequence encoding a 98 kDa outer membrane protein of a strain of Chlamydia pneumoniae... Agent: Smart & Biggar P.o. Box 2999, Station D

20090142379 - Coated products containing hydrogenated indigestible starch syrup as a binding agent: An object of the present invention is to provide a coated product with increased stiffness to reduce the chipping after manufacturing and several days of storage, and before wrapping. A coated product such as confectioneries such as chewing gum, medicines and medicinal tablets wherein the product is coated with a... Agent: Sughrue Mion, PLLC

20090142378 - Controlled release dosage forms: The invention provides stable controlled release monolithic coating compositions for use in coating pharmaceutical oral dosage forms comprising a polyglycol having a melting point greater than 55° C. and an aqueous dispersion of a neutral ester copolymer lacking functional groups.... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20090142377 - Immunogenic compositions: Described are means and methods for producing and/or selecting immunogenic compositions, comprising providing the composition with at least one cross-beta structure and testing at least one immunogenic property.... Agent: Traskbritt, P.C.

20090142381 - Lamellar oil-in-glycol gel compositions and the process of preparation: The present invention is directed to a lamellar oil-in-glycol gel comprising (a) at least one glycol, (b) at least one fatty alcohol, (c) at least one cationic surfactant and optionally (d) at least one benefit agent, said lamellar gel capable of providing enhanced mass and promoting the permeation of the... Agent: International Specialty Products William J. Davis, Esq.

20090142383 - O/w emulsion cosmetic composition: e

20090142382 - Powder cosmetic composition: Methods for preparing a solid powder cosmetic composition comprise heating a wax component and one or more cosmetic powders at a temperature sufficient to melt the wax, and subsequently cooling the mixture to provide a solid composition comprising a wax matrix having particulate materials homogenously dispersed therein.... Agent: Avon Products, Inc. Joan M. Mcgillycuddy

20090142384 - Viscoelastic material: The invention relates to a tough-elastic material based on starch, which on the one hand has high impact toughness at low humidities, and on the other hand still has a high modulus of elasticity at high humidities and has a high elongation capacity in a broad range of humidities and... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20090142380 - Cosmetic composition in powdered form: Disclosed herein is an anhydrous cosmetic composition in powdered form comprising at least one pulverulent phase and at least one fatty binder, the said pulverulent phase comprising i) 30 to 70% by weight, relative to the total weight of the composition, of at least one pigment, and ii) 30 to... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20090142385 - Compositions for treating bone defects: In certain described embodiments, implantable medical materials comprise a scaffolding material, a liquid organic binder, and entrapped calcium-containing particles. The medical materials can incorporate an osteoinductive factor such as a protein. The scaffolding material can bind the factor. In additional described embodiments, implantable medical materials include an osteoconductive scaffolding material,... Agent: Medtronic Attn: Noreen Johnson -IPLegal Department

20090142386 - Control of drug release by transient modification of local microenvironments: Methods, formulations, and devices are provided for enhancing drug delivery from a medical device. The method is provided for increasing the rate or quantity of a drug formulation released from an implantable drug delivery device, which method comprises the step of providing a release-modifying agent within or proximate to the... Agent: Sutherland Asbill & Brennan LLP

20090142387 - Method for inhibiting attachment of microorganisms to biomedical devices: A method for inhibiting adhesion of bacteria to a surface of a biomedical device is disclosed. The method involves at least (a) incorporating one or more non-functionalized polymers having one or more hydrophilic moieties into an ophthalmic device that is a polymerization product of a comonomer mixture comprising: (i) a... Agent: Bausch & Lomb Incorporated

20090142389 - Hydrogel sheet and production method thereof: Provided is a hydrogel sheet being excellent in strength and flexibility and having high water content in spite of comprising a smaller amount of polymer material; and a method for producing a hydrogel sheet which is convenient and has high productivity. More specifically, provided is a hydrogel sheet comprising (methyl... Agent: Alston & Bird LLP

20090142388 - Patch preparation: The present invention provides a patch preparation having an adhesive layer on at least one surface of a support, wherein the adhesive layer contains an adhesive, a poorly soluble drug, a first organic liquid component, a second organic liquid component, a third organic liquid component and crosslinked polyvinylpyrrolidone, the solubility... Agent: Wenderoth, Lind & Ponack, L.L.P.

20090142390 - Transdermal systems containing multilayer adhesive matrices to modify drug delivery: e

20090142391 - Conjugated rnai therapeutics: A method for modulating at least one pharmacokinetic property of a drug which degrades mRNA upon administration to a host by an siRNA mechanism is provided. In a further embodiment of this invention, a bifunctional compound comprising an siRNA and a recruiter moiety are provided. The recruiter moiety may be... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.c

20090142392 - Composition comprising a nsaid and paracetamol: A process for producing a granular composition comprising a plurality of solidified melt granules including a non-steroidal anti-inflammatory drug (NSAID) and paracetamol (acetaminophen), the process comprising the steps of: (a) forming a melt mixture by mixing a molten NSAID free acid and paracetamol, optionally with one or more excipients; and... Agent: Fish & Richardson PC

20090142393 - Stable compositions of famotidine and ibuprofen: Stable pharmaceutical compositions of famotidine and ibuprofen in a single unit dosage form are disclosed herein. The compositions comprise a famotidine core having a reduced or minimal surface area surrounded by a layer of ibuprofen. In some embodiments, the ibuprofen is in direct physical contact with the famotidine.... Agent: Townsend And Townsend And Crew, LLP

20090142395 - Deferasirox pharmaceutical compositions: The present invention provides a process of preparing a high-load formulation of deferasirox with a sufficiently high dissolution rate and good bioavailability, which reduces the effect of the active material's physical characteristics on the chemical and physical properties of the final product.... Agent: Kenyon & Kenyon LLP

20090142394 - Gastric antacid: e

20090142399 - Dispersant agent for sustained-release preparations: The present invention provides a bilayer dispersing agent for a sustained-release preparation, which contains a non water-soluble solvent and an aqueous solvent, and a sustained-release preparation wherein a microcapsule containing a physiologically active substance is dispersed in the aforementioned dispersing agent. When this preparation is subcutaneously administered, the initial release... Agent: Sughrue Mion, PLLC

20090142398 - Novel pharmaceutical compositions comprising a disintegration matrix: The present invention relates to a stable pharmaceutical composition comprising a pharmaceutically active substance having poor water solubility dispersed in a pharmaceutically acceptable disintegration matrix, said disintegration matrix comprising at least one pharmaceutically acceptable disintegrant, a pharmaceutically acceptable basic agent provided in a molar ratio of basic agent to active... Agent: Stikeman Elliott LLP

20090142397 - Reduction of dermal scarring: Methods and compositions for reducing or inhibiting dermal scarring by expressing p21WAF1/Cip1 in a wound site are provided.... Agent: Townsend And Townsend And Crew, LLP

20090142396 - Use of a regenerative biofunctional collagen biomatrix for treating visceral or parietal defects: Techniques for treating visceral or parietal membrane and tissue defects include the application of a collagen biomatrix to the defect to repair and regenerate a visceral or parietal membrane, for example in patients suffering tissue defects or undergoing visceral or parietal surgical treatment. Such approaches avoid persistent tissue leaks and... Agent: Baxter Healthcare Corporation

20090142400 - Analgesic coated medical product: Described are medical products including an analgesic such as lidocaine, bupivicaine, or a mixture thereof. Such medical products can find use in pain relief, particularly after surgery, and can be applied to tissue or can be implanted within a patient. Also described are medical products including an extracellular matrix material,... Agent: Woodard, Emhardt, Moriarty, Mcnett & Henry LLP

20090142402 - Microparticles, microparticle dispersion and method and apparatus for producing the same: A method and an apparatus enabling manufacture of a microparticle dispersion liquid at high efficiency in a short time while suppressing drug degradation, etc., are provided. In a dissolving step, a poorly soluble drug and a dispersion stabilizer are dissolved in a volatile organic solvent in a container 13. In... Agent: Drinker Biddle & Reath (dc)

20090142401 - Multiparticulates comprising low-solubility drugs and carriers that result in rapid drug release: Multiparticulates of low-solubility drugs and carriers that result in rapid release of the drug are disclosed.... Agent: Chernoff, Vilhauer, Mcclung & Stenzel

20090142403 - Organ regeneration device: An organ regeneration device adapted to be used by placing it into a defective portion of an organ to regenerate the organ is provided. The organ regeneration device has a base body having a shape corresponding to a shape of the defective portion of the organ. The organ regeneration device... Agent: Greenblum & Bernstein, P.L.C

20090142405 - Nanoparticles for protein drug delivery: The invention discloses the nanoparticles composed of chitosan, poly-glutamic acid, and at least one protein drug or bioactive agent characterized with a positive surface charge and their enhanced permeability for paracellular protein drug and bioactive agent delivery.... Agent: Hosheng Tu

20090142404 - Pharmaceutical dosage forms comprising a low-solubility drug and a polymer: A dosage form comprises a low-solubility drug, and a precipitation-inhibiting polymer. The drug is in a solubility-improved form and in the form of particles at least partially coated with the precipitation-inhibiting polymer. Exemplified low-solubility drugs are ziprasidone and sildenafil. Exemplified precipitation-inhibiting polymer is HPMCAS.... Agent: Pfizer Inc Steve T. Zelson

20090142406 - Microencapsulated pesticide: wherein X denotes either —CH2—CH2— or —CH=CH— and R1 and R2 each denote a C1-C4 alkyl group, (b) mixing the resulting suspension and water to prepare a liquid droplet, and (c) forming a coating film around the liquid droplet. A microcapsule obtained in such a way contains most of the... Agent: Foley And Lardner LLP Suite 500

20090142407 - Solid peptide preparations for inhalation and their preparation: The invention relates to solid pharmaceutical preparations, in particular for inhalatory administration in mammals, their preparation and their use such as, for example, in powder inhalers.... Agent: Goodwin Procter LLP Attn: Patent Administrator

20090142408 - Telomerase delivery by biodegradable nanoparticle: A therapeutic compound consisting of human telomerase, its catalytic subunit hTert, or a known variant of either, and a biodegradable nanoparticle carrier, which can be administered to cells in a cell culture or in a living animal, is provided herein. The therapeutic compound is envisioned as a method for treating... Agent: Guotang Zhai

20090142409 - Extracellular matrix compositions for tissue regeneration: The invention is compositions of extracellular matrix that comprise mammalian extracellular matrix from two or more tissue sources in a mammal. The invention also includes methods of using these compositions to regenerate tissue or generate new tissue at sites of defects or wounds in mammals.... Agent: Ballard Spahr Andrews & Ingersoll, LLP

20090142410 - Nutritional composition and method for increasing creatine uptake and retention in skeletal muscle, increasing muscle mass and strength, increasing exercise capacity and for aiding recovery following exercise: The present invention relates to the composition of a dietary supplement provided for increasing Creatine uptake and retention in skeletal muscle, increasing muscle mass and strength, increasing exercise capacity and aiding in recovery following exercise as well as supporting the immune system during periods of intense training. A method for... Agent: Iovate Health Science Research Inc.

20090142411 - Composition and device comprising an inorganic component (metal compound) for coagulation of protein-containing fluids: A device or composition comprising an agent for the coagulation of protein-containing fluids, wherein the agent comprises an inorganic component which is soluble in protein-containing fluids. Use of such a device or composition for the coagulation of protein-containing fluids. A coagulum of protein-containing fluid produced using such a device or... Agent: Diana Houston Smith & Nephew, Inc.

20090142412 - Skin care cosmetic cream/scrub product: A series of cosmetic scrubs and creams, some containing coffee, have the ability to moisturize, soften, scrub and revitalize body parts, create natural tanning qualities, and sooth itch from burns and bug bites.... Agent: Myers Wolin, LLC

20090142413 - Targeted short-lived drug delivery: An aspect of the disclosure includes a system for delivering therapeutic agents. In an embodiment, the system includes an implantable medical device comprising at least one reservoir that holds at least one therapeutic agent. Additionally the device includes a delivery mechanism that provides non-systemic in vivo delivery of the at... Agent: Searete LLC Clarence T. Tegreene

20090142414 - Anterminator: This invention relates to the use of mixtures of sodium tetraborate decahydrate, sodium borate, or disodium tetraborate, such as borax a white powder consisting of soft colorless crystals and, in combination with surface active agents of powdered or icing sugar and cornstarch containing fine granules of powders and crystal agents,... Agent: Charlene O'neill

20090142415 - Selective resonance of chemical structures: Chemical compositions may be selectively or preferentially excited by the application of scores comprising a series of energy inputs.... Agent: Searete LLC Clarence T. Tegreene

20090142416 - Methods for the treatment of hiv and other viruses: A treatment for the persons infected with viruses such as HIV. The method takes Advantage of the anesthetic membrane effect brought about by certain gases under pressure. A patient infected with HIV, for example, is placed in a pressurized chamber and exposed to one or more gases under pressure. In... Agent: Rodney L. Sparks

20090142417 - Process for the preparation of concentrated solutions of stabilized hypobromites: The invention is a process for the preparation of stabilized aqueous solutions of alkali hypobromites at low temperatures, which comprises reacting a concentrated alkali hydroxide aqueous solution with bromine, and adding to the reaction product, which is a non-stabilized solution, an aqueous solution of a sulfamic compound, such as sodium... Agent: Kevin D. Mccarthy Roach Brown Mccarthy & Gruber, P.C.

20090142421 - Active fraction of a polar solvent extract from the latex of euphorbiaceae plants: The present invention generally refers to an active fraction of an extract of the latex of plants from the family Euphorbiaceae in a polar solvent, as well as of one or more compounds contained therein, as well as the use of said fraction and/or said compounds, particularly in the treatment... Agent: Sughrue Mion, PLLC

20090142419 - Anti-inflammatory extract and agent and method for the production thereof: The invention relates to the pharmaceutical industry, in particular to producing herbal remedy for integrally treating various inflammatory diseases. The inventive remedy comprises a dry Boswellia extract dissolved in the oil extract of Siberian stone pine seeds and Curcuma. The remedy can be used in the form of soft gelatine... Agent: Borden Ladner Gervais LLP Gail C. Silver

20090142418 - Antiviral composition comprising alnus japonica extracts: Antiviral compositions including Alnus japonica extracts are described as useful for preventing or treating diseases caused by influenza virus infection of humans and other mammalian and avian subjects (e.g., pigs, horses, birds, and the like). Alnus japonica extracts in such use exhibit low toxicity in normal cell environments, and excellent... Agent: Intellectual Property / Technology Law

20090142420 - Cosmetic composition with anti-free radical activity: t

20090142422 - Herbal compositions for the regression of chronic inflammatory skin disorders: Herbal compositions that, when used in an effective amount, are suitable for the regression of chronic inflammatory skin disorders, including eczema, psoriasis and seborrheic dermatitis. The compositions, formulated as ointments, oils and shampoos, are comprised of a non-aqueous extract of Wrightia tinctoria, an extract of Tragia involucrata L., extracts of... Agent: Bregen Technical Consultants L.L.C.

20090142423 - Use of extracts or extractants of the guajacum types, said extracts or extractants bringing about phosphodiesterase-4 inhibition and method for producing the same: The present invention relates to the use of extracts or extractants of the guajacum types, said extracts or extractants bringing about phosphodiesterase-4 inhibition, and to a method for producing the same.... Agent: The Nath Law Group

20090142424 - Natural topical compositions for the prevention and treatment of diaper rashes and related conditions: The treatment and prevention of skin irritations, including diaper rash, is facilitated with the topical application of cranberry anthocyanins in a cosmetically acceptable vehicle.... Agent: Abelman, Frayne & Schwab

20090142425 - Physiologically active composition: A physiologically active composition is claimed which comprises effective amounts of at least one compound from the group 4-O-methyldavidigenin, 4′-O-methyldavidigenin, davidigenin, elemicin, isoelemicin, herniarin, demethoxycapillarisin, in particular 6-demethoxycapillarisin and/or 6-demethoxy-3′-methoxy-capillarisin, hispiludin and 9-hydroxy-10E, 12Z, 15Z-octadecatrienoic acid, and also glycosides thereof, in particular glucosides and/or rhamnoglucosides of 4-O-methyldavidigenin and/or 4′-O-methyldavidigenin, salts... Agent: Fulbright & Jaworski, LLP

20090142426 - Aqueous extract of tobacco leaves, its uses in the treatment of dependence: The invention relates to the use of an aqueous extract of tobacco leaves for the preparation of a medicament for the treatment of dependence, in particular tobacco dependence, and to a sterile injection solution and a kit which can be used for the treatment of dependence, in particular of tobacco.... Agent: Frost Brown Todd, LLC

20090142427 - Composition and its therapeutic use: e

20090142428 - Extracts from the bark of corynanthe species and use thereof as well as medicaments, dietetic food products and pharmaceutical preparations containing said extracts: The present invention relates to extracts from the bark of corynanthe species, in particular corynanthe pachyceras as well as to their use for the therapy and prophylaxis of diseases of the lower urinary tract, sexual disorders, lipid metabolism disorders, cardiovascular diseases and acute and chronic pain conditions. The present invention... Agent: Edwards Angell Palmer & Dodge LLP

20090142431 - Algal and algal extract dietary supplement composition: A human dietary supplement composition comprising the dried biomass of bluegreen algae (Spirulina platensis) and astaxanthin is disclosed. The composition is stable, effective and convenient for supporting the health and well-being of either healthy or health-challenged humans. Further, a method of ameliorating viral infections in human subjects by administering the... Agent: Allen, Dyer, Doppelt, Milbrath & Gilchrist P.A.

20090142430 - Methods for preventing or treating complications of airway control devices: Disclosed in certain embodiments is a method of treating or preventing complications of airway control devices comprising administering to a patient having an airway control device a pharmaceutical composition comprising botulinum neurotoxin to one or more of the upper or lower aerodigestive secretory glands, the cricopharyngeus or the gastric or... Agent: Patent Docket Administrator Lowenstein Sandler PC

20090142429 - Silicibacter sp. strain useful for genetic transformation of marine algae and production of antibiotic agents: A Silicibacter sp. strain useful for genetic transformation of marine algae and production of antibiotic agents is described. Silicibacter sp. TM1040 is a genetically tractable member of the marine Roseobacter clade of bacteria that forms an intimate and obligate interaction with algae, and is useful as a probiotic for producing... Agent: Intellectual Property / Technology Law